The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection by Mazuski, John E. et al.
University of Kentucky
UKnowledge
Surgery Faculty Publications Surgery
1-1-2017
The Surgical Infection Society Revised Guidelines
on the Management of Intra-Abdominal Infection
John E. Mazuski
Washington University in St. Louis
Jeffrey M. Tessier
JPS Health System
Addison K. May
Vanderbilt University
Robert G. Sawyer
University of Virginia
Evan P. Nadler
Children’s National Medical Center
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/surgery_facpub
Part of the Surgery Commons
This Article is brought to you for free and open access by the Surgery at UKnowledge. It has been accepted for inclusion in Surgery Faculty Publications
by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Mazuski, John E.; Tessier, Jeffrey M.; May, Addison K.; Sawyer, Robert G.; Nadler, Evan P.; Rosengart, Matthew R.; Chang, Phillip K.;
O'Neill, Patrick J.; Mollen, Kevin P.; Huston, Jared M.; Diaz, Jose J. Jr.; and Prince, Jose M., "The Surgical Infection Society Revised
Guidelines on the Management of Intra-Abdominal Infection" (2017). Surgery Faculty Publications. 37.
https://uknowledge.uky.edu/surgery_facpub/37
Authors
John E. Mazuski, Jeffrey M. Tessier, Addison K. May, Robert G. Sawyer, Evan P. Nadler, Matthew R.
Rosengart, Phillip K. Chang, Patrick J. O'Neill, Kevin P. Mollen, Jared M. Huston, Jose J. Diaz Jr., and Jose M.
Prince
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Notes/Citation Information
Published in Surgical Infections, v. 18, no. 1, p. 1-76.
© John E. Mazuski, et al., 2016; Published by Mary Ann Liebert, Inc.
This Open Access article is distributed under the terms of the Creative Commons Attribution
Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the
source are credited.
Digital Object Identifier (DOI)
https://doi.org/10.1089/sur.2016.261
This article is available at UKnowledge: https://uknowledge.uky.edu/surgery_facpub/37
The Surgical Infection Society Revised
Guidelines on the Management
of Intra-Abdominal Infection
John E. Mazuski,1 Jeffrey M. Tessier,2 Addison K. May,3 Robert G. Sawyer,4 Evan P. Nadler,5
Matthew R. Rosengart,6 Phillip K. Chang,7 Patrick J. O’Neill,8 Kevin P. Mollen,9
Jared M. Huston,10 Jose J. Diaz, Jr,11 and Jose M. Prince12
Abstract
Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were
published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline
was released, the plan was to update the guideline every five years to ensure the timeliness and appropriateness
of the recommendations.
Methods: Based on the previous guidelines, the task force outlined a number of topics related to the treatment
of patients with IAI and then developed key questions on these various topics. All questions were approached
using general and specific literature searches, focusing on articles and other information published since 2008.
These publications and additional materials published before 2008 were reviewed by the task force as a whole
or by individual subgroups as to relevance to individual questions. Recommendations were developed by a
process of iterative consensus, with all task force members voting to accept or reject each recommendation.
Grading was based on the GRADE (Grades of Recommendation Assessment, Development, and Evaluation)
system; the quality of the evidence was graded as high, moderate, or weak, and the strength of the recom-
mendation was graded as strong or weak. Review of the document was performed by members of the SIS who
were not on the task force. After responses were made to all critiques, the document was approved as an official
guideline of the SIS by the Executive Council.
Results: This guideline summarizes the current recommendations developed by the task force on the treatment
of patients who have IAI. Evidence-based recommendations have been made regarding risk assessment in
individual patients; source control; the timing, selection, and duration of antimicrobial therapy; and suggested
approaches to patients who fail initial therapy. Additional recommendations related to the treatment of pediatric
patients with IAI have been included.
Summary: The current recommendations of the SIS regarding the treatment of patients with IAI are provided in
this guideline.
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EXECUTIVE SUMMARY
Intra-abdominal infection (IAI) is a common disease pro-
cess managed by surgical practitioners. The Surgical Infec-
tion Society (SIS) developed and disseminated guidelines for
the management of these infections in 1992 [1], in 2002 [2,3],
and most recently in 2010 as a joint guideline with the In-
fectious Diseases Society of America (IDSA) [4]. Since the
2010 guideline, additional challenges have arisen in the man-
agement of these infections, in part because of the aging of the
population and the burden of chronic disease in these patients,
and in part because of the increased prevalence of resistant
bacteria and fungi in both the healthcare setting and the com-
munity. Nonetheless, advances in the management of these
infections have also been made; newer approaches to source
control are now available, as are new antibiotic agents that may
meet some of the challenges posed by resistant pathogens.
To maintain the clinical relevance of the guideline, the SIS
appointed a task force to revise the 2010 guideline. This task
force included members of the Therapeutics and Guidelines
Committee as well as additional individuals from the SIS
with expertise in the subject matter. The task force selected
subjects from the previous guideline for updating, developed
specific questions for review, and then used the best available
contemporary evidence to formulate recommendations. The
task force evaluated the quality of the evidence and the
strength of the recommendations using the GRADE (Grades
of Recommendation Assessment, Development, and Eva-
luation) nomenclature, which has now become widely ac-
cepted as a standard for guidelines. Once completed, the
entire document was subjected to external review by addi-
tional experts from the SIS, modified according to these re-
views by consensus of the task force and sent to the Executive
Council of the SIS for final approval.
All judgments regarding interpretation of this evidence
and the GRADE assignments were exercised by the members
of the task force and subsequent reviewers based on their
individual and collective expertise, recognizing that the ev-
idence could be interpreted differently by others. As with
previous guidelines, these recommendations were designed
to support clinicians in making appropriate treatment deci-
sions and not designed to supplant the judgment of the in-
dividual practitioner [4].
1. Risk assessment
Assessing the risk of an adverse outcome in patients with
IAI is important in optimizing selection of source control and
antimicrobial therapy. Specific recommendations include:
 Use phenotypic and physiologic factors, including signs
of sepsis or septic shock, extremes of age, and patient
co-morbidities; the extent of abdominal infection and
adequacy of initial source control; and the presence or
persistence of resistant or opportunistic pathogens in
assessing risk for treatment failure and mortality in
patients with IAI (Grade 1-B).
 Characterize patients as being at either lower or higher
risk for treatment failure or death, and as having either
a community-acquired IAI (CA-IAI) or a healthcare or
hospital-associated IAI (HA-IAI), including a post-
operative infection, for purposes of planning source
control and empiric antimicrobial therapy (Grade 2-C).
 Identify patients with IAI meeting Surviving Sepsis
Campaign criteria for sepsis or septic shock and those
having an Acute Physiology and Chronic Health Eval-
uation II score greater than or equal to 10 as higher-risk
patients (Grade 1-B). Consider patients with at least
two physiologic/phenotypic risk factors for an adverse
outcome, those having diffuse peritonitis, and those
having delayed or inadequate source control as poten-
tial higher-risk patients (Grade 2-B).
 Identify patients who have been hospitalized for at least
48 hours during the previous 90 days; those residing in a
skilled nursing or long-term care facility during the pre-
vious 30 days; those who have received intravenous (IV)
infusion therapy, wound care, or renal replacement ther-
apy within the preceding 30 days; those who have re-
ceived several days of broad-spectrum antimicrobial
therapy within the previous 90 days; those who have post-
operative infections; and those known to have been col-
onized or infected previously with a resistant pathogen as
having HA-IAI and at potential risk for infection because
of resistant or opportunistic organisms (Grade 2-B).
2. Source control
Source control is considered fundamental to the treatment
of most patients with IAI. Specific recommendations re-
garding source control include:
 Routinely use a source control procedure to remove
infected fluid and tissue and to prevent ongoing con-
tamination in patients with IAI except for those patients
with clinical problems for which there is clear evidence
that a non-interventional approach is associated with a
good clinical outcome (Grade 1-A).
 Undertake source control within 24 hours of the diag-
nosis of IAI, except for those infections for which
clinical evidence indicates a non-interventional or de-
layed approach is appropriate (Grade 2-B). Undertake
source control in a more urgent manner in patients with
sepsis or septic shock (Grade 2-C).
 Use the least invasive approach that is able to achieve
adequate source control, at least on a temporary basis,
in patients with IAI (Grade 1-B).
 Consider use of alternative or temporizing approaches
to source control in patients with major physiologic
instability, those with diffuse infections, and those with
ongoing bowel ischemia who are considered at higher
risk for initial source control failure (Grade 2-B).
 Use abbreviated laparotomy and temporary abdominal
closure techniques in critically ill patients with IAI if
closure of the abdomen would create meaningful intra-
abdominal hypertension, if the patient’s physiologic re-
serves are severely compromised, if there is an inability
to achieve adequate source control with the initial pro-
cedure, or if there is a plan for a second look laparotomy
because of mesenteric ischemia (Grade 1-B).
 Do not use routine planned re-laparotomy in higher-risk
patients with severe peritonitis when adequate source
control can be obtained at the time of the index pro-
cedure; treat such patients with on-demand rather than
scheduled re-laparotomy (Grade 1-B).
 Irrigate with crystalloid fluid to remove visible debris and
gross contamination before abdominal closure in patients
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undergoing laparotomy for IAI, generally limiting lavage
to those areas with gross involvement (Grade 2-B).
3. Microbiologic evaluation
Microbiologic evaluation may be useful in selected pa-
tients, but is not necessary in most. Specific recommenda-
tions include:
 Do not routinely obtain peritoneal fluid cultures in
lower-risk patients with CA-IAI for purposes of guid-
ing antimicrobial therapy (Grade 1-B).
 Obtain cultures of peritoneal fluid or infected tissue in
higher-risk patients with CA-IAI and in patients with
HA-IAI to identify potential resistant or opportunistic
pathogens (Grade 1-C).
 Consider obtaining cultures in all patients with IAI for
epidemiologic purposes if adequate resources are
available to aggregate and analyze the data and the
information can be used to guide empiric antimicrobial
therapy (Grade 2-C).
4. Intravenous antimicrobial agents
Many IV antimicrobial agents are potentially useful in the
treatment of patients with IAI, as a supplement to source
control. Specific recommendations regarding antimicrobial
agents for the management of IAI include:
A. General principles
 Use antimicrobial regimens that have activity against
the typical gram-negative Enterobacteriaceae, gram-
positive cocci, and obligate anaerobes involved in these
infections (Grade 1-A).
B. Aminoglycoside-based regimens
 Do not use aminoglycoside-based regimens routinely
for empiric therapy (Grade 1-B). Consider use of these
agents for treatment of neonatal patients and for man-
agement of IAI because of resistant gram-negative or-
ganisms in all patients, if other agents are not suitable
(Grade 2-B).
C. Penicillin–b-lactamase inhibitor combinations
 Do not use ampicillin-sulbactam routinely for empiric
therapy (Grade 2-B).
 Do not use IV amoxicillin-clavulanic acid routinely for
empiric therapy (Grade 2-B).
 Consider use of ticarcillin-clavulanic acid as an option
for empiric therapy of lower-risk adults and children, if
this agent again becomes available (Grade 2-B).
 Use piperacillin-tazobactam for empiric therapy of
adults and children (Grade 1-A), but reserve this agent
primarily for higher-risk patients because of its
broader-spectrum antimicrobial activity (Grade 2-C).
D. Cephalosporin-based regimens and cephalosporin–b-
lactamase inhibitor combinations
 Do not use cefoxitin and cefotetan routinely for empiric
therapy (Grade 2-B).
 Do not use cefazolin plus metronidazole routinely for
empiric therapy (Grade 2-C).
 Consider use of cefuroxime plus metronidazole as an
option for empiric therapy of lower-risk adults and
children (Grade 2-B).
 Use cefotaxime or ceftriaxone plus metronidazole for
empiric therapy of lower-risk adults and children
(Grade 1-A).
 Consider use of ceftazidime plus metronidazole as an
option for empiric therapy of adults and children
(Grade 2-A), but reserve this regimen primarily for
higher-risk patients because of its broader-spectrum
antimicrobial activity (Grade 2-C).
 Use cefepime plus metronidazole for empiric therapy
of adults and children (Grade 1-A), but reserve this
regimen primarily for higher-risk patients because of its
broader-spectrum antimicrobial activity (Grade 2-C).
 Consider use of cefoperazone-sulbactam as an option
for empiric therapy of lower-risk adults and children, in
areas where this agent is available (Grade 2-B).
 Consider use of ceftolozane-tazobactam plus metroni-
dazole as an option for empiric therapy of adults (Grade
2-A), but reserve this regimen primarily for higher-risk
patients strongly suspected or proven to be infected
with resistant strains of Pseudomonas aeruginosa, for
which other agents are not suitable (Grade 2-C).
 Consider use of ceftazidime-avibactam plus metroni-
dazole as an option for empiric therapy of adults (Grade
2-A), but reserve this regimen primarily for higher-risk
patients strongly suspected or proven to be infected
with Klebsiella pneumoniae carbapenemase (KPC)-
producing Enterobacteriaceae, for which other agents
are not suitable (Grade 2-C).
E. Aztreonam-based regimen
 Consider use of aztreonam plus metronidazole plus
vancomycin as an option for empiric therapy of adults
and children (Grade 2-B), but reserve this regimen
primarily for higher-risk patients, particularly those
with serious b-lactam allergies, because of its broader-
spectrum activity (Grade, 2-C).
F. Carbapenems
 Use ertapenem for empiric therapy of lower-risk adults
and children (Grade 1-A).
 Use doripenem for empiric therapy of adults (Grade 1-
A), but reserve this agent primarily for higher-risk pa-
tients because of its broader-spectrum antimicrobial
activity (Grade 2-C). Do not use doripenem for empiric
therapy of children unless no other options are avail-
able (Grade 1-C).
 Use imipenem-cilastatin or meropenem for the empiric
therapy of adults and children (Grade 1-A), but reserve
these agents primarily for higher-risk patients be-
cause of their broader-spectrum antimicrobial activity
(Grade 2-C).
G. Fluoroquinolones and fluoroquinolone-based regimens
 Use moxifloxacin for empiric therapy of lower-risk
adults, but use with caution in areas where there is a
high incidence of fluoroquinolone-resistant Escherichia
coli (Grade 1-A). Do not use moxifloxacin for the
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empiric treatment of children unless no other options
are available (Grade 1-C).
 Use ciprofloxacin plus metronidazole for empiric
therapy of lower-risk adults with CA-IAI, but use with
caution in areas where there is a high incidence of
fluoroquinolone-resistant E. coli (Grade 1-A). Consider
use of the regimen for empiric therapy of lower-risk
children if other options are not suitable (Grade 2-B).
 Consider use of levofloxacin plus metronidazole as an
option for empiric therapy of lower-risk adults, if use of
a fluoroquinolone is warranted and it is the only
fluoroquinolone available (Grade 2-C). Consider use of
this regimen for empiric therapy of lower-risk children
if other options are not suitable (Grade 2-C).
H. Tigecycline
 Do not use tigecycline for empiric therapy under most
circumstances (Grade 1-B). Consider use of this agent
for therapy of adult patients with resistant pathogens,
particularly as a component of a combination regimen,
if other agents are not suitable (Grade 2-B).
I. Anti-anaerobic agents
 Use metronidazole as the preferred anti-anaerobic agent
in combination regimens for empiric therapy in adults
and children (Grade 1-B).
 Do not use clindamycin as an anti-anaerobic agent in
combination regimens for the empiric treatment in
adults and children unless metronidazole cannot be
used (Grade 2-B). Consider use of clindamycin in
children under one month of age (Grade 2-C).
J. Anti-enterococcal and anti-staphylococcal agents
 Consider use of ampicillin for empiric or pathogen-
directed therapy of susceptible enterococcal strains in
higher-risk adults and children (Grade 2-B).
 Consider use of vancomycin for empiric or pathogen-
directed therapy of vancomycin-susceptible Enterococcus
faecium or methicillin-resistant Staphylococcus aureus
(MRSA) in higher risk adults and children (Grade 2-B).
Include vancomycin in aztreonam-based regimen for
coverage of gram-positive organisms (Grade 2-B).
 Consider use of linezolid or daptomycin for empiric
or pathogen-directed therapy of infections from
vancomycin-resistant Enterococcus spp. (VRE) and as
an alternative to vancomycin for infections from
MRSA in adults and children (Grade 2-B).
K. Antifungal agents
 Do not use amphotericin B or its lipid formulations
routinely for empiric or pathogen-directed management
of intra-abdominal candidiasis in adults or children
(Grade 2-B).
 Consider use of fluconazole for preemptive and for
pathogen-directed therapy of susceptible strains of
Candida albicans in non-critically ill adults and chil-
dren (Grade 2-B).
 Consider use of voriconazole for empiric or pathogen-
directed therapy of fluconazole–non-susceptible strains
of Candida in non-critically ill adults and in children
older than one month of age (Grade 2-B).
 Use an echinocandin (anidulafungin, caspofungin, or
micafungin) for empiric or pathogen-directed treatment
of infections from Candida spp. in severely ill adults
and children (Grade 1-B).
5. Oral antimicrobial agents
Substitution of oral for IV antibiotic agents in patients with
IAI may be considered under selected circumstances. Spe-
cific recommendations are:
 Use selected oral agents with good bioavailability as a
substitute for IV agents for therapy of patients with
return of adequate gastrointestinal function. Use oral
antibiotics only to complete a short course of treatment
and not to prolong antimicrobial use beyond current
recommendations (Grade 1-B).
 Consider use of oral amoxicillin-clavulanic acid as an
option to complete a short course of antimicrobial
therapy in adults and children (Grade 2-B).
 Consider use of oral moxifloxacin as an option to
complete a short course of antimicrobial therapy in
adults (Grade 2-B). Do not use oral moxifloxacin in
children unless no other option is available (Grade
1-B).
 Use oral ciprofloxacin plus metronidazole to complete
a short course of antimicrobial therapy in adults
(Grade 1-B). Consider use of oral ciprofloxacin plus
metronidazole to complete a short course of antimi-
crobial therapy in children if other options are not
suitable (Grade 2-B).
 Consider use of oral levofloxacin plus metronidazole, an
oral first-, second-, or third-generation cephalosporin plus
metronidazole, or oral trimethoprim-sulfamethoxazole
plus metronidazole as potential options to complete a
short course of antibiotic therapy in adults and children if
other oral agents are not suitable (Grade 2-C).
6. Selection of empiric antimicrobial therapy for adult
patients with CA-IAI
The selection of specific empiric IV antimicrobial therapy
for the treatment of patients with CA-IAI should be based on
principles of antimicrobial stewardship, using broader-
spectrum agents primarily for seriously ill patients. Specific
recommendations are:
A. Lower-risk patients with CA-IAI
 Treat lower-risk patients with narrower-spectrum anti-
microbial agents having activity against the usual
gram-negative Enterobacteriaceae, aerobic strepto-
cocci, and obligate anaerobic micro-organisms associated
with these infections (Grade 1-A). Do not routinely use
broader-spectrum or additional agents to provide anti-
pseudomonal, anti-enterococcal coverage (Grade 1-A), or
antifungal therapy (Grade 2-B).
 Use cefotaxime or ceftriaxone plus metronidazole or
ertapenem as the preferred agents for initial empiric
therapy of lower-risk patients (Grade 1-A). Consider
use of cefuroxime plus metronidazole or cefoperazone-
sulbactam, where available, as alternatives (Grade 2-
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B). Use ciprofloxacin plus metronidazole or moxi-
floxacin monotherapy for patients who have serious b-
lactam allergies (Grade 1-A). Consider use of levo-
floxacin plus metronidazole as an alternative if no other
fluoroquinolone is available (Grade 2-C).
 Use agents recommended for lower-risk patients with
perforated appendicitis, unless they meet criteria as
higher-risk patients or at risk for having resistant
pathogens (Grade 1-A).
B. Higher-risk patients with CA-IAI
 Treat higher-risk patients with broader-spectrum em-
piric antimicrobial agents to ensure coverage of less
common gram-negative pathogens potentially involved
in these infections (Grade 2-C).
 Use piperacillin-tazobactam, doripenem, imipenem-
cilastatin, meropenem, or cefepime plus metronidazole
as the preferred agents for initial empiric therapy of
higher-risk patients (Grade 2-A). Consider use of
ceftazidime plus metronidazole as an alternative regi-
men for these patients (Grade 2-B). Consider use of
aztreonam plus metronidazole plus vancomycin as an
option for higher-risk patients with a severe reaction to
b-lactam agents (Grade 2-B). Do not add an adjunc-
tive aminoglycoside or fluoroquinolone to a b-lactam
agent for empiric treatment of higher-risk patients
(Grade 1-B).
 Consider use of added ampicillin or vancomycin for
empiric anti-enterococcal treatment in higher-risk pa-
tients if the patient is not being treated with piperacillin-
tazobactam or imipenem-cilastatin (Grade 2-B).
 Do not use antifungal agents routinely for empiric therapy
of higher-risk patients (Grade 1-B). Consider use of an-
tifungal agents for empiric therapy of critically ill patients
with an upper gastrointestinal source (Grade 2-B).
C. Other considerations for empiric antimicrobial therapy
of patients with CA-IAI
 Consider use of fluoroquinolone-based regimens for
initial empiric therapy of lower-risk patients who have
major reactions to b-lactam antibiotics (Grade 2-B).
Consider use of an aztreonam-based regimen for initial
empiric therapy of higher-risk patients who have major
reactions to b-lactam antibiotics (Grade 2-B). Consider
use of a non-penicillin b-lactam for empiric therapy of
patients for whom a severe penicillin allergy has not
been documented and for whom the risk-benefit ratio is
believed acceptable (Grade 2-B).
 Donot use cephalosporin-, aztreonam-, or fluoroquinolone-
based regimens for empiric therapy of patients who
reside in geographic areas where there is a high prev-
alence of extended-spectrum b-lactamase (ESBL)-
producing Enterobacteriaceae in the community (Grade
1-B). Use ertapenem for empiric therapy in lower-risk
patients or a broad-spectrum carbapenem for higher-
risk patients who reside in such areas (Grade 1-B).
 Consider use of locally available IV or oral agents
having activity against common intra-abdominal path-
ogens for empiric therapy in patients who reside in
geographic areas where there are major resource limi-
tations (Grade 2-C).
7. Selection of empiric antimicrobial therapy for adult
patients with HA-IAI
Because patients with HA-IAI are at risk for infection from
resistant organisms, additional antimicrobial agents may
lessen the risk of inadequate initial therapy and subsequent
treatment failure. The recommendations include:
A. General approach
 Assess patients with respect to their separate risks of
infection from Enterococcus spp., MRSA, resistant
gram-negative bacilli, and Candida spp. (Grade 2-B).
 Use the broader-spectrum agents recommended for
higher-risk patients with CA-IAI for initial empiric
therapy of patients with HA-IAI. Consider addition of
other empiric agents based on the patient’s risk for an
infection from Enterococcus spp., MRSA, resistant
gram-negative bacilli, and Candida spp. (Grade 2-B).
B. Anti-enterococcal therapy
 Identify patients with HA-IAI who have post-operative
infections, recent exposure to broad-spectrum antimi-
crobial therapy, signs of severe sepsis or septic shock,
or known to be colonized with VRE as at risk for in-
fection with Enterococcus spp. (Grade 2-B).
 Consider use of vancomycin or teicoplanin for empiric
therapy of HA-IAI in patients at risk for infection from
Enterococcus spp. Consider use of linezolid or daptomy-
cin for empiric therapy of patients known to be colonized
with or at high risk for infection with VRE (Grade 2-B).
C. Anti-staphylococcal therapy
 Identify patients with HA-IAI with multiple healthcare-
associated risk factors for MRSA colonization, including
advanced age, co-morbid medical conditions, previous
hospitalization or surgery, and significant recent expo-
sure to antibiotic agents, or known to be colonized with
MRSA at risk for infection due to MRSA (Grade 2-B).
 Consider use of vancomycin or teicoplanin, where
available, or linezolid or daptomycin as alternatives, for
empiric therapy of patients known to be colonized or at
high risk for infection with MRSA (Grade 2-B).
D. Antibacterial therapy for resistant gram-negative
organisms
 Identify patients who have received substantial previ-
ous broad-spectrum antimicrobial therapy, had pro-
longed hospitalizations, undergone multiple invasive
interventions, or known to have been colonized or in-
fected with a resistant gram-negative organism at risk for
infection from a resistant gram-negative pathogen (Grade
2-B). Consult local epidemiologic data and antibiograms
for assistance in selecting empiric antimicrobial therapy
in patients considered at risk for infection with resistant
gram-negative pathogens (Grade 2-B).
 Consider use of a broad-spectrum carbapenem, or
ceftolozane-tazobactam or ceftazidime-avibactam as
alternatives, for empiric therapy of patients at risk for
infection with ESBL-producing Enterobacteriaceae
(Grade 2-B).
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 Consider use of a broad-spectrum carbapenem, with
ceftazidime-avibactam as an alternative, for empiric
therapy of patients at risk for infection with Amp C-b-
lactamase–producing Enterobacteriaceae (Grade 2-B).
 Consider use of combinations of a carbapenem or
ceftazidime-avibactam as an alternative, an aminoglyco-
side, a polymyxin, and/or tigecycline for empiric therapy
of patients at risk for infection with carbapenem-resistant
Enterobacteriaceae (Grade 2-B).
 Consider use of combinations of a b-lactam antibiotic,
including ceftolozane-tazobactam, an aminoglycoside,
and/or a polymyxin, for empiric therapy of patients at
risk for infection with multi-drug resistant (MDR)-,
extensively drug resistant (XDR)-, or pandrug resistant
(PDR)-strains of P. aeruginosa (Grade 2-B). Consider
use of combinations of a carbapenem, an aminoglyco-
side, a polymyxin, and/or tigecycline for empiric ther-
apy of patients at risk for infection with MDR-, XDR-,
or PDR-strains of Acinetobacter spp. (Grade 2-B).
E. Antifungal therapy
 Identify patients with HA-IAI because of upper gastro-
intestinal perforations, recurrent bowel perforations,
surgically treated pancreatitis, those who have received
prolonged courses of broad-spectrum antibiotic therapy,
and those who are known to be heavily colonized with
Candida at increased risk for infection from Candida
spp. (Grade 2-B). Consider patients found to have yeast
on a Gram stain of infected peritoneal fluid or tissue as
having an infection with Candida spp. (Grade 2-B).
 Use an echinocandin (anidulafungin, caspofungin, or
micafungin) for empiric therapy of severely ill patients
at risk for infection with Candida spp. (Grade 1-B).
Consider use of fluconazole for antifungal therapy of
less severely ill patients at risk for infection with
Candida spp. (Grade 2-B). Consider use of an echino-
candin or voriconazole for empiric therapy of patients
at risk for infection with a fluconazole-resistant strain
of Candida (Grade 2-B).
8. Timing of antimicrobial therapy
Antimicrobial therapy for patients with IAI needs to be
timed to optimize management of the infection as well as
prevent secondary infections following source control.
 Initiate empiric antimicrobial therapy within one hour,
if possible, once a diagnosis of IAI is made in patients
presenting with sepsis or septic shock (Grade 2-B).
Initiate antimicrobial therapy as soon as feasible in
other patients with IAI, taking into account plans for
subsequent source control (Grade 2-C).
 Re-administer an antimicrobial agent within one hour
before the start of a source control procedure if two
half-lives of the agent have passed at the time the in-
tervention is initiated (Grade 1-B).
9. Dosing of antimicrobial agents in adult patients
Antimicrobial dosing in adult patients with IAI should be
optimized based on the patient’s physiologic conditions and
co-morbidities. Specific recommendations related to anti-
microbial dosing and administration include:
 Use standard dosages of antimicrobial agents for lower-
risk patients who are not severely obese and who do not
have substantial renal or hepatic impairment (Grade 1-
B). Consider use of higher dosages of antimicrobial
agents in selected higher-risk patients (Grade 2-B).
 Use adjusted dosages of antimicrobial agents, based on
available clinical outcome data, standard pharmacoki-
netic parameters, and therapeutic drug monitoring,
where applicable, in patients with significant renal
impairment (Grade 2-B).
 Use adjusted dosages of selected, hepatically elimi-
nated or metabolized antimicrobial agents in patients
with substantial hepatic impairment (Grade 2-B).
 Consider use of adjusted dosages of selected antimi-
crobial agents, based on available clinical outcome data
and pharmacokinetic parameters, in obese patients
(Grade 2-B).
 Do not use prolonged or continuous infusion of b-
lactam antibiotic agents routinely in all patients, but
consider use of these approaches as options in critically
ill patients and those at risk for infection with resistant
gram-negative pathogens (Grade 2-B).
10. Duration of antimicrobial therapy
The duration of antimicrobial therapy in the patient with
IAI needs to be specific for each clinical condition. Specific
recommendations include:
 Do not use antibiotic agents to prevent infection in
patients with severe or necrotizing pancreatitis (Grade
1-B).
 Consider deferral of antibiotic therapy in lower-risk
patients with uncomplicated acute colonic diverticulitis
(Grade 2-B).
 Limit antimicrobial therapy to no more than 24 hours in
patients with traumatic bowel perforations operated on
within 12 hours (Grade 1-A), patients with gastroduo-
denal perforations operated on within 24 hours (Grade
1-C), patients with acute or gangrenous appendicitis in
the absence of perforation (Grade 1-A), patients with
acute or gangrenous cholecystitis in the absence of
perforation (Grade 1-A), and patients with ischemic,
non-perforated bowel (Grade 1-C).
 Limit antimicrobial therapy to four days (96 h) in
patients who have had adequate source control (Grade
1-A).
 Consider limiting antimicrobial to 5–7 days in patients
with established IAI in whom a definitive source con-
trol procedure is not performed. Consider use of clini-
cal parameters of fever, leukocytosis, and adequacy of
gastrointestinal function to determine whether antimi-
crobial therapy can be discontinued sooner. Re-assess
patients who do not respond fully to antimicrobial
therapy within 5–7 days for a potential source control
intervention (Grade 2-C).
 Consider limiting antimicrobial therapy to seven days
in patients with secondary bacteremia because of IAI,
who have undergone adequate source control and are
no longer bacteremic (Grade 2-B).
 There are insufficient data to evaluate duration of therapy
in patients receiving immunosuppressive medications (no
recommendation).
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11. Pathogen-directed antimicrobial therapy
Changing antimicrobial therapy based on culture results
should be considered in selected patients. Specific recom-
mendations include:
 Do not change antimicrobial therapy on the basis of
culture results in lower-risk patients who have had a
satisfactory clinical response to source control and
empiric therapy (Grade 1-B).
 Consider modification of antimicrobial therapy in
higher-risk patients if culture results identify organisms
resistant to the initial empiric regimen and further an-
timicrobial therapy is planned (Grade 2-C).
 There are insufficient data to make a recommendation
regarding modification of antimicrobial therapy in pa-
tients who have a highly resistant organism isolated as
a minor component of a mixed peritoneal culture (no
recommendation).
 Routinely de-escalate or streamline antimicrobial therapy
in higher-risk patients to the narrowest-spectrum agent or
agents having activity against the isolatedmicro-organisms
once definitive culture results are available (Grade 1-B).
12. Treatment failure
Treatment of patients who fail initial therapy follows the
same principles used in initial management of IAI. Specific
recommendations include:
A. Source control for treatment failure
 Use measures of ongoing or progressive systemic in-
flammation or organ system dysfunction to identify
patients with likely source control failure (Grade 1-B).
 Assess patients for source control failure if there is
progressive organ dysfunction within the first 24–
48 hours after source control, if there is no clinical im-
provement in organ dysfunction 48 hours or more after
source control, or if there are persistent signs of in-
flammation 5–7 days after source control (Grade 2-C).
 Consider abdominal exploration in patients who deteri-
orate clinically or fail to improve within 48–72 hours of
the initial procedure (Grade 2-C). Use computed to-
mography scanning, with percutaneous aspiration or
drainage of any potentially infected fluid collections, in
patients suspected of treatment failure after 48–72 hours
of the initial source control procedure (Grade 1-B).
 Use the least invasive approach that will achieve de-
finitive source control or sufficiently control the in-
fection to allow resolution of the inflammatory
response and organ dysfunction (Grade 1-B).
 Undertake further source control within 24 hours when
source control failure is identified (Grade 2-C), but as
soon as feasible in patients with physiologic instability
or progressive organ dysfunction (Grade 2-B).
 Obtain routine peritoneal cultures in patients with
source control failure so that pathogen-directed anti-
microbial therapy can be utilized (Grade 1-C).
B. Antimicrobial therapy for treatment failure
 Do not routinely change antimicrobial therapy when
patients have early treatment failure and undergo repeat
source control within 48 hours of the initial source
control intervention (Grade 2-C). Consider altering
antimicrobial therapy, using an alternative antibiotic
class if feasible, in patients who have late treatment
failure (Grade 2-C).
 Consider discontinuation of antimicrobial therapy in
patients with clinical evidence of treatment failure but
negative results of imaging studies for recurrent or
persistent IAI (Grade 2-B).
 Consider a trial of further antimicrobial therapy in
patients with clinical evidence of treatment failure and
imaging studies showing ongoing intra-abdominal
inflammation; if there is no clinical response to this
antimicrobial trial within a few days, discontinue
antimicrobial therapy and re-instate only if there is
evidence of clinical deterioration (Grade 2-C).
 Consider continuation of antimicrobial therapy in pa-
tients with clinical evidence of treatment failure and
imaging studies showing recurrent or persistent IAI, in
whom further source control cannot be achieved; dis-
continue antimicrobial therapy when clinical signs of
systemic inflammation or organ dysfunction abate
(Grade 2-C). Monitor these patients for resistant path-
ogens, adjusting antimicrobial therapy as necessary
(Grade 2-C).
13. Treatment of pediatric IAI
Management of IAI in pediatric patients with IAI follows
the same general principles as treatment of adult patients.
Specific recommendations on treatment of pediatric patients
with IAI include:
 Use cefotaxime or ceftriaxone plus metronidazole or
ertapenem as preferred agents for empiric therapy of
lower-risk pediatric patients greater than one month of
age (45wks post-conceptional age, Grade 1-A). Consider
use of cefuroxime plus metronidazole or cefoperazone-
sulbactam, where available, as alternatives (Grade 2-B).
Consider use of ciprofloxacin plus metronidazole, or le-
vofloxacin plusmetronidazole if no other fluoroquinolone
is available, for empiric treatment of selected pediatric
patients if other agents cannot be used, particularly for
those patients with life-threatening b-lactam reactions
(Grade 2-B).
 Use piperacillin-tazobactam, imipenem-cilastatin, or
meropenem as the preferred agents for empiric therapy
of higher-risk pediatric patients greater than one month
of age (45wks post-conceptional age) with CA-IAI
(Grade 2-A) or with HA-IAI (Grade 2-B). Consider use
of ceftazidime or cefepime plus metronidazole as al-
ternatives (Grade 2-B). Consider use of aztreonam plus
metronidazole plus vancomycin as an option if other
agents cannot be used, particularly for those with life-
threatening b-lactam reactions (Grade 2-B). Consider
addition of ampicillin or vancomycin as empiric anti-
enterococcal therapy of higher-risk patients if the pa-
tient is not being treated with piperacillin-tazobactam
or imipenem-cilastatin (Grade 2-B).
 Limit antimicrobial therapy to five days (120 h) in pe-
diatric patients older than one month (45wks post-
conceptional age) who have had adequate source con-
trol (Grade 1-A).
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 Use oral antimicrobial agents with good bioavailability
to complete a five-day course of therapy in patients
with adequate source control when feasible, but do not
use oral antimicrobial agents to extend total antimi-
crobial duration beyond five days (Grade 1-B).
 Do not use additional outpatient IV antimicrobial
therapy in patients with adequate source control unless
administered to complete a total antimicrobial course of
five days (Grade 1-B).
 Treat pediatric patients with failure of treatment in an
analogous fashion to adult patients with treatment
failure (Grade 1-C). Use the least invasive means of
providing adequate source control and a standard
course of IV antibiotic agents, preferably with a change
in the antibiotic class, to treat these patients (Grade 2-
C). Do not extend a course of IV antibiotic agents be-
yond seven days in children with perforated appendi-
citis who have a post-operative abscess (Grade 1-C).
 Employ either laparotomy or peritoneal drainage as
source control in addition to antimicrobial therapy for
pediatric patients less than one month of age (45wks
post-conceptional age) with necrotizing enterocolitis or
intestinal perforation (Grade 1-A).
 Use ampicillin, gentamicin, and either metronidazole
or clindamycin; ampicillin, cefotaxime, and either
metronidazole or clindamycin; or meropenem in
pediatric patients less than one month of age (45 wks
post-conceptional age). Consider use of vancomycin
instead of ampicillin if there is suspected infec-
tion with penicillin-resistant Enterococcus spp. or
MRSA. Consider use of fluconazole or amphotericin
B if there is a suspected infection with Candida
spp. (Grade 2-C).
 Use a 7–10 day course of antimicrobial therapy in
pediatric patients less than one month of age (45 wks
post-conceptional age), particularly for those with
necrotizing enterocolitis (Grade 2-C).
 Use standard pediatric dosages for various antimicro-
bial agents for lower-risk pediatric patients with CA-
IAI (Grade 1-B). Consider use of higher pediatric
dosages, where applicable, for higher-risk patients with
CA-IAI and those with HA-IAI (Grade 2-C).
Intra-abdominal infection (IAI) is a common diseaseprocess managed primarily by surgical practitioners. It is
associated with substantial morbidity and death, despite thera-
peutic advances made over the past decades. Key components
of the management of these infections include expeditious di-
agnosis, early resuscitation of the patient, timely and appropriate
source control, and adequate antimicrobial therapy directed
against the micro-organisms involved in the infection.
The Surgical Infection Society (SIS) has released various
evidence-based guidelines for the management of these in-
fections. The initial guideline developed by the Antimicrobial
Agents Committee (now the Therapeutics and Guidelines
Committee) was published in 1992 [1]. A subsequent revision
based on published evidence through early 2001was published
in 2002 [2]. Accompanying this publication was a compilation
of the evidence used to develop the recommendations [3].
These initial guidelines focused primarily on appropriate an-
timicrobial therapy for these infections. Subsequently, in 2010,
amore comprehensive documentwritten jointly by the SIS and
the Infectious Diseases Society of America (IDSA) was pub-
lished, which included some recommendations regarding di-
agnosis, initial resuscitation, and source control for these
infections, as well as treatment of children with IAI [4]. This
guideline revised both the 2002 SIS guideline and a similar
guideline published by the IDSA in 2003 [5].
Since the 2010 guideline, additional challenges have arisen
in the management of these infections. With the advancing
age and increased burden of chronic disease in the popula-
tion, IAI is being diagnosed more commonly and managed in
patients with impaired host defenses and limited physiologic
reserves. In addition, the prevalence of resistant bacteria and
fungi has been growing worldwide, with resistant micro-
organisms identified not only in patients whose infections
arise in the healthcare setting, but also in patients in whom
their infections develop in the community. This has led to
declining efficacy of some antimicrobial agents traditionally
used to treat these patients.
Nonetheless, advances have been made in the management
of IAI as well. An increasingly standardized and successful
approach to the resuscitation of patients with sepsis, includ-
ing those with IAI, has been provided through the various
iterations of the Surviving Sepsis Campaign guidelines [6].
More targeted and less morbid techniques for achieving
source control are being increasingly used in patients with
IAI. Finally, a few newer antimicrobial agents are now
available that have activity against some resistant pathogens,
although the problem of resistance remains a major problem
for managing nearly any type of infection.
This revision of the 2010 guideline was undertaken by a
task force from the SIS including members of the Ther-
apeutics and Guidelines Committee as well as additional
individuals with expertise in the subject. Because the previ-
ous guideline did not include an in-depth evidence review,
the task force elected to review not only the literature related
to management of IAI published since dissemination of the
2010 guideline, but to also re-analyze the literature published
between 2001 and 2008 that had been used in part for the
previous revision. The guideline was also constructed in a
manner such that it might be amenable for use in an algo-
rithmic format for treating patients with IAI.
Previous guidelines have used various approaches to
grading the quality of evidence and the strength of the
recommendations. Increasingly, the GRADE (Grades of
Recommendation Assessment, Development, and Evalua-
tion) nomenclature has been used for guideline develop-
ment. The GRADE approach calls for a clearly transparent
methodology to guideline development. It also separates
issues related to the quality of the evidence from the
overall strength and importance of the recommendation.
Evidence is characterized according to the quality of the
study design and its execution, but also considers problems
of consistency, directness, and potential bias in grading
quality [7]. The recommendations themselves are strongly
influenced by the quality of the evidence behind them, but
also take into consideration the balance between desirable
and undesirable effects, values and preferences in different
settings, and the resources needed to fully implement the
recommendation [8].
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The current guideline uses this basic approach to grading the
evidence and the resultant recommendations, as summarized
in Tables 1 and 2. Because of the limited quantity of meth-
odologically rigorous studies investigating key questions in
the management of IAI, the task force did not undertake a
detailed statistical analysis for most of these recommenda-
tions, but relied on a process of iterative consensus among task
force members to develop the recommendations and their final
grading.
Methods
The task force undertook a formalized process of guideline
development and review, which is outlined here. This process
was based on that outlined by the GRADEWorking Group [9].
The initial selection of the task force chair and working
group leaders was made by the Executive Council of the SIS.
These individuals then named additional SIS members
identified as content experts in the management of IAI to the
task force, supplemented by the members from the Ther-
apeutics and Guidelines Committee with an interest in the
topic. An initial series of teleconferences and one face-to-
face meeting were held in 2014 and 2015, but much of the
initial and subsequent work was done via electronic mail.
Members of the task force first agreed on the scope of the
guideline and developed an outline of a series of topics for
review (Table 3). Working groups then developed specific
questions to be addressed under each of these topics, which
were supplemented by additional suggestions from members
of the task force. These questions were then refined by iter-
ative review until a consensus was achieved on the specific
questions that would be investigated.
Evidence was then collected to investigate these questions.
The primary tactic employed was a systematic search of the
Medline database using various strategies in an effort to
identify all literature related to IAI published between 2007 and
mid-2014. Abstracts ofmore than 8,000 articles were subjected
to a first review by task force members to identify articles
relevant to the current revision. These publications were
combined with literature published between 2000 and 2007,
which had been selected from a similar search of the Medline
database performed for preparation of the previous guideline.
Secondary searches were performed to supplement the
primary search when evidence was found to be lacking for
examination of a specific question. The focus of such search-
es was prevention or management of infections other than
IAI, and identification of side effects or complications related
to specific antimicrobial agents or therapeutic approaches. In
addition, literature relevant to the topic was identified during
systematic evaluations of review articles for pertinent refer-
ences, including those published as part of the Cochrane
Database of Systematic Reviews [10].
Table 1. Class of Evidence
A High quality
evidence
The evidence was primarily obtained from RCTs, meta-analyses of such trials,
or methodologically sound epidemiologic studies. If the preponderance of evidence
is based on studies that do not directly address the question being posed, the overall
grade is downgraded to B or C. If there are conflicts in Class A data, the evidence grade
is lowered to B or C, depending on the degree of conflict.
B Moderate
quality
evidence
The evidence was obtained from lower quality prospective studies, retrospective case
control studies, and large observational, cohort, or prevalence studies, and was based
on clearly reliable data. If there are significant conflicts in Class B data, the evidence
grade is lowered to C.
C Weak quality
evidence
The evidence was obtained from smaller observational studies, studies relying on retrospective
or less reliable data, authoritative opinions expressed in reviews, or expert opinions
of task force members.
None Insufficient
evidence
There was little or no relevant evidence to address a question, or the evidence reviewed
was highly conflicting.
RCT = randomized controlled trial.
Table 2. Rating Scale for Recommendations
1 Strong
recommendation
The task force concluded that the intervention is a desirable approach for the care of those
patients to whom the question applies. This rating is generally based on moderate to
high quality evidence. The conclusion is unlikely to be changed with future research.
The magnitude of the effect is also sufficient to justify the recommendation. A strong
recommendation was also used to describe interventions that are likely to have a
significant effect on patient outcome, even if based on weak evidence. These
recommendations are prefaced as ‘‘We recommend .’’.
2 Weak
recommendation
The task force concluded that the intervention is a reasonable approach for the care
of patients. Not all patients and clinicians, however, would necessarily want to follow
the recommendation. A decision not to follow the recommendation is unlikely to result
in a major adverse outcome. This rating was generally based on weak to moderate quality
evidence. Both the magnitude of the treatment effect and its direction might be altered
by future research. These recommendations are prefaced as ‘‘We suggest .’’.
None No
recommendation
The evidence was considered inadequate or too inconsistent to allow any meaningful
conclusion to be reached.
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Before final review of the guideline, an additional com-
prehensive Medline search was performed to uncover relevant
articles published between 2014 and early 2016 that had not
been already identified during the previous or supplementary
searches. Selected publications from before 2000 were added
to the database when necessary. The final literature database
included 778 articles identified during the primary screening
process, 565 identified via secondary and supplementary
searches, and 89 identified in the final search of themost recent
literature.
The literature database was screened for randomized
controlled trials (RCTs) related to use of antimicrobial ther-
apies for treatment of patients with IAI published between
2000 and 2016. These trials underwent formal review; studies
that enrolled patients with multiple types of infections were
reviewed if outcomes in patients with IAI were reported
separately from the outcomes of all patients with infections.
The RCTs related to surgical or other interventional ap-
proaches were selected for formal review only if they related
to strategies for treating patients with IAI. The task force
elected not to study questions related to technical aspects of
managing specific disease entities, such as studies comparing
laparoscopic versus open approaches for acute appendicitis.
The RCTs were reviewed by at least two members of the
task force, using the criteria employed during the previous
evidence review [3]. The primary end point assessed was
clinical cure in the clinically evaluable population at the time
point (generally a test of cure visit) specified by the specific
trial design; where available, clinical cure in the modified
intent-to-treat population (those receiving at least one dose of
study drug) was also used. Severity of illness in the study
populations was gauged by overall death, the percentage of
patients having an appendiceal source of infection, and Acute
Physiology and Chronic Health Evaluation II (APACHE II)
scores, where reported. Quality was graded on a scale of 0–5
based on adequacy of randomization, blinding, and descrip-
tion of patients excluded from the study, according to the
system of Jadad et al. [11]. Quality was also assessed based
on whether or not patients enrolled in the trial met the criteria
for complicated IAI, as specified by IDSA criteria [12].
Discrepancies between the two reviewers were resolved by a
third reviewer.
Working groups were obligated to use the data from all
relevant RCTs when formulating recommendations for spe-
cific questions. These data were evaluated according to
GRADE criteria for precision, directness, consistency, and
risk of bias [7], but formal GRADE tables were not prepared.
This assessment was incorporated into the final evidence
grade applied to each recommendation (Table 2).
Data from RCTs were available for only a small fraction of
questions developed by the subgroups. Thus, heavy reliance
was placed on data from other types of studies to formulate
many recommendations. Working groups used selected pub-
lications from the literature database for these questions, with
the choice of specific references being based on the perceived
quality and relevance of the study to the question at hand.
Because no generally accepted system exists for evaluating
quality of these studies, they were not objectively graded.
Summaries of RCTs and selected additional literature perti-
nent to treatment of IAI are provided in the Supplementary
Tables, which are available on the Surgical Infections website
(www.liebertpub.com/overview/surgical-infections/53/).
Based on these literature reviews, individual working
groups drafted and graded provisional recommendations. The
GRADE criteria of quality of evidence, balance between
desirable and undesirable effects, values and preferences, and
resource allocation [8] were used for this, emphasizing the
first two criteria (Table 3). The entire task force repeatedly
reviewed and refined these recommendations until a final
consensus was achieved.
The guideline was then submitted to independent review-
ers from the SIS who were not members of the task force. The
task force responded to these critiques by either modifying
the specific recommendation or leaving it unchanged, pro-
viding a detailed rationale for its decision. After a final vote
was taken on all recommendations, the guideline along with
supporting materials was presented to the Executive Council
of the SIS for approval as an official guideline of the SIS.
Documentation regarding individual votes or recusals on
recommendations by task force members as well as minutes
of the SIS Executive Council deliberations are maintained by
the Executive Director of the SIS.
Background
1. Scope of the guideline
Intra-abdominal infection refers to a wide variety of in-
fections encountered in clinical practice. The term, however,
is used generally in the context of disease processes within
the abdominal cavity treated with some type of mechanical
intervention, such as a surgical procedure. It has been tradi-
tional to separate IAI into uncomplicated and complicated
IAI. With some pathologic entities, however, the distinction
between uncomplicated and complicated IAI becomes
somewhat arbitrary, as will be more fully discussed in the
subsequent section.
Past IAI guidelines have focused primarily on complicated
IAI. Although the vast majority of this document emphasizes
treatment of patients with complicated IAI, it also includes
some recommendations relevant to the treatment of patients
with uncomplicated IAI and some non-infectious disease
processes that can lead to IAI. When referring to uncompli-
cated IAI, the guideline will usually describe the specific
disease entity, such as acute appendicitis, acute cholecystitis,
Table 3. Guideline Topics
Risk assessment
Source control
Microbiologic evaluation
Intravenous antimicrobial agents
Oral antimicrobial agents
Selection of empiric antimicrobial therapy for adult patients
with CA-IAI
Selection of empiric antimicrobial therapy for adult patients
with HA-IAI
Timing of antimicrobial therapy
Dosing of antimicrobial agents in adult patients
Duration of antimicrobial therapy
Pathogen-directed antimicrobial therapy
Treatment failure
Management of pediatric IAI
CA-IAI= community-acquired intra-abdominal infection; HA-
IAI= healthcare- or hospital-acquired intra-abdominal infection;
IAI= intra-abdominal infection.
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or uncomplicated diverticulitis, rather than combining these
disparate infections under the term ‘‘uncomplicated IAI.’’
Throughout the document, the term ‘‘IAI’’ should generally
be considered synonymous with the term ‘‘complicated IAI.’’
As with previous guidelines, management of certain dis-
ease entities occurring in the abdomen is not considered in
this guideline, including primary peritonitis, catheter-related
peritonitis, and infections in solid abdominal organs arising
from hematogenous spread. Diseases developing as a result
of transmural enteritis or inflammatory bowel disease, and
diseases primarily involving the genitourinary tract have also
been excluded.
Management of IAI generally involves expeditious diag-
nosis, initial resuscitation of the patient, source control, and
antimicrobial therapy. Diagnosis of IAI is usually undertaken
by other persons, such as emergency medicine physicians or
primary care providers, and may use various approaches,
depending on the actual disease entity being investigated.
The task force elected not to review this subject. Initial re-
suscitation of the patient is frequently the responsibility of a
number of persons, including surgeons as well as emergency
medicine providers, anesthesiologists, and critical care phy-
sicians. Guidance on the care of the patient with sepsis and
septic shock, including patients with IAI, is provided in the
Surviving Sepsis Campaign guideline [6], which is currently
being updated. The reader is referred to that guideline, which
has been endorsed by the SIS, for further information on
this topic.
As emphasized in the Surviving Sepsis Campaign guide-
line, early source control and provision of appropriate em-
piric antimicrobial therapy are key to the survival and
recovery of seriously ill patients with infection, including
those with IAI. The task force has elected to focus on these
issues in this guideline, because these are the aspects of
management most directly under the control of the surgical
practitioner. Source control refers to a large variety of me-
chanical techniques for treating patients with IAI, with a goal
of decreasing the bacterial inoculum and allowing the pa-
tient’s host defenses to control the infection. This guideline
expands the discussion of source control somewhat compared
to the previous guideline. Nonetheless, because of the wide
variety of potential approaches to source control, only gen-
eral concepts of source control are addressed, and interven-
tional therapies for specific disease entities have been left to
be addressed by more focused guidelines. Antimicrobial
therapy is likewise approached from a relatively broad per-
spective. With the advent of increasingly resistant microbial
strains in both the hospital and community environments,
however, the treatment of patients with resistant or oppor-
tunistic micro-organisms has been given further weight. Fi-
nally, although initial treatment using an evidence-based
approach is frequently successful, it fails in approximately
20% of patients. Patients with initial treatment failure are at
increased risk for further adverse outcomes. Thus, treatment
of patients with failure of treatment has been given additional
emphasis in this guideline.
The goal of this document is to provide guidance to cli-
nicians by describing reasonable approaches to the use of
therapeutic modalities. An important consideration stressed
in this guideline is that most management decisions should be
tempered according to an individualized assessment of the
patient, taking into account not only the risk of the specific
interventions being contemplated, but also the likelihood of a
poor outcome if inadequate therapeutic efforts are employed.
It is also important to recognize, however, that collective
decisions on the use of these modalities have impacts on the
healthcare system and the overall population as well. For
instance, widespread use of expensive imaging or therapeutic
equipment, particularly in areas of substantial resource limi-
tations, may limit the opportunity to use other therapies of
equal or greater value to the community. Hence, the task force
has attempted to take into account the cost-effectiveness of
certain interventions in its recommendations. Further, with
regard to antimicrobial therapy, overuse of antimicrobial re-
sources leads to the development of microbial resistance and
loss of effective anti-infective agents for all. The principles of
antimicrobial stewardship have therefore been stressed
throughout this document.
2. Definitions
Much of the published literature regarding management of
IAI uses the concept of uncomplicated and complicated IAI.
Traditionally, infections limited to a hollow viscus were
called uncomplicated IAI, whereas those that extended into a
normally sterile area of the abdomen, such as the peritoneal
cavity, mesentery, retroperitoneum, another abdominal or-
gan, or the abdominal wall, were defined as complicated IAI
[4,13]. Nonetheless, there are borderline conditions, such as
localized colonic diverticulitis, which may be difficult to
categorize as a complicated or uncomplicated IAI. Compli-
cated IAI have also traditionally been described as those
disorders managed with a source control procedure; in part,
this has been to satisfy the requirements of regulatory bodies,
such as the United States Food and Drug Administration
(FDA), which require that microbiologic cultures be obtained
for approval of anti-infectives for complicated IAI. None-
theless, there are conditions, such as a peri-appendiceal
phlegmon, which are clearly a complicated IAI, but may be
managed without a source control procedure and microbio-
logic analysis.
Patients with complicated IAI may be characterized as
manifesting secondary or tertiary peritonitis, single or multiple
intra-abdominal abscesses, or an intra-abdominal phlegmon.
Secondary peritonitis, arising as a result of perforation of a
hollow viscus, is the most straightforward of these terms
[4,13]. The term secondary peritonitis, however, does not al-
ways imply an infection, because peritoneal inflammationmay
be the result of chemical irritation in the absence of an overt
infection, as may be found in patients with a perforated gas-
troduodenal ulcer. The term also does not convey important
information about the extent of the infection—i.e., whether or
not it is a localized or diffuse process—nor about the chro-
nicity of the infection, both of which may affect prognosis.
There is much less agreement as to what constitutes ter-
tiary peritonitis. One consensus group defined tertiary peri-
tonitis as that which persisted or recurred more than 48 hours
after apparently successful management of secondary peri-
tonitis [14]. Many patients, however, such as those with a
recurrent abscess after initial management of perforated ap-
pendicitis, could be included under this definition. This
would result in a group of patients with a mixed severity of
illness rather than a group of patients generally considered to
be those most seriously ill as a result of IAI. Instead of
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attempting to specifically define tertiary peritonitis, other
authors have developed the concept that there is a continuum
between secondary and tertiary peritonitis; thus, describing
any specific patient as having secondary versus tertiary
peritonitis is somewhat arbitrary, unless the patient is clearly
at one of the extremes of the spectrum [13,15,16]. Given
these variable definitions, it is unlikely that patients described
as having tertiary peritonitis in various publications are
necessarily comparable. Therefore, recommendations have
not been made specifically for patients with tertiary perito-
nitis, but have been included with the recommendations re-
garding the most severely ill patients with IAI.
3. Microbiology of IAI
The microbiology of IAI varies according to source of the
infection and whether or not the patient has been exposed to
the healthcare setting; exposure to previous antimicrobial
therapy may be of particular importance in this regard [17–
19]. The microbiology of community-acquired IAI (CA-IAI)
has been well characterized. These are generally mixed in-
fections involving a number of enteric micro-organisms. The
principal gram-negative micro-organisms cultured from in-
fected abdominal fluid or tissue are Escherichia coli and, to a
much lesser extent, other Enterobacteriaceae such as Kleb-
siella spp. or non-fermenting gram-negative aerobes such as
Pseudomonas aeruginosa. Streptococci, primarily of the
Streptococcus milleri group, are also isolated frequently;
enterococci are identified much less frequently in patients
with CA-IAI. Enteric anaerobes, with Bacteroides spp., B.
fragilis predominating, are also common, although clinical
laboratories frequently do not isolate most of anaerobic
micro-organisms involved in these infections. Anaerobic
micro-organisms are more prevalent for sources of infection
in the distal gastrointestinal tract [18–28].
Although the prevalence of these micro-organisms in CA-
IAI has not changed appreciably over time, susceptibilities of
these pathogens to various antibiotics have changed, partic-
ularly in certain geographic localities. This is particularly
true of Enterobacteriaceae. Globally, there is significant re-
sistance of E. coli to ampicillin-sulbactam, as well as to
fluoroquinolones. Further, the prevalence of extended spec-
trum b-lactamase-producing strains of E. coli and Klebsiella
spp. among patients with IAI has been increasing in Latin
America, Asia, and parts of Europe. These resistant organ-
isms are increasingly being isolated from patients with CA-
IAI, and not just from those with risk factors for healthcare-
associated/hospital-acquired infection (HA-IAI) [28–31].
In patients with HA-IAI, the types of micro-organisms
isolated vary to a much greater extent. Most of the pathogens
isolated are still enteric flora, but other micro-organisms, such
as staphylococci, are also encountered. The incidence of E.
coli as a causative pathogen decreases somewhat, whereas the
incidence of other Enterobacteriaceae, such as Enterobacter
spp., as well as lactose-negative gram-negative bacilli, such as
P. aeruginosa and Acinetobacter spp., have increased.Aerobic
streptococci are found much less commonly, but other gram-
positive micro-organisms, particularly Enterococcus spp.,
become much more prevalent, particularly in the post-
operative setting. Staphylococci, both coagulase-negative
species and Staphylococcus aureus, although still uncommon,
are also identified more frequently in patients with HA-IAI
than those with CA-IAI. The frequency with which anaerobic
micro-organisms are present in these HA-IAI may be some-
what lower than in CA-IAI, although this has been less well
documented. Non-bacterial pathogens, particularly yeast such
as Candida spp., are encountered more frequently in patients
with HA-IAI, particularly if there has been previous exposure
to broad-spectrum antibiotics [22–28].
Resistance of the micro-organisms involved in HA-IAI to
various antimicrobial agents is quite common. This is par-
ticularly notable among patients who received multiple
courses of antimicrobial therapy, who are frequently among
those described as having tertiary peritonitis. Among the
micro-organisms encountered in these patients are various
multi–drug-resistant (MDR) gram-negative pathogens, such
as Pseudomonas spp. and Acinetobacter spp., resistant gram-
positive cocci, including vancomycin-resistant Enterococcus
spp. (VRE) and methicillin-resistant S. aureus (MRSA), and
non-C. albicans spp. [15,32,33].
4. General management of IAI
Once the diagnosis is made, initial management of IAI
includes physiologic stabilization of the patient using intra-
venous (IV) fluid therapy and other modalities where war-
ranted, an appropriate intervention to control the source of the
problem, and early initiation of antimicrobial therapy di-
rected against the likely pathogenic microbial agents [4,34].
Source control and antimicrobial therapy, however, should be
individualized to a given patient based on an assessment of
that patient’s risk for an adverse outcome. This concept of
risk stratification of therapy was introduced in previous
guidelines [3–5]. As will be detailed subsequently, this risk is
influenced by many different factors, some of which may
have greater importance for decisions with regard to specific
source control modalities and others with regard to selection
of antimicrobial therapy [3,35].
After employment of source control and initiation of anti-
microbial therapy, subsequent treatment of the patient with IAI
will be based in large part on that patient’s response to the
therapeutic measures actually employed. Typically, signs and
symptoms of infection will abate in patients responding fa-
vorably to initial treatment. In such patients, further inter-
ventions should be minimized, with early discontinuation of
antimicrobial therapy. In contrast, patients who do not exhibit
resolution of the signs and symptoms of infection within the
first several days of treatment may have an ongoing or recur-
rent IAI, a secondary infection that is potentially the result of
collateral damage from antimicrobial therapy, or a non-
infectious source of inflammation. In such patients, directed
diagnostic and treatment modalities are warranted and not just
an extension or alteration of the current therapeutic regimen.
Recommendations
1. Risk assessment
Q 1.1. What are the important risk factors for treatment
failure and death in patients with IAI?
Q 1.2. How should patient risk be categorized when
making decisions regarding management of IAI, includ-
ing source control and antimicrobial therapy?
Q 1.3. What specific criteria should be used to identify
patients with IAI as being at lower or higher risk for
treatment failure or death?
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Q 1.4. How should patients be identified as having a HA-
IAI or otherwise at risk for an IAI because of resistant or
opportunistic pathogens?
A large number of investigators have used multivariable
analyses to identify factors that predict initial treatment
failure or death in patients with IAI. These publications have
studied distinct patient subsets and used various definitions of
treatment failure [24,26,27,36–74]. Data from individual
studies are summarized in Supplementary Table A (see online
supplementary material at www.liebertpub.com/overview/
surgical-infections/53/).
Not surprisingly, a wide variety of risk factors have been
identified. For clarity, these risk factors have been divided
into (1) those related to patient characteristics and physio-
logic changes associated with the infection, both at the time
of presentation and after initial source control; (2) those re-
lated to the source and extent of the infection itself, as well as
the adequacy and timing of source control; and (3) those
related to the presence or likely presence of resistant patho-
gens, and whether or not initial empiric antimicrobial therapy
had activity against the microbial pathogens eventually iso-
lated. It should be emphasized that assignment of a particular
clinical finding to one of these categories is somewhat arbi-
trary, and the categories certainly overlap to some extent.
This division of risk factors, however, may have some utility
in identifying specific interventions for higher-risk patients.
For example, identifying the patient at risk for treatment
failure because of the extensive nature of the infection within
the abdominal cavity may be relevant to selecting a specific
source control intervention, whereas identifying a patient at
risk for an infection because of a resistant or opportunistic
pathogen may suggest a different approach to antimicrobial
therapy. Risk factors identified in these multivariable ana-
lyses are summarized in Table 4.
In addition to identifying patients as lower or higher risk
according to these criteria, the task force has also chosen to
continue the previous approach of stratifying patients as
having a CA-IAI or an HA-IAI [2,4,5]. This results in a tri-
partite division into lower-risk patients with CA-IAI, higher-
risk patients with CA-IAI, and patients with HA-IAI. This
system then provides a framework for making stratified
recommendations without creating undue complexity.
Lower-risk patients with CA-IAI, such as those with perfo-
rated appendicitis, typically have good outcomes, with very
low deaths and a 10%–20% incidence of treatment failure
[26,75,76] Outcomes in more severely ill, higher-risk pa-
tients with CA-IAI are substantially worse, with higher rates
of mortality, organ system dysfunction, and treatment fail-
ure [27,38,60,77–79]. Patients with HA-IAI represent a
distinct class for purposes of therapeutic recommendations.
Outcomes are somewhat variable, depending on what other
risk factors are present aside from having a HA-IAI, but are
quite poor in a substantial number of these patients
[27,38,50,52,56,58,60,77–79].
Previous guidelines suggested certain characteristics to
guide patient stratification, but these had not been prospec-
tively validated [2,4]. Other attempts have been made to es-
tablish evidence-based scoring systems for stratifying
patients with IAI according to risk [55]; however, thus far, no
system for classifying patients with IAI into different risk
categories has gained widespread acceptance.
Definitions of sepsis, severe sepsis, and septic shock pro-
vided by the Surviving Sepsis Campaign have generally been
well accepted and provide a means of identifying the most
severely ill patients with IAI [6]. These definitions have un-
dergone revision recently, and the term ‘‘severe sepsis’’ has
been dropped. The new definitions of sepsis and septic shock
are thought to correspond to patient groups with an estimated
10% and 40% overall death (Table 5) [80]. Thus, the task
force recommends that patients with IAI meeting the criteria
of severe sepsis or septic shock by the older criteria or of
sepsis or septic shock by the newer criteria be considered
higher-risk patients.
In various studies, APACHE II scores are frequently
identified as the strongest predictors of outcome among all
clinical variables collected [26,27,36,38,40,42–46,48,49–
51,60–62,67,78,79,81]. APACHE II scores reflect both pre-
morbid factors, such as patient age and chronic medical
conditions, and acute changes in clinical and laboratory
values because of physiologic alterations as a result of the
infection. The APACHE II scores, however, require access to
a large number of clinical and laboratory variables, making
them difficult to calculate in an urgent situation; further, they
are subject to inter-rater variability. If these scores are ob-
tained, the task force recommends that patients with a score
greater than or equal to 10 be considered at higher risk, be-
cause treatment failure rates are at least 20%–30% in this
group [45,82].
Many patients with IAI will not meet criteria for sepsis or
septic shock and may not be able to be assessed by APACHE
II scores. Nonetheless, these patients may have a number of
the risk factors for an adverse outcome. Based on the multi-
variable analyses summarized previously, the task force has
recognized advanced age (70 years of age or greater), pres-
ence of malignant disease, major compromise of cardiovas-
cular, hepatic, or renal function, and hypoalbuminemia as
being the most consistently identified physiologic/pheno-
typic risk factors predicting an adverse outcome [26,36–
39,42–44,48–50,55,57,59,61,62,65–67,69]. The task force
has suggested that patients having two or more of these risk
factors be considered higher-risk patients (Table 6).
Other characteristics related to the abdominal infection
itself have also been identified as placing the patient at higher
risk for an adverse outcome. The source of the infection has
not been a consistent predictor of outcome in multivariable
analyses [26,56,59,60,61,63]; the task force does not rec-
ommend taking this into consideration when stratifying pa-
tients for risk. Infections associated with diffuse peritonitis
involving all abdominal quadrants, however, have more
consistently been associated with an adverse outcome
[24,57]. The Mannheim peritonitis index (MPI) includes this
as a component, along with several other factors. Although
infrequently obtained, an elevatedMPI score is also associated
with an adverse outcome [15,44,46,68,69,79,83]. A delay in
source control after IAI is diagnosed [26,49,63] and an inability
to achieve adequate initial source control [37,48,51,61,71,84]
also correlate highly with an adverse outcome. Based on these
findings, the task force has suggested that patients with diffuse
peritonitis, an elevated MPI score (if obtained), and those who
have delayed or inadequate initial source control be considered
higher-risk patients (Table 6).
Patients infected with resistant or opportunistic micro-
organisms have been identified as being at increased risk for
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Table 4. Risk Factors for Adverse Outcomes with Intra-Abdominal Infection
Treatment failure Death
Phenotypic/physiologic risk factors
Present at diagnosis
Age [39,55] Age [26,36,37,40,43,48,49,51,52,59,61,62,65,69]
Younger age [38,57] Malignancy [37,48,61,62]
Male gender [51] Significant cardiac disease [38,62]
Malignancy [67] Significant liver disease/cirrhosis [48,50,61,62]
Peripheral vascular disease [63] Significant renal disease/renal replacement therapy [48,61,62]
Alcohol abuse [63] Unconsciouness [51]
Increased Charlson score [64] Malnutrition [36]
Tachycardia [66] Corticosteroid therapy [40]
Body mass index ‡29 [63] Any medical comorbidity [24]
Elevated white blood cell count [39] Any pre-operative organ impairment [37,44]
Hypoalbuminemia [38,55,66] ASA score ‡3 [68]
Low PaO2/FiO2 ratio [55] ICU admission [26,62]
APACHE II score [38,45,51,67] Temperature [62]
SAPS II score [58] Hypoalbuminemia [38,44]
Hypocholesterolemia [44]
Peak lactate concentration [70]
Peak procalcitonin concentration [70]
APACHE II score [27,36,38,40,43,44,46,48,49,50,61,62]
SAPS II score [58,60]
Severe sepsis/septic shock/vasopressor use [26,43,61]
Sequential (sepsis-related) organ failure assessment
(SOFA) score [74] of 1 or greater [65,68,70]
Any marker of disease severity [24]
Developing after initial source control
Post-operative temperature >39C [57] Decreasing urinary output [72]
Post-operative tachycardia [57] Worsening thrombocytopenia [72,73]
Low post-operative PaO2/FiO2 ratio [57] Worsening hyperbilirubinemia [72]
Low post-operative hemoglobin concentration [57] Worsening Glasgow Coma Scale SOFA score [72]
Elevated post-operative serum sodium concentration [57] Worsening renal SOFA score [72]
MODS scores [59] MOF/MODS scores [50]
Cardiac event [59]
Catheter-related blood stream infection [59]
Infection characteristics
Diffuse peritonitis [57]
Non-appendiceal source [59] Diffuse peritonitis [24]
Presence of bowel ischemia [63] MPI score [44,46,68,69]
Upper GI source [56,61]
Biliary source [60]
Small bowel, colonic source [26]
Non-appendiceal source [58]
Non-colonic source [61]
Source control
Inadequate source control [51] Inadequate source control [37,48,51,61,71]
Delayed source control [63] Delayed source control [26,49]
Laparotomy vs. laparoscopy for source control [58] Laparotomy vs. laparoscopy for source control [58]
No abdominal fascial closure [50]
Any surgical complication [50]
Microbiologic characteristics
Resistant pathogen [39] Growth of Enterococcus spp. in culture [49]
Growth of Enterococcus spp. in culture [58] Candida peritonitis [56,68]
Prolonged hospitalization before source control [45] Growth of resistant pathogens in culture [62]
HA-IAI [67] CA-IAI [27]
Antimicrobial therapy
Inadequate initial antimicrobial therapy [42,53,54] Inadequate initial empiric antimicrobial
therapy [43,58,61, 71]
ASA=American Society of Anesthesiologists; ICU = intensive care unit; APACHE =Acute Physiology and Chronic Health Evaluation;
SAPS II= Simplified Acute Physiology Score II; MOF=multiple organ failure; MODS=multiple organ dysfunction syndrome;
MPI =Mannheim Peritonitis Index; GI = gastrointestinal; HA-IAI = healthcare- or hospital-associated; CA-IAI= community-acquired intra-
abdominal infection.
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Table 5. Surviving Sepsis Campaign Criteria for Sepsis, Severe Sepsis, and Septic Shock
2012 Criteria [8]
Sepsis
Documented or suspected infection plus some of the following:
General variables
Fever (>38.3C)
Hypothermia (core temperature <36C)
Heart rate >90/min or more than two SD above the normal value for age
Tachypnea
Altered mental status
Significant edema or positive fluid balance (>20mL/kg over 24 h)
Hyperglycemia (plasma glucose >140mg/dL or 7.7mmol/L) in the absence of diabetes mellitus
Inflammatory variables
Leukocytosis (WBC count >12,000 mL)
Leukopenia (WBC count <4,000 mL)
Normal WBC count with greater than 10% immature forms
Plasma C-reactive protein more than two SD above the normal value
Plasma procalcitonin more than two SD above the normal value
Hemodynamic variables
Arterial hypotension (SBP <90mm Hg, MAP <70mm Hg, or a SBP decrease >40mm Hg in adults
or less than two SD below normal for age)
Organ dysfunction variables
Arterial hypoxemia (PaO2/FiO2 <300)
Acute oliguria (urine output <0.5mL/kg/h for at least 2 h despite adequate fluid resuscitation)
Creatinine increase >0.5mg/dL or 44.2 mmol/L
Coagulation abnormalities (INR >1.5 or aPTT >60 sec)
Ileus (absent bowel sounds)
Thrombocytopenia (platelet count <100,000mL–1)
Hyperbilirubinemia (plasma total bilirubin >4mg/dL or 70 mmol/L)
Tissue perfusion variables:
Hyperlactatemia (>1mmol/L)
Decreased capillary refill or mottling
Severe sepsis
Sepsis-induced tissue hypoperfusion or organ dysfunction (any of the following thought to be because of the infection):
Sepsis-induced hypotension
Lactate above upper limits laboratory normal
Urine output <0.5mL/kg/h for more than 2 h despite adequate fluid resuscitation
Acute lung injury with PaO2/FiO2 <250 in the absence of pneumonia as infection source
Acute lung injury with PaO2/FiO2 <200 in the presence of pneumonia as infection source
Creatinine >2.0mg/dL (176.8mmol/L)
Bilirubin >2mg/dL (34.2mmol/L)
Platelet count <100,000 mL
Coagulopathy (INR >1.5)
Septic shock
Sepsis-induced hypotension persisting despite adequate fluid resuscitation
2016 Criteria [80]
Sepsis
Documented or suspected infection plus either:
(1) An acute change in the total SOFA score ‡2 points, or
(2) A qSOFA score of ‡2 points, based on at least two of the following suspected to be because of infection:
Respiratory rate ‡22/min
Altered mentation
Systolic blood pressure £100mm Hg
Septic shock
Sepsis with persisting hypotension requiring vasopressors to maintain MAP ‡65mm Hg and having a serum lactate level
>2mmol/L (18mg/dL) despite adequate volume resuscitation.
SD = standard deviation; WBC=white blood cell; SBP = systolic blood pressure; MAP=mean arterial pressure; INR = International
Normalized Ratio; aPTT = activated partial thromboplastin time; SOFA =Sequential Organ Failure Assessment; qSOFA = quick Sequential
Organ Failure Assessment.
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an adverse outcome [24,39,42,43,45,49,58,62,68]. There is a
broad body of evidence that patients with HA-IAI, including
patients with post-operative infections, are at increased risk
for infection with resistant or opportunistic pathogens
[15,17,22–24,26,32,33,62,77,85–90]. Patients who are not
hospitalized, however, may nonetheless be at risk for IAI
because of these micro-organisms. Patients at risk for infec-
tions with resistant or opportunistic pathogens, including IAI,
include those who are known carriers of a resistant organism
[91–106] and those who have had recent exposure to broad-
spectrum antimicrobial therapy [17,19,99,106–123]. The
task force would include such patients in the category of
patients having HA-IAI (Table 7).
Patients exposed to other healthcare settings outside the
hospital may also be at risk of harboring more resistant
pathogens. This concept had been applied to patients with
healthcare-associated pneumonia, but this concept has re-
cently come into question [124]. Risk factors described pre-
viously included hospitalization for greater than 48 hours
within the preceding 90 days, residence in a skilled nursing or
other long-term care facility, and a history of home infusion
therapy, home wound care, or renal replacement therapy
within the preceding 30 days [125]. Unfortunately, there are
little data to determine whether these risk factors identify
patients at risk for IAI because of resistant pathogens. For
now, the task force would suggest classifying these patients
as potentially having HA-IAI, such that a decision whether or
not to direct therapy against resistant pathogens would be
considered.
1.1. We recommend considering phenotypic and physio-
logic factors, including signs of sepsis or septic shock, ex-
tremes of age, and patient co-morbidities; the extent of
abdominal infection and adequacy of initial source control;
and the presence or persistence of resistant or opportunistic
pathogens in assessing risk for treatment failure and death in
patients with IAI (Grade 1-B).
1.2. We suggest that patients be characterized as being at
either lower or higher risk for treatment failure or death and
as having either CA-IAI or HA-IAI (including post-operative
infection) for purposes of planning source control and em-
piric antimicrobial therapy (Grade 2-C).
1.3.We recommend that patients with IAI meeting Surviving
Sepsis Campaign criteria for sepsis or septic shock and those
having an APACHE II score greater than or equal to 10 be
considered higher-risk patients (Grade 1-B). We suggest that
patients having at least two physiologic/phenotypic risk fac-
tors for an adverse outcome, those having diffuse peritonitis,
and those having delayed or inadequate source control also be
considered higher-risk patients (Grade 2-B).
1.4. We suggest that patients who have been hospitalized
for at least 48 hours during the previous 90 days; those re-
siding in a skilled nursing or long-term care facility during
the previous 30 days; those who have received IV infusion
therapy, wound care, or renal replacement therapy within the
preceding 30 days; those who have received several days of
broad-spectrum antimicrobial therapy within the previous
90 days; those who have post-operative infections; and those
known to have been colonized or infected previously with a
resistant pathogen be considered as having HA-IAI and at
risk for infection because of resistant or opportunistic or-
ganisms (Grade 2-B).
2. Source control
Q 2.1. What is the role of source control in the manage-
ment of IAI?
Q 2.2. When should the initial source control procedure
be undertaken?
Q 2.3. What procedures should be used to obtain source
control in patients with IAI?
Q 2.4. What risk factors identify patients with IAI who are
likely to fail initial efforts at source control?
Q 2.5. How should source control be approached in high-
risk patients undergoing laparotomy?
Q 2.6. Should higher-risk patients with severe or diffuse
peritonitis in whom adequate source control is achieved at
the index procedure undergo planned re-laparotomy?
Q 2.7. How should intra-operative lavage be used during
source control?
Source control has been summarized as drainage of infected
fluid collections, debridement of necrotic infected tissue, and
definitive measures to control contamination and restore nor-
mal gastrointestinal anatomy and function [34]. Source control
should not only reduce bacterial and toxin load by removing the
focus of infection and ongoing contamination, but also trans-
form the local environment such that further microbial growth
is impeded and host defenses can be optimized [126–130].
Studies of patients with IAI have demonstrated repeatedly that
a failure to obtain adequate source control is one of the factors
most strongly associated with an adverse outcome, including
death (Supplementary Table B; see online supplementary
Table 6. Factors Potentially Identifying Patients
with Intra-Abdominal Infection at Higher Risk
Phenotypic/physiologic risk factors
Advanced age (‡70 y)
Malignancy
Significant cardiovascular compromise
Significant liver disease or cirrhosis
Significant renal disease
Hypoalbuminemia
Extent of infection/adequacy of initial source control
Diffuse, generalized peritonitis
Elevated MPI score
Delayed initial source control
Inability to achieve adequate source control
Microbiologic characteristics
Suspected infection with resistant pathogens
MPI =Mannheim Peritonitis Index.
Table 7. Criteria for Healthcare- or Hospital-
Acquired Intra-Abdominal Infection
Infection developing greater than 48 h after initial source
control.
Hospitalized for greater than 48 h during current admission
or within the previous 90 d.
Residence in a skilled nursing or other long-term care
facility within the previous 30 d.
Home infusion therapy, home wound care, or dialysis within
the preceding 30 d.
Use of broad-spectrum antimicrobial therapy for 5 d or more
during the preceding 90 d.
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material at www.liebertpub.com/overview/surgical-infections/
53/) [37,48,51,61,71,84]. Thus, even though not definitively
tested using RCTs, the magnitude of the increase in death and
other adverse outcomes associated with inadequate source
control makes it clear that these interventions are of prime
importance in treating most patients with IAI.
Although expeditious source control is the standard of care
for most patients with IAI, certain highly selected patients
with a localized IAI have been treated successfully with anti-
infective therapy alone. Source control has been omitted or
delayed in patients with acute colonic diverticulitis, when the
inflammatory process extends only into the peri-colonic tis-
sues [131,132], in patients with perforated appendicitis and a
peri-appendiceal phlegmon [133–135], in selected patients
with localized upper gastrointestinal perforations [136–138],
and in patients with relatively small diverticular or peri-
appendiceal abscesses (generally less than 3–4 cm in diam-
eter) [131,132,139–142].
There are also some patients for whom a more delayed
approach to source control is advocated. For instance, early
surgical intervention is associated with increased morbidity
and death in patients with infected pancreatic necrosis, and a
delay in definitive therapy for days or even weeks may be
warranted [128,143–145]. Outside of clinical situations in
which there has been well-documented success using a non-
interventional approach, however, an expeditious source
control procedure is considered essential for patients with
IAI. Careful clinical observation is mandatory in patients
treated without source control, and patients who fail to im-
prove on antimicrobial therapy alone should undergo a source
control intervention [81,129,131,132].
There is sparse evidence regarding the ideal timing of
source control interventions. Short delays may be needed to
mobilize technical expertise and other resources for optimal
treatment of the patient with IAI. Multivariable analyses have
identified the time between diagnosis and source control as a
predictor of death in patients with IAI [49,63]. One reviewer
concluded that most patients with peritonitis should undergo
a source control procedure within 24 hours of the diagnosis of
the infection [146]. Studies of septic patients undergoing
source control for IAI and other types of infection, however,
suggested that delays of only 3–6 hours were associated with
increased death [147,148]. Based on these limited data, the
recommendations found in previous guidelines and reviews,
and the opinions of the members of this task force, most
patients with IAI should undergo source control within
24 hours; patients with sepsis or septic shock should undergo
earlier source control, although a short delay to allow for
rapid resuscitation may be needed in the hemodynamically
unstable patient with sepsis [4,6,49,90,128,146].
Selection of a specific source control procedure for a given
patient should be predicated both on the characteristics of the
infection and the patient, as well as the availability of
technical expertise at the local institution. Operative and
other invasive procedures present additional stresses to
patients whose physiologic reserves have already been
challenged by the infection, so limiting the extent of the
source control procedure may be advantageous under some
circumstances. If source control is inadequate, however,
persistence of the infectious insult may result in an adverse
outcome. The balance between the competing demands of
optimally managing the infection and ameliorating the ef-
fects of source control on the patient’s physiologic function
requires individualized patient assessment and careful
clinical judgment [128].
The utility of less invasive source control interventions has
been confirmed for many patients with IAI. A robust body of
evidence has shown that percutaneous drainage of infected
intra-abdominal fluid collections provides adequate source
control [128,149]. Success rates range from 82%–91% in
various series using these techniques [150–153]. In general,
minimally invasive approaches are reasonable for most pa-
tients with localized IAI, when feasible. The efficacy of less
invasive approaches for patients with more diffuse IAI is
uncertain, however. Although case series had demonstrated
good outcomes using laparoscopic drainage without colonic
resection for the treatment of selected patients with Hinchey
class III or IV diverticulitis [154–157], recent prospective
trials suggested that this approach was less successful than
colectomy [158,159]. Overall, based on the available evi-
dence, the task force concluded that the least invasive inter-
vention that will fulfill the goal of establishing adequate
source control should be used preferentially in most patients
with IAI. Unless clearly shown to be effective, however, less
invasive approaches may not be warranted in patients with
diffuse peritonitis. This echoes the recommendations from
the previous guideline and those of other authors [4,
6,128,149].
The identification of certain risk factors for an adverse
outcome in patients with IAI might be useful in selecting al-
ternative approaches to source control interventions. Higher-
risk patients, particularly those identified as having an acute
compromise of their physiologic status, are a group of patients
whomight benefit from such alternative approaches [4, 6,128].
Patients with diffuse peritonitis, identified directly or through
an elevated MPI score, are another such group of patients
[15,24,44,46,51,57,68,69,79,81,83]; however, the utility of
such observations in modifying approaches to source control
remains conjectural for the most part [160].
The use of abbreviated or damage control laparotomy with
delayed fascial closure is an approach that has been used to
treat severely ill patients with IAI [161,162]. There are ob-
servational data supporting the use of this approach in certain
patients. One such group of patients are those whose physi-
ologic reserves are exhausted, as manifested by parameters
such as pH less than 7.2, a temperature less than 35C, or
clinically evident coagulopathy [162–164]. The use of open
abdominal techniques to manage or prevent abdominal
compartment syndrome is also widely accepted [163–165];
this syndromemay occur in patients who have IAI with sepsis
and have received large amounts of IV fluids for resuscita-
tion. An inability to obtain full source control at the time of
the index procedure is another indication for use of damage
control laparotomy and temporary abdominal closure to fa-
cilitate early re-laparotomy for more definitive source control
[149,162–164,166–169]. Patients with bowel ischemia may
also benefit from abbreviated laparotomy and temporary
abdominal closure to facilitate planned second-look proce-
dures [162,163,166,168,169],
The use of planned or mandatory re-laparotomy had been
suggested as an approach for treating all patients with severe,
diffuse secondary peritonitis. A RCT comparing mandatory
planned re-laparotomy to re-laparotomy based on clinical in-
dications in patients with severe secondary peritonitis,
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however, showed no significant benefit of planned re-
laparotomy in terms of peritonitis-related morbidity or death
(Supplementary Table C; see online supplementary material
at www.liebertpub.com/overview/surgical-infections/53/);
moreover, resource utilization was higher in patients under-
going mandatory re-laparotomy [170,171]. Additional, non-
randomized studies have also questioned the need for planned
re-laparotomy in patients with severe peritonitis when ade-
quate source control can be achieved [149,170,172–177].
Based on these data, the task force concluded that damage
control laparotomy may be useful in selected patients, but that
neither this approach nor mandatory re-laparotomy should be
applied universally to patients with severe, diffuse peritonitis.
Irrigation or lavage of the peritoneal cavity is widely used
in the management of IAI. A review of the available data
concluded that there was no overall benefit for peritoneal
lavage beyond that necessary for removal of gross contami-
nation [178]. Several more recent series and one prospective
trial of patients with perforated appendicitis likewise have
found that aspiration and limited irrigation to remove gross
contamination were as effective as lavage [179–182]. The use
of continuous post-operative lavage in patients with perito-
nitis has not been supported by reviews of the available ev-
idence [178,183]. The inclusion of antibiotic agents in lavage
fluid has also been used in an effort to reduce complications
related to IAI. A meta-analysis of seven older studies of di-
verse patient populations, not all of whom had IAI, suggested
that the inclusion of antibiotic agents in lavage fluid reduced
post-operative septic complications, but had no effect on
death. Because of the poor methodology used in these studies,
however, the authors of this meta-analysis did not believe that
the data supported the efficacy of antibiotic lavage, and that
this remained an open question [178].
The precise definition of what constitutes adequate source
control remains elusive [126]. Approaches to source control
have changed as new techniques develop and evidence ac-
cumulates regarding various management options. Even
when detailed descriptions of adequate source control are
provided, interobserver variation in assessing source control
adequacy is quite high [184,185]. Local variations in practice
patterns may also lead to different, but not necessarily in-
appropriate, approaches to source control [185], Given the
complexity of defining adequate source control, the task force
does not believe that assessments of source control adequacy
in patients with IAI would be a useful performance measure
by which to evaluate surgical competence.
2.1. We recommend routine use of a source control pro-
cedure to remove infected fluid and tissue and to prevent
ongoing contamination in patients with IAI except for those
patients with clinical problems for which clear evidence has
shown that a non-interventional approach is associated with
a good clinical outcome (Grade 1-A).
2.2. We suggest that source control be undertaken within
24 hours of the diagnosis of IAI, except for those infections
for which clinical evidence indicates non-interventional or
delayed management is appropriate (Grade 2-B). We suggest
that patients with sepsis or septic shock undergo source
control in a more urgent manner (Grade 2-C).
2.3. We recommend use of the least invasive approach that
is able to achieve adequate source control, at least on a
temporary basis, for patients with IAI (Grade 1-B).
2.4. We suggest that patients with major physiologic in-
stability, those with diffuse infections, and those with ongoing
bowel ischemia be considered at higher risk for failure of
initial source control and for use of alternative or tempo-
rizing approaches to source control (Grade 2-B).
2.5. We recommend that an abbreviated laparotomy and
temporary abdominal closure techniques be used in critically
ill patients with IAI if closure of the abdomen would create
meaningful intra-abdominal hypertension, if the patient’s
physiologic reserves are severely compromised, if there is an
inability to achieve adequate source control with the initial
procedure, or if there is a plan for a second-look laparotomy
because of mesenteric ischemia (Grade 1-B).
2.6. We recommend against routine planned re-
laparotomy in high-risk patients with severe peritonitis when
adequate source control can be obtained at the time of the
index procedure; such patients should be treated with on-
demand rather than scheduled re-laparotomy (Grade 1-B).
2.7. We suggest use of irrigation with crystalloid fluid to
remove visible debris and gross contamination before ab-
dominal closure in patients with IAI, generally limiting la-
vage to those areas with gross involvement as an adjunct to
the source control procedure (Grade 2-B).
3. Microbiologic evaluation
Q 3.1. Should cultures be obtained in lower-risk patients
with CA-IAI?
Q 3.2. Should cultures be obtained in higher-risk patients
with CA-IAI and those with HA-IAI?
Q 3.3. Should routine peritoneal cultures be obtained from
patients with IAI for epidemiologic purposes?
The value of routine culture data in guiding antimicrobial
therapy for lower-risk patients with CA-IAI has not been rig-
orously evaluated in prospective trials [186]. Nevertheless, a
number of observational studies have suggested that these
cultures rarely, if ever, provide information useful to the cli-
nician [187–191]. The majority of lower-risk patients with
CA-IAI are successfully treated with standard approaches to
source control and antimicrobial therapy. When treatment
failure is attributed to inadequate antimicrobial therapy in such
patients, it is generally because the initial empiric regimen
lacked activity against the common Enterobacteriaceae or
enteric anaerobes responsible for the infection [54,187,192].
Nonetheless, the increased prevalence of extended-spectrum
b-lactamase (ESBL)-producing Enterobacteriaceae strains in
certain geographic areas may necessitate a modification of the
recommendation against obtaining routine cultures, particu-
larly if this phenomenon leads to a substantial increase in
treatment failure in lower-risk patients with CA-IAI.
There is a greater rationale for obtaining routine peri-
toneal cultures in higher-risk patients with CA-IAI and
those with HA-IAI. In patients with sepsis, use of appro-
priate antimicrobial therapy is considered essential [8];
inadequate empiric antimicrobial therapy has been asso-
ciated with higher deaths in patients with sepsis, including
those with IAI [43,54,58,187,193–195]. Higher-risk patients
with CA-IAI may be infected with somewhat more resistant
pathogens than lower-risk patients [22–24,26,27], and the
likelihood of encountering resistant pathogens is substantially
higher in patients with HA-IAI [15,17,22–24,26,32,33,62,
77,85,87,90].
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To provide adequate antimicrobial therapy to higher-risk
patients, use of broad-spectrum empiric antimicrobial regi-
mens is recommended [4,6,13,127]. To avoid excessive ex-
posure of the patient to broad-spectrum antimicrobial therapy
and potential selection of further resistant microorganisms,
however, de-escalation of therapy based on culture results is
also recommended [4, 6,196–198]. In addition to de-
escalating antimicrobial therapy, culture and susceptibility
results can be used to guide pathogen-directed therapy when
an unexpected or resistant pathogen is encountered; even
though such therapy may be delayed, it is still more likely to
be successful than continued administration of an inappro-
priate empiric regimen [197,199,200].
There have been substantial increases in resistance of mi-
crobial pathogens involved in IAI to previously effective an-
timicrobial agents, particularly inAsia and Latin America [28–
31]. Ideally, epidemiologic investigations could identify
problematic pathogens in a specific geographic locale, and the
results could be used to guide selection of preferred empiric
antimicrobial regimens for that region [186]. To track these
epidemiologic changes, culture results from an unbiased
sample of patients must be obtained. Thus, culture and sus-
ceptibility data from even lower-risk patients with CA-IAI are
needed, although the culture results themselves will provide
little direct benefit to the patient. For such an approach to be
viable, however, adequate resources are needed for aggrega-
tion, analysis, and dissemination of this information. Given the
increasing incidence of resistant pathogens in bothCA-IAI and
HA-IAI and the limited antimicrobial armamentarium avail-
able to treat patients with such micro-organisms, such inves-
tigations will likely be increasingly vital in the future.
Optimal techniques for obtaining peritoneal cultures were
reviewed in the previous guideline [4]. At least one mL of
peritoneal fluid or infected tissue should be collected and placed
in a suitable transport system for examination by the microbi-
ologic laboratory. If anaerobic cultures are to be obtained, these
specimens need to be sent in an anaerobic transport system.
Direct inoculation of fluid specimens into blood culture bottles
is an additional option. In any case, use of peritoneal swabs
instead of fluid or tissue for cultures is strongly discouraged.
3.1. We do not recommend routinely obtaining peritoneal
fluid cultures in lower-risk patients with CA-IAI for purposes
of guiding antimicrobial therapy (Grade 1-B).
3.2. We recommend obtaining cultures of peritoneal fluid
in higher-risk patients with CA-IAI and in patients with HA-
IAI to identify potential resistant or opportunistic pathogens
(Grade 1-C).
3.3. We suggest obtaining cultures in all patients with CA-IAI
andHA-IAI if adequate resourcesareavailable toaggregateand
analyze the epidemiologic data and the information can be used
to guide empiric antimicrobial therapy (Grade 2-C).
4. Intravenous antimicrobial agents
A. General principles
Q 4.1. What are the general principles regarding antimi-
crobial therapy for patients with IAI?
Standard antimicrobial therapy for patients with IAI should
include agents with activity against aerobic gram-negative En-
terobacteriaceae, aerobic streptococci, and obligate enteric an-
aerobic organisms found in the gastrointestinal tract, although
coverage of the latter may not be absolutely essential in patients
with an upper gastrointestinal source of infection. Additional
antimicrobial agents, providing coverage of less common re-
sistant or opportunistic pathogens, may be warranted in more
severely ill patients. Awide variety of antimicrobial agents have
activity against these various micro-organisms. This section
summarizes the task force’s interpretation of the utility of var-
ious antimicrobial agents in treating patients with IAI. A syn-
opsis of these recommendations is available in Table 8.
Summaries of older RCTs evaluating antimicrobial therapy for
IAI are included in the previous evidence review [3]; summaries
of more recent RCTs are provided in the Supplementary Tables
(see online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/).
The basic principle of providing empiric antimicrobial
therapy effective against gram-negative Enterobacteriaceae,
aerobic streptococci, and obligate enteric anaerobic organ-
isms in patients with IAI was described several decades ago
and has been a component of all previous guidelines [1,2,4,5].
Observational studies have demonstrated an increased risk of
treatment failure and death when this basic principle is not
followed (Supplementary Table D; (see online supplemen-
tary material at www.liebertpub.com/overview/surgical-
infections/53/) [54,58,187,201,202]. A recent large data-
base study of more than 6000 patients confirmed that patients
who received regimens lacking activity against anaerobic
organisms had a significantly increased rate of treatment
failure compared with patients who received agents effective
against both gram-negative Enterobacteriaceae and anaero-
bic pathogens (Supplementary Table D) [192].
4.1. We recommend use of antimicrobial regimens having
activity against the typical gram-negative Enterobacteriaceae,
gram-positive cocci, and obligate anaerobes involved in these
infections (Grade 1-A).
B. Aminoglycoside-based regimens
Q 4.2. What is the role of aminoglycoside-based regimens
in the treatment of patients with IAI?
At one time, aminoglycosides (gentamicin, tobramycin,
amikacin, netilmicin), in combination with an anti-anaerobic
agent (clindamycin, metronidazole) and variably with an agent
active against gram-positive organisms, were considered the
‘‘gold standard’’ for treatment of patients with IAI. These
regimens were recommended in early guidelines [1,2], but not
in subsequent guidelines [4,5]. Aminoglycosides were used in
four RCTs published since 2000 (Supplementary Table E (see
online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/)). In one, the clinical effi-
cacy of amikacin, in combination with ceftazidime and met-
ronidazole, was found to be inferior to cefoperazone-sulbactam
[203]. No significant differences in outcome were noted in the
other three studies; however, one only compared once daily to
multiple daily doses of amikacin [204–206].
Two meta-analyses published since 2000 found that
aminoglycoside-based regimens were inferior to comparators
for treating patients with IAI (Supplementary Table F; see
online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/) [207,208]. In the previous
evidence review [3], four trials also showed higher treatment
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failure rates with aminoglycoside-based regimens compared
with other agents [209–212], whereas one trial demonstrated
superiority of an aminoglycoside-based regimen compared
with ampicillin-sulbactam [213]. The nephrotoxicity and
ototoxicity of these agents as well as the need for therapeutic
drug monitoring further complicates their use. Given the
availability of alternative agents, the task force concluded
that these agents should not be used routinely for empiric
therapy of patients with IAI. These agents may be useful,
however, for treating patients with an infection because of a
resistant gram-negative pathogen for which other classes of
agents are not suitable. Unfortunately, many of these micro-
organisms are also resistant to aminoglycosides [28].
Aminoglycoside-based regimens are still used when treating
neonatal patients with IAI, as will be discussed in Section 13.
4.2. We recommend against the routine use of
aminoglycoside-based regimens for the empiric treatment of
patients with IAI (Grade 1-B). We suggest that these regimens
may be useful for treatment of IAI in neonatal patients and
in adults and children because of resistant gram-negative
organisms, if other agents are not suitable (Grade 2-B).
C. Penicillin-b-lactamase inhibitor combinations
Q 4.3a. What is the role of ampicillin-sulbactam in the
treatment of patients with IAI?
Q 4.3b. What is the role of IV amoxicillin-clavulanic acid
in the treatment of patients with IAI?
Q 4.3c. What is the role of ticarcillin-clavulanic acid in
the treatment of patients with IAI?
Q 4.3d. What is the role of piperacillin-tazobactam in the
treatment of patients with IAI?
Ampicillin-sulbactam was recommended for treatment of
patients with IAI in an older guideline [2], but not in the more
recent guidelines [4,5]. The RCTs evaluating the efficacy of
ampicillin-sulbactam for the treatment of IAI are limited. Since
2008, two studies have been published using ampicillin-
sulbactam (Supplementary Table G; see online supplementary
material at www.liebertpub.com/overview/surgical-infections/
53/) [214,215], one of which found ampicillin-sulbactam in-
ferior to ertapenem [214]. Three older articles were previously
reviewed [3], one of which found ampicillin-sulbactam inferior
to a regimen of gentamicin plus clindamycin [213]. Micro-
biologic data have documented substantial resistance of gram-
negative Enterobacteriaceae globally to ampicillin-sulbactam;
in the most recent Study for Monitoring of Antimicrobial
Resistance Trends (SMART) data, only 34% of hospital-
associated strains and 45% of community-acquired strains of
E. coli were susceptible to this agent [28].
Based on the clinical and microbiologic data, the task force
concluded that other agents were preferable to ampicillin-
sulbactam for the empiric treatment of patients with IAI.
Ampicillin-sulbactam does have some activity against A.
baumannii, primarily because of the sulbactam entity, and
may have some use in pathogen-directed therapy of patients
with infections from that micro-organism [216]; however, the
majority of Acinetobacter strains isolated from patients with
IAI are not susceptible [28].
The IV preparation of amoxicillin-clavulanic acid is not
available for use in the United States but is available in
Europe and other parts of the world. The literature search did
not identify any RCTs published since 2000 evaluating this
agent. In the previous evidence review [3], one small pro-
spective trial comparing use of IV amoxicillin-clavulanic
acid plus metronidazole to IV ciprofloxacin plus metronida-
zole found lower success rates with the amoxicillin-
clavulanic acid plus metronidazole regimen, although this
difference was not statistically significant [217]. In a recent
observational study of patients with peritonitis in The Neth-
erlands, the authors concluded that amoxicillin-clavulanic
acid-resistant E. coli was increasingly common, and that use
of this agent in such patients was associated with increased
death [218].
Microbiologic studies suggest that in vitro resistance of E.
coli to amoxicillin-clavulanic acid is high; in one study,
susceptibility of E. coli isolates from various sources to
amoxicillin-clavulanic acid was 50%–51%, which was only
marginally better than that of ampicillin-sulbactam (45%–
47%) [219]. Because of concerns regarding efficacy and re-
sistance of E. coli as well as the lack of recent RCTs on use of
this agent, the task force does not support use of amoxicillin-
clavulanic acid for empiric treatment of patients with IAI.
Ticarcillin-clavulanic acid had been recommended for
empiric treatment of patients with IAI in previous guidelines
[1,2,4,5]. Since 2000, only one small RCT has evaluated this
agent (Supplementary Table G; see online supplementary
material at www.liebertpub.com/overview/surgical-infections/
53/). No significant differences in success rates were dem-
onstrated comparing use of this agent with ertapenem, but
only 11 clinically evaluable patients were treated with
ticarcillin-clavulanic acid [220]. In the previous evidence
review [3], three prospective trials demonstrated efficacy of
ticarcillin-clavulanate for the treatment of lower-risk patients
with IAI. Contemporary data on the activity of this agent
against gram-negative pathogens found with IAI are limited.
Although the activity spectrum of ticarcillin-clavulanic acid
includes P. aeruginosa, in vitro susceptibility has declined in
recent years [221]. Ticarcillin-clavulanic acid may have some
activity against MDR organisms such as A. baumannii, al-
though less than ampicillin/sulbactam [222], and some activity
against ESBL-producing strains of Enterobacteriaceae, but
less than piperacillin-tazobactam [223]. Ticarcillin-clavulanic
acid is no longer available in the United States [224]. The task
force concluded that this agent was acceptable for empiric
treatment of patients with IAI, although other agents would be
preferable because of the lack of contemporary data demon-
strating efficacy of this agent. This recommendation is moot,
however, unless production of it resumes.
Piperacillin-tazobactam is a commonly used agent for
treating patients with IAI. It has been recommended for the
treatment of higher-risk patients or those with higher severity
infections in previous guidelines [2,4,5]. Six RCTs compar-
ing this agent with other regimens for IAI have been pub-
lished since 2000 (Supplementary Table G; see online
supplementary material at www.liebertpub.com/overview/
surgical-infections/53/) [225–230], one of which was re-
viewed previously [3]. There were no significant differences
noted in the clinical success rates between patients receiving
piperacillin-tazobactam and those receiving various compar-
ators. Eight other trials evaluating this agent were reviewed
previously [3], including one in severely ill patients comparing
use of piperacillin-tazobactam with the combination of this
agent plus an aminoglycoside. It was also concluded that
SIS GUIDELINES ON INTRA-ABDOMINAL INFECTION 23
piperacillin-tazobactam was as effective as the various com-
parators [3]. In vitro susceptibility data generally document
good activity of this agent against E. coli, although there has
been some decline in this over the past decade. Piperacillin-
tazobactam is active against many ESBL-producing En-
terobacteriaceae but generally less so than carbapenems [28].
Based on the continued evidence of good efficacy of
piperacillin-tazobactam, the task force recommends this
agent for the treatment of patients with IAI. To avoid ex-
cessive use and potential promotion of resistance to broad-
spectrum agents such as piperacillin-tazobactam, the task
force suggests that this agent be reserved primarily for use in
higher-risk patients.
4.3a. We suggest that ampicillin-sulbactam not be used for
the empiric treatment of adults and children with IAI (Grade
2-B).
4.3b. We suggest that IV amoxicillin-clavulanic acid not be
used for the empiric treatment of adults and children with IAI
(Grade 2-B).
4.3c. We suggest that ticarcillin-clavulanic acid is an ac-
ceptable agent for the empiric treatment of lower-risk adults
and children greater than one month of age with CA-IAI, if it
is available (Grade 2-B).
4.3d. We recommend piperacillin-tazobactam as an ac-
ceptable agent for the empiric treatment of adults and chil-
dren older than one month with IAI (Grade 1-A). We suggest
that this agent be reserved primarily for higher-risk patients
because of its broader-spectrum antimicrobial activity
(Grade 2-C).
D. Cephalosporin-based regimens and cephalosporin-b-
lactamase inhibitor combinations
Q 4.4a. What is the role of cephamycin antibiotic agents
(cefoxitin, cefotetan) in the treatment of patients with IAI?
Q 4.4b. What is the role of cefazolin plus metronidazole
in the treatment of patients with IAI?
Q 4.4c. What is the role of cefuroxime plus metronidazole
in the treatment of patients with IAI?
Q 4.4d. What is the role of cefotaxime or ceftriaxone plus
metronidazole in the treatment of patients with IAI?
Q 4.4e. What is the role of ceftazidime plus metronidazole
in the treatment of patients with IAI?
Q 4.4f. What is the role of cefepime plus metronidazole in
the treatment of patients with IAI?
Q 4.4g. What is the role of cefoperazone-sulbactam in the
treatment of patients with IAI?
Q 4.4h. What is the role of ceftolozane-tazobactam plus
metronidazole in the treatment of patients with IAI?
Q 4.4i. What is the role of ceftazidime-avibactam plus
metronidazole in the treatment of patients with IAI?
Cephamycin antibiotic agents have been recommended
variably in previous guidelines as monotherapy for the
treatment of patients with IAI [1,2,4,5]. The literature search
did not identify any RCTs published since 2000 that evalu-
ated the use of these agents. In the previous evidence review
[3], eight trials evaluated cefoxitin in patients with IAI, the
most recent published in 1996, and three trials evaluated
cefotetan, the most recent published in 1994. None of these
demonstrated significant differences in clinical outcomes
comparing cephamycins with other agents.
Because of the lack of contemporary data on the use of
these agents, recent studies analyzing use of these antibiotic
agents for surgical prophylaxis in colorectal procedures were
also reviewed. One RCT found cefotetan inferior to ertape-
nem for this indication [231]. Two recent, large database
studies found that cephamycins were less efficacious than
other recommended agents for prophylaxis for colorectal
procedures [232,233]. Microbiologic data indicate that about
90% of E. coli strains isolated from patients with IAI in North
America are susceptible to cefoxitin [234], but this is lower in
other parts of the world [31,235]. Resistance of anaerobic
micro-organisms, including B. fragilis, to cephamycins is
increasing, however [236,237]. A concern specific to cefox-
itin is its short half-life of 0.7–1.1 hours. Because of this,
intra-operative re-dosing every two hours is recommended
for surgical site infection prophylaxis [238].
Overall, given the lack of contemporary data and the po-
tential for decreased efficacy of cephamycin antibiotic
agents, as reflected in the indirect evidence from studies of
colorectal surgical procedure prophylaxis, the task force
suggests use of regimens other than cephamycins for empiric
treatment of patients with IAI. It is recognized that this
conflicts with a recent guideline on surgical prophylaxis,
which recommends cephamycins for appendectomy and co-
lorectal procedures [238]. Nevertheless, because there are
alternative regimens for lower-risk patients with CA-IAI, the
task force believes that these should be used preferentially to
cephamycins.
Unlike other cephalosporins, cephamycins have in vitro
activity against many ESBL-producing Enterobacteriaceae.
This suggests their potential utility in treating those resistant
pathogens; however, there are virtually no data evaluating
their clinical efficacy for this indication [239].
The combination of cefazolin plus metronidazole was in-
cluded as a recommended regimen in some previous guide-
lines [4,5]. Cefazolin has been approved by the FDA for the
treatment of patients with biliary tract disease, but not for
management of complicated IAI. There are essentially no
prospective data evaluating the efficacy of this regimen
compared with others for IAI. One trial from 1989 studied
this regimen in patients with complicated appendicitis but did
not compare it with an alternative regimen [240]. There are
two large database studies that evaluated antibiotic agents for
colorectal prophylaxis, both of which suggested cefazolin
plus metronidazole was efficacious for this indication
[232,233]. Relatively recent data show that 92% of E. coli
strains from patients with acute and perforated appendicitis are
susceptible to cefazolin [241]. Nevertheless, because there is
only indirect evidence supporting the use of cefazolin plus
metronidazole for treatment of patients with IAI, the task force
suggests using alternative regimens for empiric therapy.
The combination of cefuroxime plus metronidazole was
also recommended in previous guidelines for the treatment of
patients with IAI [2,4,5]. This recommendation was sup-
ported by three trials showing efficacy of this regimen, which
were included in the previous evidence review [3]. There are
no recent trials re-evaluating this regimen for IAI and rela-
tively few recent microbiologic studies. A study of appen-
diceal isolates demonstrated 95% susceptibility of E. coli to
cefuroxime [241], but a global survey of urinary isolates
found only 82% susceptibility of E. coli to this agent [242].
The task force concluded that this regimen was acceptable for
24 MAZUSKI ET AL.
empiric treatment of lower-risk patients with CA-IAI but
suggested preferential use of other regimens for which more
recent evidence is available.
The combination of a third-generation cephalosporin plus
an anti-anaerobic agent has been recommended in all previ-
ous guidelines [1,2,4,5]; the 2010 guideline specifically
recommended use of cefotaxime or ceftriaxone plus metro-
nidazole for lower-risk patients with CA-IAI [4]. Cefotaxime
plus metronidazole was compared with piperacillin-
tazobactam in one study published since 2000 (Supplemen-
tary Table H; see online supplementary material at www.
liebertpub.com/overview/surgical-infections/53/); this study
demonstrated similar outcomes with either regimen [225].
The previous evidence review [3] included five studies
comparing cefotaxime plus an anti-anaerobic agent with
other agents. In one of these studies, success rates were sig-
nificantly higher with cefotaxime plus metronidazole than
with meropenem [243], whereas the opposite was true in a
second study [244]. In one additional small study comparing
a regimen of cefotaxime plus gentamicin plus metronidazole
with ciprofloxacin plus metronidazole, the fluoroquinolone-
based regimen appeared to be more efficacious [245].
Nine studies have been published since 2000 comparing
ceftriaxone and a nitroimidazole (generally metronidazole)
with other agents (Supplementary Table H; see online sup-
plementary material at www.liebertpub.com/overview/
surgical-infections/53/) [204,246–253]. Three additional tri-
als were cited in the previous evidence review [3]. None of
the more recent studies demonstrated any significant differ-
ence in outcomes between patients receiving ceftriaxone plus
a nitroimidazole and those receiving the comparator; one of
the older studies found ceftriaxone plus metronidazole to be
superior to an aminoglycoside-based regimen.
Approximately 90% of E. coli obtained from patients with
IAI in North America are susceptible to cefotaxime or cef-
triaxone. Susceptibility rates are appreciably lower in other
parts of the world, however, particularly Asia, the Middle
East, and Latin America, where there is a high prevalence of
ESBL-producing Enterobacteriaceae [28,31,234,235]. Based
on the evidence available, the task force recommends use of
cefotaxime or ceftriaxone plus metronidazole for the treat-
ment of lower-risk patients with CA-IAI. In areas of the
world where ESBL-producing E. coli are prevalent, however,
other agents would be preferable.
Previous guidelines recommended the combination of the
third-generation anti-pseudomonal cephalosporin, ceftazi-
dime, plus metronidazole for the treatment of higher-risk
patients with IAI [2,4,5]. The task force did not identify any
recent RCTs evaluating ceftazidime plus metronidazole only,
although one recent trial compared ceftazidime plus amika-
cin and metronidazole with cefoperazone/sulbactam mono-
therapy (Supplementary Table H; see online supplementary
material at www.liebertpub.com/overview/surgical-infections/
53/); this study, performed in a region where there is a high
incidence of ESBL-producing E. coli, found greater efficacy
with cefoperazone-sulbactam than the ceftazidime-based
regimen [203]. In the previous review [3], two studies com-
pared ceftazidime plus an anti-anaerobic agent to other
agents; one of these demonstrated superiority of ceftazidime
plus metronidazole over an aminoglycoside plus metronida-
zole [210]. In vitro susceptibilities of E. coli to ceftazidime
remain greater than 90% in North America and Europe;
however, the susceptibility of this organism to ceftazidime is
appreciably lower in Asia, the Middle East, and Latin
America, where ESBL-producing strains of E. coli are
prevalent [28,31,234,235].
Based on the available data, the task force suggests that
ceftazidime plus metronidazole can be used for the treatment
of patients with IAI, although this is graded as a weak rec-
ommendation because of the lack of contemporary data. As
with most other agents with broad-spectrum activity against
gram-negative organisms, this regimen should be reserved
primarily for empiric treatment of higher-risk patients with
IAI. A ceftazidime-based regimen should most likely be
avoided in regions where there is a high prevalence of ESBL-
producing Enterobacteriaceae. In general, the task force
prefers use of cefepime rather than ceftazidime for those
patients in whom an anti-pseudomonal cephalosporin is be-
lieved warranted.
The fourth-generation anti-pseudomonal cephalosporin,
cefepime, in combination with metronidazole, was also re-
commended for the treatment of higher-risk patients with IAI
in previous guidelines [2,4,5]. Cefepime plus metronidazole
was evaluated in two RCTs published since 2000 (Supple-
mentary Table H; see online supplementary material at www
.liebertpub.com/overview/surgical-infections/53/) [254,255]
and in two RCTs included in the previous evidence review
[3]. Two of these trials demonstrated significantly higher
success rates with cefepime plus metronidazole compared
with imipenem-cilastatin [45,255], although this statistical
difference disappeared in one study when the results were
adjusted for an imbalance in the severity of illness between
the study groups [45]. As with ceftazidime, microbiologic
data indicate in vitro susceptibility of E. coli to cefepime is
greater than 90% in North America and Europe but appre-
ciably lower in Asia, the Middle East, and Latin America
[28,31,234,235]. Cefepime is less susceptible to hydrolysis by
AmpC b-lactamases than are other broad-spectrum cephalo-
sporins, so it may be a therapeutic alternative to carbapenems
for patients with infections because of gram-negative bacteria
expressing those enzymes [256–259].
Overall, based on the available data, the task force rec-
ommends cefepime plus metronidazole for the treatment of
patients with IAI. The task force suggests that this regimen be
used primarily for empiric therapy of higher-risk patients
because of its potent anti-pseudomonal activity.
Several combinations of a cephalosporin with a b-
lactamase inhibitor are now available that may be able to
overcome some the resistance mediated by ESBL enzymes.
Cefoperazone-sulbactam is one such combination. This agent
is not available in the United States. In one recent trial,
cefoperazone-sulbactam was superior to a regimen of ami-
kacin, ceftazidime, and metronidazole for the treatment
of patients with IAI (Supplementary Table H; see online
supplementary material at www.liebertpub.com/overview/
surgical-infections/53/); of note, this trial took place in a
region with a high prevalence of ESBL-producing Entero-
bacteriaceae [203]. Two additional trials using cefoperazone-
sulbactam were described in the previous evidence review [3],
one of which found cefoperazone-sulbactam superior to an
aminoglycoside-based regimen [209].
Cefoperazone-sulbactam has activity against a number of
ESBL-producing strains of E. coli, although this varies
somewhat from country to country [260–262]. This agent has
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been tested primarily in lower-risk patients with IAI. Overall,
the task force concluded that cefoperazone-sulbactam is an
effective agent for the treatment patients with IAI and may be
of value for use in lower-risk patients with CA-IAI who live
in parts of the world where the prevalence of ESBL-
producing Enterobacteriaceae is appreciable.
Two new cephalosporin-b-lactamase inhibitor combina-
tions, ceftolozane-tazobactam and ceftazidime-avibactam,
used in combination with metronidazole, have been approved
by the FDA for the treatment of patients with complicated
IAI. These agents have also now been approved for use by the
European Commission. In phase II and phase III trials,
ceftolozane-tazobactam, in combination with metronidazole,
appeared to have similar efficacy to meropenem for the
treatment of patients with IAI (Supplementary Table H; see
online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/) [263,264]. Ceftolozane-
tazobactam is active in vitro against many ESBL-producing
Enterobacteriaceae, although not against K. pneumoniae
carbapenemase (KPC)-producing strains or metallo-b-
lactamase (MBL)-producing strains. It is also active against
many strains of P. aeruginosa and appears to be the most
potent currently available b-lactam or b-lactam-b-lactamase
inhibitor combination against this organism [265–268]. Of
particular note is the substantial activity of ceftolozane-
tazobactam against many MDR and extremely drug resistant
(XDR) strains of P. aeruginosa, including strains that are
resistant to ceftazidime and carbapenems [269–273].
Ceftazidime-avibactam also has an expanded, albeit
somewhat different spectrum of activity against gram-
negative micro-organisms. As with ceftolozane-tazobactam,
the clinical efficacy of ceftazidime-avibactam in combination
with metronidazole was compared with meropenem for the
treatment of patients with IAI in phase II and phase III trials
(Supplementary Table H; see online supplementary material
at www.liebertpub.com/overview/surgical-infections/53/).
Success rates in patients treated with this agent were non-
inferior to those observed in patients treated with meropenem
[274,275]. Ceftazidime-avibactam has activity against most
strains of Enterobacteriaceae, including ESBL-producing
strains andAmpCb-lactamase-producing strains. Ceftazidime-
avibactam is the only currently available b-lactam-b-
lactamase inhibitor combination with substantial in vitro
activity against KPC-producing Enterobacteriaceae but is not
active against MBL-producing micro-organisms [268,276–
278]. Ceftazidime-avibactam also has good in vitro activity
against P. aeruginosa, including a number of MDR and XDR
strains [277,279].
Based on the clinical and microbiologic data, the task force
concluded that both ceftolozane-tazobactam plus metroni-
dazole and ceftazidime-avibactam plus metronidazole are
acceptable regimens for the treatment of patients with IAI. Of
some concern, however, was the finding that both agents were
less effective than meropenem in subgroups of patients with
renal impairment [275,280]. Further research will be needed
to clarify the role of these agents in the treatment of patients
with IAI. For now, the task force suggests that these regimens
be reserved for the treatment of higher-risk patients with CA-
IAI or HA-IAI who are either known or strongly suspected of
being infected with one of the resistant pathogens that are
uniquely susceptible to one of these agents, when other an-
tibiotics are not suitable.
4.4a. We suggest that cefoxitin and cefotetan not be used
for the empiric treatment of adults and children with IAI
(Grade 2-B).
4.4b. We suggest that cefazolin plus metronidazole not be
used for the empiric treatment of adults and children with IAI
(Grade 2-C).
4.4c. We suggest that cefuroxime plus metronidazole is an
acceptable regimen for the empiric treatment of lower-risk
adults and children older than one month with CA-IAI (Grade
2-B).
4.4d. We recommend cefotaxime or ceftriaxone plus met-
ronidazole for the empiric treatment of lower-risk adults and
children older than one month with CA-IAI (Grade 1-A).
4.4e. We suggest that ceftazidime plus metronidazole is an
acceptable agent for the empiric treatment of adults and
children older than one month with IAI (Grade 2-A). We
suggest that this regimen be reserved primarily for higher-
risk patients because of its broader-spectrum antimicrobial
activity (Grade 2-C).
4.4f. We recommend cefepime plus metronidazole for the
empiric treatment of adults and children older than one
month with IAI (Grade 1-A). We suggest that this regimen be
reserved primarily for higher-risk patients because of its
broader-spectrum antimicrobial activity (Grade 2-C).
4.4g. We suggest that cefoperazone-sulbactam, where
available, is an acceptable agent for the empiric treatment of
lower-risk adults and children older than one month with CA-
IAI (Grade 2-B).
4.4h. We suggest that ceftolozane-tazobactam plus met-
ronidazole is an acceptable regimen for the empiric treat-
ment of adults with IAI (Grade 2-A). Because of the unique
spectrum of activity of ceftolozane-tazobactam against cer-
tain ESBL-producing Enterobacteriaceae and against resis-
tant strains of P. aeruginosa, we suggest this regimen be used
primarily for selected patients with IAI strongly suspected or
proven to be caused by one of those resistant pathogens, for
whom other agents are not suitable (Grade 2-C).
4.4i. We suggest that ceftazidime/avibactam plus metro-
nidazole is an acceptable regimen for the empiric treatment
of adults with IAI (Grade 2-A). Because of the unique spec-
trum of activity of ceftazidime-avibactam against many
ESBL-producing Enterobacteriaceae, particularly KPC-
producing Enterobacteriaceae, we suggest this regimen be
used primarily for selected patients with IAI strongly suspected
or proven to be caused by one of those resistant pathogens, for
whom other agents are not suitable (Grade 2-C).
E. Aztreonam-based regimen
Q 4.5. What is the role of an aztreonam-based regimen in
the treatment of patients with IAI?
Previous guidelines recommended an aztreonam-based reg-
imen for the treatment of patients with IAI [1,2,4,7]. There have
been no RCTs published since 2000 evaluating use of this agent
for the treatment of such patients. The previous evidence review
[3] identified three RCTs evaluating aztreonam plus clin-
damycin for the treatment of patients with IAI, all of which
demonstrated non-inferiority of this regimen. Aztreonam has
no anti-anaerobic activity and is almost devoid of activity
against gram-positive organisms [281]. The current and some
previous guidelines recommend use of metronidazole rather
than clindamycin as the preferred anti-anaerobic agent when
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combination regimens are needed. If metronidazole is used in-
stead of clindamycin in conjunction with aztreonam, however,
the regimen lacks activity against most gram-positive cocci.
Therefore, for use in patients with IAI, aztreonam should be
combinedwithmetronidazole andwith an agent that has activity
against aerobic gram-positive cocci, such as vancomycin.
Although aztreonam has good in vitro activity against
many gram-negative bacteria, it has relatively poor activity
against ESBL-producing strains of E. coli andK. pneumoniae
[282]. Aztreonam appears to be safe for use in patients with
serious allergic reactions to other b-lactams [283]; thus, an
aztreonam-based regimen may be of utility in such patients
when other b-lactam agents cannot be used.
Overall, the task force believes that the regimen of az-
treonam in combination with metronidazole and vancomycin
is acceptable for treatment of patients with IAI, particularly
those patients with serious b-lactam allergies for whom other
alternatives may not be suitable. Use of alternative agents
would be preferable, however, when such an option is
available, because of the lack of contemporary data on the
efficacy of this combination regimen. The task force also
suggests that this aztreonam-based regimen be reserved pri-
marily for higher-risk patients, because of its broad-spectrum
activity against gram-negative pathogens.
4.5. We suggest that the regimen of aztreonam plus met-
ronidazole plus vancomycin is acceptable for the empiric
treatment of adults and children older than one month with
IAI (Grade 2-B). We suggest this regimen be reserved pri-
marily for higher-risk patients, particularly those with seri-
ous b-lactam allergies, because of its broader-spectrum
activity against gram-negative pathogens (Grade 2-C).
F. Carbapenem
Q 4.6a. What is the role of ertapenem in the treatment of
patients with IAI?
Q 4.6b. What is the role of the broad-spectrum carbape-
nem, doripenem, in the treatment of patients with IAI?
Q 4.6c. What is the role of the broad-spectrum carbape-
nems, imipenem-cilastatin, and meropenem, in the treat-
ment of patients with IAI?
Ertapenem was been recommended for the treatment of
patients with IAI in previous guidelines [2,4,5]. The task force
identified nine RCTs published since 2000 evaluating use of
this agent as monotherapy for IAI (Supplementary Table I; see
online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/) [205,214,220,226,228,230,
246,247,284], one of which [226] was reviewed before publi-
cation in the previous evidence review [3]. Success rates with
ertapenem have been similar to those of comparators except in
one trial, in which ertapenem was found to be superior to
ampicillin-sulbactam [214]. Ertapenem is active against the
most common strains of ESBL-producing Enterobacteriaceae
but is not active against KPC-producing and MBL-producing
strains [265,285]. Increased use of carbapenems may lead to
selection of gram-negative pathogens expressing these resis-
tance genes. Thus far, little decline in the susceptibilities of intra-
abdominal isolates of E. coli to carbapenems has been detected,
but there have been some decrease in K pneumoniae suscepti-
bilities [28]. Ertapenem does not have appreciable antibacterial
activity against Enterococcus spp. or P. aeruginosa [286,287].
The task force concluded that ertapenem is an acceptable
agent for monotherapy for lower-risk patients with CA-IAI.
Because its spectrum of activity is narrower than that of other
carbapenems, the task force recommends use of broader-
spectrum carbapenems for empiric treatment of higher-risk
patients with CA-IAI and those with HA-IAI, although
treatment could be de-escalated to ertapenem if resistant
pathogens were not identified in definitive cultures. Ertape-
nem is also a good option for treating patients in areas of the
world where there is a high prevalence of ESBL-producing
E. coli in the community.
The broad-spectrum carbapenems—doripenem, imipenem-
cilastatin, and meropenem—have been recommended for the
treatment of patients with IAI in previous guidelines as they
have become available [1,2,4,5]. Doripenem was compared
with meropenem for the treatment of adult patients with IAI
in two large RCTs (Supplementary Table I; see online sup-
plementary material at www.liebertpub.com/overview/
surgical-infections/53/) [288,289]. No significant differ-
ences were observed in clinical success rates between the two
carbapenems. An aborted clinical trial was also reported
comparing doripenem with meropenem in pediatric patients
with IAI, nearly all of whom had perforated appendicitis
[290]; both agents appeared to be effective in the limited
number of patients completing this trial before it was termi-
nated. Doripenem, however, has not been approved for use in
pediatric patients [291].
Imipenem-cilastatin has been evaluated in seven RCTs
published since 2000 (Supplementary Table I; see online
supplementary material at www.liebertpub.com/overview/
surgical-infections/53/) [227,255,292–296] and in 19 RCTs
cited in the previous evidence review [3]. In one small recent
study, success rates in patients treated with imipenem-
cilastatin were significantly lower than in patients treated
with cefepime plus metronidazole [255]. Among studies re-
viewed previously, one found imipenem-cilastatin superior
to comparators [211]; however, two found imipenem-
cilastatin inferior to comparators [45,297], although a higher
severity of illness in patients receiving imipenem-cilastatin
may have accounted for the decreased efficacy observed in
one trial [45].
Meropenem has also been evaluated extensively in RCTs,
including eight published since 2000 (Supplementary Table
I; see online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/) [263,264,274,275,288–
290,292]. There were no statistically significant differences
in outcomes between meropenem and comparators in these
recent trials. In 11 RCTs reviewed previously [3], two found
significant differences betweenmeropenem and comparators,
with one favoring meropenem and one favoring the com-
parator [243,244].
As with ertapenem, the broad-spectrum carbapenems gen-
erally retain activity against the common ESBL-producing
strains of gram-negative bacteria, but not against KPC- or
MBL-producing strains [286,287]. Increased resistance to
broad-spectrum carbapenems has been observed for some
gram-negative microorganisms, however, particularly P.
aeruginosa and A. baumannii, which may be a reflection of
increased reliance on carbapenems in areas of high preva-
lence of ESBL-producing bacteria [298]. Based on the
available data, the task force recommends the use of
doripenem, imipenem-cilastatin, or meropenem for the
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treatment of adult patients with IAI, and imipenem-cilastatin
or meropenem for the treatment of pediatric patients with IAI.
Because of their broad-spectrum activity, their use as empiric
therapy should be restricted to higher-risk patients with CA-
IAI or HA-IAI.
4.6a. We recommend ertapenem for the empiric treatment
of lower-risk adults and children older than one month with
CA-IAI (Grade 1-A).
4.6b. We recommend doripenem for the empiric treatment
of adults with IAI (Grade 1-A). We do not recommend the use
of doripenem for empiric treatment of children older than one
month with IAI unless no other options are available (Grade
1-C). We suggest that this agent be reserved primarily for
higher-risk patients because of its broader-spectrum anti-
microbial activity (Grade 2-C).
4.6c. We recommend imipenem-cilastatin and meropenem
for the empiric treatment of adults and children older than
one month with IAI (Grade 1-A). We suggest that these agents
be reserved for higher-risk patients because of their broader-
spectrum antimicrobial activity (Grade 2-C).
G. Fluoroquinolones and fluoroquinolone-based regimens
Q 4.7a. What is the role of moxifloxacin in the treatment
of patients with IAI?
Q 4.7b. What is the role of ciprofloxacin plus metroni-
dazole in the treatment of patients with IAI?
Q 4.7c. What is the role of levofloxacin plus metronida-
zole in the treatment of patients with IAI?
The previous guideline recommended moxifloxacin
monotherapy for the treatment of patients with IAI [4].
Moxifloxacin has been evaluated in five RCTs published
since 2000 (Supplementary Table J; see online supplemen-
tary material at www.liebertpub.com/overview/surgical-
infections/53/) [215,229,250,251,284]. No significant dif-
ferences were observed in success rates using moxifloxacin
compared with other agents in any of these trials. A meta-
analysis also found moxifloxacin monotherapy to be non-
inferior to treatment with comparators (Supplementary
Table K; see online supplementary material at www.
liebertpub.com/overview/surgical-infections/53/) [299].
Moxifloxacin has not been evaluated in pediatric patients.
Concerns have been raised about resistance of anaerobic
micro-organisms to moxifloxacin, but a recent analysis
showed no correlation between anaerobic susceptibility
data and clinical outcome with use of moxifloxacin [300].
Similarly, the decreased susceptibility of E. coli and other
gram-negative organisms to ciprofloxacin and levofloxacin
[28] would be expected to apply to moxifloxacin as well.
These decreases in susceptibility, however, have not led to
obvious increases in failure rates in recent clinical trials.
Based on the available data, the task force still recom-
mends use of moxifloxacin as monotherapy for lower-risk
patients with CA-IAI, particularly for patients who have se-
rious or life-threatening reactions to b-lactam antibiotic
agents. Other agents would be preferable, however, if there is
an appreciable prevalence of fluoroquinolone-resistant
E. coli in the local environment.
The regimen of ciprofloxacin plus metronidazole was
recommended for use in patients with IAI in previous
guidelines [2.4.5]. Two RCTs evaluating ciprofloxacin plus
metronidazole have been published since 2000 (Supple-
mentary Table J; see online supplementary material at www.
liebertpub.com/overview/surgical-infections/53/) [247,249]
these are in addition to four studies included in the previous
evidence review [3]. Success rates using ciprofloxacin plus
metronidazole have been equivalent to comparators in all of
these studies, with two of the older studies reporting a sig-
nificantly higher success rate with this regimen [245,301]. A
meta-analysis of RCTs reported higher success rates with use
of ciprofloxacin plus metronidazole than comparators for
treatment of patients with IAI (Supplementary Table K; see
online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/) [302]. Although cipro-
floxacin has been approved for certain pediatric indications,
concern has been expressed about potential side effects in
pediatric patients. Recent reviews have concluded that this
agent is relatively safe to use in children [303,304]. The in-
creasing world-wide resistance of E. coli to ciprofloxacin is
also of concern [28], although it has not been clearly asso-
ciated with decreased clinical responses to fluoroquinolones
in patients with IAI.
Based on all data, the task force concludes that cipro-
floxacin plus metronidazole is a reasonable option for the
treatment of lower-risk patients with CA-IAI. In geographic
localities with a high prevalence of fluoroquinolone-resistant
E. coli, however, a non-fluoroquinolone-based regimen
would be preferable. For higher-risk patients, the task force
believes that ciprofloxacin should be used primarily in a
pathogen-directed fashion, only if peritoneal cultures reveal
susceptible gram-negative micro-organisms. As with other
fluoroquinolones, use of ciprofloxacin plus metronidazole
may be an appropriate option in patients who cannot receive
b-lactam antibiotic agents.
Levofloxacin plus metronidazole has been used for the
treatment of patients with IAI, but its use has not been re-
ported in any published RCT. Levofloxacin has not received
FDA approval for treatment of patients with IAI. Based on its
spectrum of activity, it would be expected to have efficacy
similar to that of other recommended fluoroquinolones. Si-
milar to ciprofloxacin, levofloxacin has been approved by the
FDA for certain pediatric indications. As with other fluor-
oquinolones, resistance of E.coli to levofloxacin is increasing
worldwide [28]. Because levofloxacin may be the sole
fluoroquinolone on many hospital formularies, the task force
has included levofloxacin plus metronidazole as an accept-
able regimen for the treatment of lower-risk patients with
CA-IAI. Because of the lack of data documenting its efficacy
for treating patients with IAI, however, its use should be
limited to situations in which patients cannot be treated with
alternative agents, and levofloxacin is the only fluor-
oquinolone available because of formulary restrictions.
4.7a. We recommend moxifloxacin as an acceptable agent
for the empiric treatment of lower-risk adults with CA-IAI,
although it should be used with caution in areas of the world
where there is a high incidence of fluoroquinolone-resistant
E. coli (Grade 1-A). We do not recommend the use of moxi-
floxacin for empiric treatment of children with IAI unless no
other options are available (Grade 1-C).
4.7b. We recommend ciprofloxacin plus metronidazole as
an acceptable regimen for the empiric treatment of lower-risk
adults with CA-IAI, although it should be used with caution in
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areas of the world where there is a high incidence of
fluoroquinolone-resistant E. coli (Grade 1-A). We suggest
that ciprofloxacin plus metronidazole may be used for em-
piric treatment of children older than one month CA-IAI, if
other options are not suitable (Grade 2-B).
4.7c. We suggest that levofloxacin plus metronidazole is an
acceptable regimen for the empiric treatment of lower-risk
adults with CA-IAI, if use of a fluoroquinolone is warranted
and it is the only fluoroquinolone available for use (Grade 2-
C). We suggest that levofloxacin plus metronidazole may be
used for empiric treatment of children older than one month
with IAI, if other options are not suitable (Grade 2-C).
H. Tigecycline
Q 4.8. What is the role of tigecycline in the treatment of
patients with IAI?
Tigecycline is a glycylcycline that is less susceptible to
some of the common mechanisms producing resistance of
bacteria to tetracyclines [305]. It was recommended for em-
piric use in lower-risk patients with CA-IAI in the previous
guideline [4]. Use of tigecycline in the treatment of patients
with IAI has been described in five RCTs published since 2000
(Supplementary Table L; see online supplementary material at
www.liebertpub.com/overview/surgical-infections/53/) [252,
253,294–296]. None of these demonstrated any statistically
significant difference in success rates between tigecycline
and other agents. In meta-analyses of these RCTs, there was a
trend toward lower clinical success rates with tigecycline,
which did not reach statistical significance (Supplementary
TableM; see online supplementarymaterial at www.liebertpub
.com/overview/surgical-infections/53/) [306,307]. Aggregated
data from clinical trials using tigecycline for any indication,
however, revealed higher deaths in tigecycline-treated patients,
which was significant in some of the analyses [306–310].
These data resulted in a black box warning from the FDA
indicating that tigecycline should be reserved for situations in
which other agents are not suitable.
Tigecycline has in vitro activity against many ESBL-
producing strains of Enterobacteriaceae and A. baumannii,
although not against P. aeruginosa [311,312]. In observational
studies, tigecycline has been successful in the treatment of
patients with IAI likely to harbor resistant micro-organisms
[313–315]; however, tigecycline was frequently administered
in conjunctionwith other effective agents in these studies, so its
efficacy as a single agent remains uncertain [316–318]. Tige-
cycline could also offer a carbapenem-sparing option for the
treatment of ESBL-producing strains of Enterobacteriaceae.
Overall, the task force concluded that the possibility of lower
efficacy and higher deaths argued against a continued recom-
mendation for the routine use of tigecycline as an empiric agent
to treat patients with IAI. There are clinical scenarios in which
pathogen-directed use of tigecycline for the management of
resistant bacteria could be an option, particularly in patients
who cannot be treated with other agents, however.
4.8a. We do not recommend tigecycline for the empiric
treatment of patients with IAI under most circumstances
(Grade 1-B). We suggest that tigecycline may be of use in the
treatment of adult patients with resistant pathogens, partic-
ularly as a component of a combination regimen, when other
agents are not suitable (Grade 2-B).
I. Anti-anaerobic agents
Q 4.9a. What is the role of metronidazole as an anti-
anaerobic agent in combined regimens for the treatment
of patients with IAI?
Q 4.9b. What is the role of clindamycin as an anti-
anaerobic agent in combined regimens for the treatment
of patients with IAI?
Metronidazole is commonly used for the treatment of pa-
tients with IAI to provide anti-anaerobic activity, if the agent
being used to treat gram-negative micro-organisms lacks
such activity. Nearly all recent RCTs have used metronida-
zole as the anti-anaerobic agent in combination regimens
[203–205,225,246,247,249–255,263,264,274,275,319]. Me-
tronidazole was also used extensively in studies reviewed
previously [3]. There are no current data and only limited
older data fromRCTs comparing the efficacy ofmetronidazole
with other anti-anaerobic agents; however, the breadth of
studies using this agent attests to its efficacy. The development
of major resistance of anaerobic micro-organisms to metro-
nidazole has yet to be observed [236]. Overall, the task force
concluded that metronidazole remains the preferred agent for
management of anaerobic bacteria when combination regi-
mens are used for the treatment of patients with IAI.
The use of clindamycin as an anti-anaerobic agent to treat
patients with IAI has fallen into disfavor. Since 2000, only
three RCTs using clindamycin have been published
[204,206,320], all in pediatric patients with perforated ap-
pendicitis. Clindamycin was used much more frequently in
studies published before that date [3]. Use of clindamycin for
treatment of patients with IAI has been curtailed because of
increased in vitro resistance of anaerobic bacteria, particu-
larly B. fragilis, to this agent [236,321] and the heightened
concern for the development of Clostridium difficile-
associated disease after exposure to clindamycin [322,323].
Based on these considerations and the availability of alter-
native agents, the task force considers clindamycin to be a
second-line anti-anaerobic agent in combination regimens,
although it is an option if metronidazole cannot be used.
4.9a. We recommend metronidazole as the preferred anti-
anaerobic agent to be used in combination regimens for the
empiric treatment of IAI in adults and children older than one
month (Grade 1-B).
4.9b. We suggest that clindamycin not be used as an anti-
anaerobic agent in combination regimens for the empiric
treatment of IAI in adults and children older than one month
(Grade 2-B) unless other agents cannot be used. We suggest
use of this agent is acceptable in children under one month of
age (Grade 2-C).
J. Anti-enterococcal and anti-staphylococcal agents
Q 4.10a. What is the role of ampicillin in the treatment of
patients with IAI?
Q 4.10b. What is the role of vancomycin in the treatment
of patients with IAI?
Q 4.10c. What are the roles of linezolid and daptomycin
in the treatment of patients with IAI?
Treatment of Enterococcus spp. should be considered in
higher-risk patients with CA-IAI and those with HA-IAI.
Nearly all strains of E. faecalis, including some strains of
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vancomycin-resistant E. faecalis, are susceptible to ampicillin
[89,324]. This agent is used frequently for the treatment of
patients with serious infections because of E. faecalis, such as
endocarditis or bacteremia [325,326]. Ampicillin has been
used frequently also as a component of combination (‘‘triple’’)
antibiotic therapy for IAI, particularly in pediatric patients,
although its necessity for that has not been demonstrated
[204,327,328]. The task force has concluded that ampicillin is
an acceptable agent for managing a proven or suspected IAI
because of E. faecalis in higher-risk patients, if the selected
regimen lacks activity against that micro-organism.
In IAI, E. faecium is increasingly encountered as a path-
ogen, particularly in patients with HA-IAI. In contrast to E.
faecalis, nearly all strains of E. faecium are resistant to am-
picillin [89,324,329–332]. Although the incidence of VRE is
increasing, vancomycin-susceptible strains of E. faecium can
be treated with vancomycin or other glycopeptides such as
teicoplanin [324,329,331,332]. The efficacy of empiric van-
comycin or teicoplanin as anti-enterococcal agents in patients
with IAI has not been evaluated definitively. Broad experi-
ence has been gained with use of glycopeptides to manage
serious enterococcal infections, however. Therefore, the task
force considers vancomycin (or teicoplanin where available)
to be the first-line agent for treating most patients with HA-
IAI proven or suspected to be because of vancomycin-
susceptible strains of E. faecium.
Vancomycin should not be used as empiric anti-
enterococcal therapy in patients known to be infected or
considered to be at high risk for infection with VRE. Ampi-
cillinmay be an option for patients with IAI from vancomycin-
resistant strains of E. faecalis, although susceptibilities should
be monitored [333,334]. For patients with vancomycin-
resistant E. faecium, linezolid or daptomycin are the pre-
ferred agents. Both linezolid and daptomycin have good
in vitro activity against vancomycin-resistant E. faecium
[322,329,333,335], and linezolid has been approved by the
FDA for the treatment of patients with infections from this
resistant pathogen. Observational studies have reported that
both agents have been used successfully to treat patients with
various types of infections because of VRE, including HA-
IAI [115,334–337]. Recent meta-analyses of patients with
VRE bacteremia suggested lower mortality rates after treat-
ment with linezolid rather than daptomycin; however, the
component studies used in these analyses were all retro-
spective in nature [338,339]. Because of the lack of pro-
spective data, the task force did not attempt to indicate a
preference between linezolid and daptomycin for the treat-
ment of IAI from VRE.
Although relatively uncommon, MRSA strains are en-
countered in patients with HA-IAI, particularly those with
post-operative HA-IAI [23,24,26,62,340–342]. There are no
published studies specifically evaluating antimicrobial ther-
apy for the treatment of patients with IAI involving MRSA.
For patients with serious infections from MRSA, a glyco-
peptide is frequently described as the preferred agent
[334,343–345]. Thus, vancomycin or teicoplanin (where
available) would be appropriate choices for empiric therapy of
HA-IAI when MRSA is a suspected or proven pathogen.
Concerns have been expressed, however, about the efficacy of
glycopeptides for managing MRSA infections [345–349] and
the nephrotoxicity of these agents [350–352]. Among other
agents with activity against MRSA [345,353–355], the task
force considered linezolid and daptomycin to be the most
reasonable alternatives. Linezolid is at least as effective as
vancomycin for the management of infections from MRSA,
with some data suggesting superiority [344,348,355–358].
There are some observational data describing successful use of
linezolid to treat patients with IAI from MRSA [336]. Dap-
tomycin, likewise, appears to be equivalent to vancomycin for
the management of serious MRSA infections [337,354,359]
and could be used to treat patients with IAI from MRSA.
4.10a. We suggest that ampicillin may be used for treatment
of IAI in adults and children to provide pathogen-directed
therapy against susceptible enterococcal strains (Grade 2-B).
4.10b. We suggest that vancomycin may be used for
treatment of IAI in adults and children to provide empiric or
pathogen-directed therapy for suspected or proven infections
from vancomycin-susceptible E. faecium or methicillin-
resistant S. aureus (MRSA) (Grade 2-B). We suggest inclu-
sion of vancomycin in an aztreonam-based regimen for
coverage of gram-positive organisms (Grade 2-B).
4.10c. We suggest that linezolid and daptomycin may be
used for management of IAI in adults and children to provide
empiric or pathogen-directed therapy for suspected or pro-
ven infections from vancomycin-resistant Enterococcus spp.,
and as an alternative to vancomycin for suspected or proven
infections because of MRSA (Grade 2-B).
K. Antifungal agents
Q 4.11a. What is the role of amphotericin B and its lipid
formulations in the treatment of patients with IAI?
Q 4.11b. What is the role of fluconazole in the treatment
of patients with IAI?
Q 4.11c. What is the role of voriconazole in the treatment
of patients with IAI?
Q 4.11d. What is the role of echinocandins (anidula-
fungin, caspofungin, micafungin) in the treatment of pa-
tients with IAI?
The antifungal agents most commonly used to treat pa-
tients with HA-IAI because of Candida spp. include the
polyene amphotericin B and its various formulations; azoles,
including fluconazole and voriconazole; and echinocandins,
including anidulafungin, caspofungin, and micafungin. Most
RCTs evaluating these agents have enrolled primarily pa-
tients with candidemia and only limited numbers of patients
with candidal IAI. In a number of these RCTs, outcomes of
these latter patients have not been reported separately.
Use of amphotericin B has fallen into disfavor because of
toxicity, despite the development of alternative formulations
designed to combat that problem [360]. Two RCTs published
since 2000 reported lower success rates in small numbers of
adult patients with intra-abdominal candidiasis treated with
either amphotericin B or liposomal amphotericin B versus
those treated with caspofungin or micafungin (Supplemen-
tary Table N; see online supplementary material at www.
liebertpub.com/overview/surgical-infections/53/) [361,362].
In a previously reviewed study [3], success rates in treating a
confirmed candidal IAI appeared higher with amphotericin B
than with fluconazole, but only very small numbers of patients
were treated with either agent [363]. Among all patients with
invasive candidal infections, a meta-analysis found no overall
difference in treatment failure comparing amphotericin B
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formulations with echinocandins or azoles, but a better safety
profile with echinocandins and less nephrotoxicity with flu-
conazole [364].
Fluconazole has been used extensively to treat patients
with intra-abdominal candidal infections, but there are only
limited new prospective data regarding this use. One RCT
found higher success rates with anidulafungin compared with
fluconazole in patients with invasive candidiasis, primarily
from an abdominal source (Supplementary Table N; see
online supplementary material at www.liebertpub.com/
overview/surgical-infections/53/) [365]. In the previous evi-
dence review [3], one RCT showed that pre-emptive ad-
ministration of fluconazole was more effective than placebo
for preventing Candida peritonitis [366]; however, as indi-
cated above, another RCT suggested fluconazole was less
effective than amphotericin B in a very limited number of
patients with abdominal candidiasis [363]. In patients with
any type of candidal infection, the meta-analysis by Gafter-
Gvili et al. [364] identified a trend toward higher treatment
failure rates with use of fluconazole, but this did not reach
statistical significance.
There are few data available regarding management of
intra-abdominal candidiasis with other azoles. Voriconazole
has better in vitro activity than fluconazole against C. glabrata
and C. krusei, although not all strains are susceptible [367–
369]. Voriconazole appeared to be equivalent to amphotericin
B followed by fluconazole for the management of candidal
infections in non-neutropenic patients, but the results in the
very small number of patients with invasive candidiasis rather
than candidemia were not reported separately [370].
Several RCTs have suggested that echinocandins are at
least as effective as other agents for the treatment of patients
with IAI from Candida spp.[361,362,365,371]. An uncon-
trolled trial of pre-emptive caspofungin suggested that this
prevented an overt clinical infection from Candida in nearly
all patients [372]. For the management of candidal infections
in general, caspofungin and micafungin appear to be non-
inferior to amphotericin B formulations, and anidulafungin
may be superior to fluconazole [364,373]. Adverse events
appear to be lower with echinocandins than with polyenes or
azoles. A cost-effectiveness analysis has suggested lower
overall costs with use of an echinocandin compared with
other agents, because of reduced adverse events, including
persistent infection [374]. Guidelines by the IDSA recom-
mend use of echinocandins over fluconazole in patients with
moderately severe to severe illness from Candida [375].
Overall, the task force concluded that echinocandins can be
recommended for the treatment of severely ill patients sus-
pected or proven to have an IAI from Candida. Fluconazole
can be used to treat less severely ill patients infected with C.
albicans, but voriconazole or an echinocandin would be pre-
ferred for the treatment of patients infected with fluconazole-
resistant species of Candida. Because less toxic alternatives
are available, the task force does not recommend routine use of
polyenes for treatment of patients with candidal IAI.
4.11a. We do not recommend routine use of amphotericin
B or its lipid formulations for empiric or pathogen-directed
treatment of adults or children with intra-abdominal candi-
diasis (Grade 2-B).
4.11b. We suggest use of fluconazole for pre-emptive
management of IAI in non-critically ill adults and children
who are at high risk for intra-abdominal candidiasis, and for
pathogen-directed treatment of non-critically ill patients in-
fected with susceptible strains of C. albicans (Grade 2-B).
4.11c. We suggest use of voriconazole for empiric or
pathogen-directed management of IAI in non-critically ill
adults and children older than one month who are suspected
or proven to be infected with strains of Candida that are not
susceptible to fluconazole (Grade 2-B).
4.11d. We recommend an echinocandin (anidulafungin,
caspofungin, or micafungin) for empiric or pathogen-
directed management of IAI in severely ill adults and chil-
dren older than one month who are suspected or proven to be
infected with Candida spp. (Grade 1-B).
5. Oral antimicrobial agents
Q 5.1. When can oral antimicrobial agents be used in the
treatment of patients with IAI?
Q 5.2a. What is the role of oral amoxicillin-clavulanic
acid in the treatment of patients with IAI?
Q 5.2b. What is the role of oral moxifloxacin in the
treatment of patients with IAI?
Q 5.2c. What is the role of oral ciprofloxacin plus met-
ronidazole in the treatment of patients with IAI?
Q 5.2d. What other oral antimicrobial agents can poten-
tially be used for the treatment of patients with IAI?
An accepted principle of antimicrobial stewardship is
conversion from IV to oral anti-infective agents when the
patient’s condition permits [196]. This principle can be ap-
plied to patients with IAI as well and was recommended in
previous guidelines [2,4,5]. As with IV antimicrobial agents,
oral agents should have activity against the common aerobic
gram-negative bacilli, gram-positive cocci, and anaerobic
micro-organisms involved in these infections. Although the
use of oral agents in patients with IAI is frequently not fea-
sible immediately after a source control procedure because of
gastrointestinal intolerance, it is often possible to switch the
patient to oral agents later, once the patient has return of
gastrointestinal function.
A number of RCTs have permitted use of oral antibiotics as
a substitute for IV antibiotics. Only a few of these have di-
rectly tested the hypothesis that a switch to oral agents is
equivalent to use of exclusive IV therapy for patients with
IAI. In two studies, pediatric subjects were randomized to a
regimen of IV antibiotics only or to a regimen of IV antibi-
otics in which a switch to oral amoxicillin-clavulanic acid
was allowed after three or four days of IV therapy (Supple-
mentary Table O; see online supplementary material at www.
liebertpub.com/overview/surgical-infections/53/) [319,320].
An older study, reviewed previously [3], randomized one
group of patients to an arm in which oral ciprofloxacin plus
metronidazole was permitted as continuation therapy [376].
Outcomes were similar in patients allowed the oral switch
and those who received IV antibiotics only.
Indirect evidence in support of a switch to oral antibiotic
agents has come from additional RCTs in which patients
were allowed to receive oral agents [215,217,229,245–
247,249,251,288,289,301,377]. It should be noted that many
of these trials allowed for prolonged antimicrobial therapy,
well beyond the previous recommendation of a maximum
four to seven days of total antimicrobial therapy [2,4] or the
current recommendation of a maximum of four days in adult
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patients or five days in pediatric patients (Sections 10 and 13).
Thus, much of these data on use of oral antimicrobial therapy
are irrelevant to current recommendations. Patients in these
RCTs were frequently switched to oral agents different from
the IV ones they had received, and in some cases to oral
agents from an entirely different class of antibiotic. Thus,
there does not appear to be an obligatory need to continue the
same agent or agents when making a switch to oral therapy.
Overall, the task force concluded that use of oral antimicro-
bial therapy is a valid option, but only if it shortens the course
of IV therapy, and not if it is used to prolong the total duration
of antimicrobial therapy beyond current recommendations.
Oral amoxicillin-clavulanic acid was directly evaluated as
step-down therapy in two small RCTs of pediatric patients
with perforated appendicitis [319,320], and allowed as step-
down therapy in a number of other trials [217,229,251,
288,301,320,377]. No increase in treatment failure was
observed in patients who were switched to this oral agent.
There is a relatively high prevalence of E. coli resistant to
amoxicillin-clavulanic acid throughout the world, however
[219]. Thus, the task force would recommend some caution
when using this agent for oral step-down therapy, and it should
not be used if culture results reveal a resistant organism.
A switch from IV to oral moxifloxacin was permitted in
several RCTs testing this agent [214,228,250]. There was no
indication of any adverse events associated with a switch to
oral moxifloxacin therapy. No trials directly compared pa-
tients permitted oral therapy with those assigned to receive
IV therapy only, however. Use of oral moxifloxacin has not
been studied in pediatric patients with IAI.
One relatively large RCT included in the previous evi-
dence review [3] directly compared patients permitted a
switch to oral ciprofloxacin plus metronidazole with patients
who received IV therapy only with ciprofloxacin plus met-
ronidazole or with imipenem-cilastatin. No significant differ-
ences in outcome were demonstrated between any of the study
groups [376]. Additional trials also permitted a switch to oral
ciprofloxacin plus metronidazole as an option [217,245–
247,249,301]. Clinical outcomes were not adversely affected
by this switch to oral agents. Use of oral ciprofloxacin in pe-
diatric patients appears to be relatively safe [303,304] and can
be considered when other agents are not suitable.
There is relatively scant evidence with regard to the use of
other oral agents for the treatment of patients with IAI. Oral
first-, second-, and third-generation cephalosporins, includ-
ing cephalexin, cefadroxil, cephradine, cefuroxime, cefaclor,
cefprozil, cefdinir, and cefpodoxime, in combination with
metronidazole, are potential options, as they have reasonable
activity against non–ESBL-producing strains of E. coli [378–
385]. One small RCT found no adverse effect of a change from
IV therapy to oral cephalexin, but this switch occurred fairly
late during a prolonged course of antibiotic treatment [386].
Oral levofloxacin in combination with metronidazole is also a
potential option, but there are no published RCTs describing
use of either IV or oral levofloxacin in patients with IAI. Use of
oral trimethoprim-sulfamethoxazole plus metronidazole as
continuation therapy appeared to be successful in two obser-
vational studies in pediatric patients, but this switch also oc-
curred fairly late in the antibiotic course [387,388].
5.1. We recommend use of selected oral agents with good
bioavailability as a substitute for IV agents in the treatment of
patients with IAI when the patient has return of adequate
gastrointestinal function. Oral antibiotics should only be
used to complete a short course of treatment and not to
prolong antimicrobial use beyond current recommendations
for duration of therapy (Grade 1-B).
5.2a. We suggest use of oral amoxicillin-clavulanic acid as
an acceptable regimen to complete a short course of anti-
microbial therapy for the treatment of IAI in adults and
children older than one month with IAI (Grade 2-B).
5.2b. We suggest use of oral moxifloxacin as an acceptable
regimen to complete a short course of antimicrobial therapy
for the treatment of IAI in adults (Grade 2-B). We do not
recommend the use of oralmoxifloxacin for the treatment of IAI
in children, unless no other option is available (Grade 1-B).
5.2c. We recommend use of oral ciprofloxacin plus metro-
nidazole as an acceptable regimen to complete a short course
of antimicrobial therapy for the treatment of IAI in adults
(Grade 1-B). We suggest that oral ciprofloxacin plus metro-
nidazole may be used to complete a short course of antimi-
crobial therapy for the treatment of IAI in children older than
one month, if other options are not suitable (Grade 2-B).
5.2d. We suggest that oral levofloxacin plus metronidazole,
an oral first-, second-, or third-generation cephalosporin
plus metronidazole, or oral trimethoprim-sulfamethoxazole
plus metronidazole are potential regimens that could be used
selectively to complete a short course of antibiotic therapy
for the treatment of IAI in adults and children older than one
month, if other oral agents are not suitable (Grade 2-C).
6. Selection of empiric antimicrobial therapy for adult
patients with CA-IAI
A. Lower-risk patients with CA-IAI
Q 6.1. What are the general principles for selection of
empiric antimicrobial therapy of CA-IAI in lower-risk
patients?
Q 6.2a. What are the preferred agents for initial empiric
antimicrobial therapy of CA-IAI in lower-risk patients?
Q 6.2b. Should patients with perforated appendicitis be
treated with different empiric antimicrobial agents than
other lower-risk patients with CA-IAI?
The established principle of antimicrobial therapy for pa-
tients with IAI has been to administer agents with activity
against gram-negative Enterobacteriaceae, aerobic strepto-
cocci, and obligate enteric anaerobes [1,2,4,5]. As detailed in
Section 4, a large number of antimicrobial agents or regimens
meet these criteria, with efficacy information about many of
them available from RCTs. In these clinical trials, lower-risk
patients with CA-IAI have predominated, even in those eval-
uating broad-spectrum antimicrobial regimens [3,389]. Based
on these trials, the breadth of antimicrobial coverage does not
appear to have a major impact on clinical outcomes in lower-
risk patients with CA-IAI. Several RCTs published since 2000
have compared regimens with and without anti-pseudomonal
activity [204,205,220,225,228–230,294–296] and with or
without anti-enterococcal activity [204,205,225,228–230,252,
255,274].
By and large, these trials have not demonstrated significant
differences in outcome when comparing narrow-spectrum and
broad-spectrum regimens. A detailed meta-analysis concluded
that antimicrobial regimens used for secondary peritonitis
were all essentially equivalent [390]. A large database study
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did not identify any major differences in outcome comparing
narrow-spectrum regimens with broad-spectrum regimens, as
long as the regimen covered standard gram-negative En-
terobacteriaceae and obligate anaerobes [192].
There are relatively little data available regarding use of
antifungal agents in lower-risk patients with CA-IAI. Typi-
cally, RCTs have not permitted concomitant use of antifungal
therapy. Treatment failures attributed to a lack of antifungal
coverage, however, have rarely been evident in these trials.
Moreover, microbiologic studies indicate that isolation of
Candida spp. is quite uncommon in patients with CA-IAI
[21,24,391–394].
Based on these data, the task force supports previous
guidelines on avoiding use of broad-spectrum antimicrobial
therapy, including antifungal therapy, in lower-risk patients
with CA-IAI. Limiting the exposure of lower-risk patients
with CA-IAI to broad-spectrum antimicrobial therapy would
be consistent with the goals of antimicrobial stewardship
programs [196,395,396]. In keeping with the goal of using
narrow-spectrum agents for lower-risk patients with CA-IAI,
the task force recommends use of agents that may not have
much activity against Pseudomonas spp. or Enterococcus
spp. These include ertapenem as monotherapy, and cefotax-
ime or ceftriaxone with metronidazole as combination ther-
apy. Where available, cefoperazone-sulbactam is also an
option. The use of cefuroxime plus metronidazole is rea-
sonable but has been less well supported by contemporary
data. Ticarcillin-clavulanic acid would be acceptable but will
now only be an option if production resumes.
Use of fluoroquinolone-based regimens requires additional
consideration. The finding that nearly 30% of E. coli strains
isolated from patients with IAI in North America are resistant
to fluoroquinolones is of concern [28], although the preva-
lence of resistant strains in lower-risk patients with CA-IAI
may be lower than this. Recent clinical studies have described
good results using moxifloxacin alone or ciprofloxacin
plus metronidazole in patients with CA-IAI, despite being
performed while there was increasing in vitro resistance of
Enterobacteriaceae to fluoroquinolones [215,229,247,249–
251,284]. Thus, the task force recommends moxifloxacin or
ciprofloxacin plus metronidazole for use in lower-risk
patients with CA-IAI, but would prefer that such use be re-
strictedprimarily topatientswith contraindications to the use of
b-lactam antibiotics. A paucity of data exists supporting use of
levofloxacin plus metronidazole for treatment of patients with
IAI, and it has not beenapprovedby theFDAfor this indication.
Because it may be the only fluoroquinolone available on some
hospital formularies, however, the regimenof levofloxacin plus
metronidazole is acceptable under those circumstances.
Table 9 outlines these recommendations for selection of
empiric antimicrobial therapy in lower-risk patients with CA-
IAI. In regions of the world where there is a much higher prev-
alence of fluoroquinolone-resistant and ESBL-producing strains
of Enterobacteriaceae in the community [28,235,397], these
recommendations would likely need to be modified, as will be
discussed further in Section C under recommendations 6.6.
Perforated appendicitis is usually the most common cause
of IAI among participants in clinical trials [3]. Overall deaths
are lower in these patients than in patients with IAI from other
sources, even after adjusting for age and co-morbidities
[59,75,187,398]. Post-operative infections, however, includ-
ing intra-abdominal abscesses, occur in a substantial number
of patients with appendiceal perforations [187,399–401].
These treatment failures are associated with longer hospitali-
zations and increased use of resources [192]. Thus, the task
force believes that the same antimicrobial regimens outlined
for use in lower-risk patients with CA-IAI apply to lower-risk
patients with perforated appendicitis, and that potentially
lower cost but inferior regimens should not be substituted.
6.1. We recommend treatment of CA-IAI in lower-risk
patients with narrower-spectrum antimicrobial agents hav-
ing activity against the usual gram-negative En-
terobacteriaceae, aerobic streptococci, and obligate
anaerobic microorganisms associated with these infections
(Grade 1-A). We recommend against the use of broader-
spectrum or additional agents specifically to provide anti-
pseudomonal or anti-enterococcal coverage (Grade 1-A). We
suggest that antifungal coverage is unnecessary for man-
agement of CA-IAI in lower-risk patients (Grade 2-B).
6.2a. We recommend cefotaxime or ceftriaxone plus met-
ronidazole or ertapenem as the preferred antimicrobial
agents for the management of CA-IAI in lower-risk patients
(Grade 1-A). We recommend ciprofloxacin plusmetronidazole
ormoxifloxacin monotherapy for the management of CA-IAI in
lower-risk patients who have serious b-lactam allergies
(Grade 1-A), and suggest levofloxacin plus metronidazole as
an alternative if no other fluoroquinolone is available (Grade
2-C). We suggest use of cefuroxime plus metronidazole (Grade
Table 9. Recommended Empiric Antimicrobial
Regimens for Patients with Community-
Acquired Intra-Abdominal Infection
Lower-risk patientsa,b Higher-risk patients
Single agents
Ertapenem Piperacillin-tazobactam
Moxifloxacinc Doripenemf
Imipenem-cilastatin
Meropenemf
Combination regimens
Cefotaxime or ceftriaxone
plus metronidazoled
Cefepime plus
metronidazolef,g
Ciprofloxacin plus
metronidazolec,e
Aztreonam plus
metronidazole plus
vancomycinh
aTicarcillin-clavulanate is no longer available in the United States.
bCefoperazone-sulbactam is also an option, where available.
cUse of fluoroquinolones is suggested primarily for patients with
significant reactions to b-lactam antibiotic agents.
dCefuroxime plus metronidazole is also an option, but is less well
supported by contemporary data.
eIf levofloxacin is the only fluoroquinolone available on a
formulary, it may be substituted for ciprofloxacin. There is little
evidence with regard to its efficacy, and it is not approved by the
Food and Drug Administration for treatment of patients with
complicated intra-abdominal infection.
fUse of an agent such as ampicillin or vancomycin effective
against Enterococcus spp. can be considered in patients with severe
sepsis-septic shock and other higher-risk patients who receive
doripenem or meropenem, and should be added to a cephalosporin-
based regimen.
gCeftazidime plus metronidazole is also an option, but is less well
supported by contemporary data.
hAztreonam plus metronidazole plus vancomycin is an option for
patients with significant reactions to b-lactam antibiotic agents, but
is less well supported by contemporary data.
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2-B), or cefoperazone-sulbactam, where available (Grade 2-
B), as alternative empiric antimicrobial regimens for the
management of CA-IAI in lower-risk patients.
6.2b. We recommend treatment of patients with perforated
appendicitis with the same agents or regimens recommended
for other lower-risk patients with CA-IAI, unless they meet
criteria identifying them as higher-risk patients or at risk for
having resistant pathogens (Grade 1-A).
B. Higher risk patients with CA-IAI
Q 6.3. What are the general principles for selection of
empiric antimicrobial therapy of CA-IAI in higher-risk
patients?
Q 6.4a. What are the preferred agents for initial empiric
antimicrobial therapy of CA-IAI in higher-risk patients?
Q 6.4b. Should empiric anti-enterococcal therapy be used
to treat CA-IAI in higher-risk patients?
Q 6.4c. Should empiric antifungal therapy be used to treat
CA-IAI in higher-risk patients?
Inadequate antimicrobial therapy has been associated with
higher deaths in patients with sepsis and septic shock from any
source [193–195]. A number of studies have also demonstrated
an association of inadequate antimicrobial therapy with worse
outcomes in patients with IAI [43,54,58,71,187,194], although
this finding has not been replicated by all investigators
[18,402,403]. The infecting flora of higher-risk patients with
CA-IAI are generally similar to those of lower-risk patients.
Some patients with CA-IAI, however, are infected with path-
ogens such as Enterobacter spp., P. aeruginosa and En-
terococcus spp., which are resistant to the narrower-spectrum
agents recommended for use in lower-risk patients [22–
24,26,27]. Higher-risk patients infected with these pathogens
might therefore receive inadequate antimicrobial therapy if
narrower-spectrum agents were used.
A limited number of observational studies have suggested
that the failure to treat seriously ill patients infected with
micro-organisms such as Enterococcus spp. and P. aerugi-
nosa does result in higher deaths [24,111,330,404]. The task
force therefore suggests that higher-risk patients with CA-
IAI, particularly those with sepsis or septic shock, receive
broader-spectrum empiric antimicrobial therapy to minimize
the risk of inadequate initial therapy. The agents that have
been included in this category are piperacillin-tazobactam,
the broad-spectrum carbapenems, imipenem-cilastatin, mer-
openem, and doripenem, and cefepime plus metronidazole.
The use of ceftazidime plus metronidazole is an option, al-
though less well supported by contemporary data. Similarly,
the use of aztreonam plus metronidazole plus vancomycin
can be considered, particularly for patients with severe b-
lactam reactions, although it too has not been evaluated in
recent publications (Table 9).
Previous guidelines did not support the use of combination
gram-negative therapy when treating higher-risk patients
with CA-IAI. MDR gram-negative pathogens are uncommon
in higher-risk patients with CA-IAI [24]. Two RCTs pub-
lished since 2000 did not find the combination of an ami-
noglycoside with a cephalosporin to be any more efficacious
than use of a cephalosporin-based regimen alone, although
different agentswere used in each arm of these trials [203,254].
Another large RCT did not identify any improvement in out-
come with addition of moxifloxacin to meropenem for treat-
ment of patients with sepsis; this study included a large number
of patients with IAI, but did not report the results of those
patients separately [405]. A recent meta-analysis did not find
any benefit of combination regimens on outcomes in patients
with bacteremia because of P. aeruginosa [406]. Two ran-
domized trials included in the previous evidence review [3] did
not demonstrate any improvement in outcome with addition of
an aminoglycoside to a b-lactam antibiotic agent in severely ill
patients with IAI [22,407]. The task force, therefore, does not
believe that combination gram-negative therapy is necessary
for empiric treatment of higher-risk patients with CA-IAI.
Although there is strong evidence that anti-enterococcal
therapy is unnecessary in lower-risk patients with CA-IAI, it
is less clear if this applies to higher-risk patients with CA-IAI.
Most of the evidence is derived from observational studies.
The frequency with which Enterococcus spp. is isolated ap-
pears to be increased in higher-risk as compared with lower-
risk patients with CA-IAI [27,89,408]. Isolation of En-
terococcus spp. has also been associated with worse clinical
outcomes, including death, in some studies of higher-risk
patients with CA-IAI [24,27,111]. Thus, the task force con-
cluded that there is rationale for providing empiric anti-
enterococcal coverage in seriously ill patients with CA-IAI.
Although both E. faecalis and E. faecium have been iso-
lated from peritoneal cultures of patients with CA-IAI,
E. faecalis predominates [24,26]. Thus, coverage ofE. faecalis
is likely to be the primary concern when potentially using
an anti-enterococcal agent to treat higher-risk patients with
CA-IAI. Ampicillin and piperacillin generally have good ac-
tivity against E. faecalis in vitro [89,324,409]. Among the
broad-spectrum carbapenems, imipenem-cilastatin also has
good in vitro activity, but doripenem and particularly mer-
openem have somewhat less activity [329,332,409–411].
Based on these data, the task force judged piperacillin-
tazobactam or imipenem-cilastatin, and the regimen of az-
treonam, metronidazole, and vancomycin as adequate for
empiric treatment of Enterococcus spp. in higher-risk patients
with CA-IAI. With use of other broad-spectrum carbapenems,
addition of ampicillin or vancomycin could be considered.
Supplemental ampicillin or vancomycin for coverage of
E. faecalis should be added routinely to combinations of ce-
fepime or ceftazidime with metronidazole, because these
regimens lack anti-enterococcal coverage. Routine therapy
directed against E. faecium was not considered necessary for
higher-risk patients with CA-IAI, but if there were a high
suspicion that this organism was a component of the infecting
flora, supplemental vancomycin should be used.
It is also uncertain whether the recommendation against
use of empiric antifungal therapy in lower-risk patients with
CA-IAI should apply to higher-risk patients with CA-IAI.
Observational studies have provided somewhat contradictory
findings as to whether or not isolation of Candida is associ-
ated with increased deaths in critically ill patients with
CA-IAI [56,412]. One RCT, which included critically ill
patients with both CA-IAI and HA-IAI, did not find empiric
use of fluconazole associated with any improvement in out-
come [413]. Retrospective studies have also failed to docu-
ment a benefit to routine use of empiric antifungal therapy in
patients with CA-IAI [27,414]. Thus, in agreement with other
authorities [56,415], the task force believes that routine an-
tifungal therapy is unnecessary for most higher-risk patients
with CA-IAI.
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Critically ill patients with CA-IAI from upper gastroin-
testinal perforations, however, have a particularly high inci-
dence of Candida peritonitis [110,416,417], and the overall
deaths in these patients is quite high [412,418]. A retro-
spective study of patients with gastroduodenal perforations
suggested that delayed antifungal therapy contributed to in-
creased deaths [416]. Based on these limited data, the task
force suggested that empiric antifungal therapy be considered
for critically ill patients with CA-IAI because of upper gas-
trointestinal perforations.
6.3. We suggest treatment of CA-IAI in higher-risk patients
with broader-spectrum empiric antimicrobial agents to en-
sure coverage of less common gram-negative pathogens
potentially involved in these infections (Grade 2-C).
6.4a. We suggest piperacillin-tazobactam, imipenem-
cilastatin, meropenem, doripenem, or cefepime plus metro-
nidazole as the preferred antimicrobial agents for empiric
treatment of CA-IAI in higher-risk patients (Grade 2-A). We
suggest ceftazidime plus metronidazole as an alternative
regimen for these patients (Grade 2-B). We suggest az-
treonam plus metronidazole plus vancomycin for empiric
treatment of patients with a severe reaction to b-lactam
agents (Grade 2-B). We do not recommend addition of an
adjunctive aminoglycoside or fluoroquinolone to a b-lactam
agent for empiric management of CA-IAI in higher-risk pa-
tients (Grade 1-B).
6.4b. We suggest addition of ampicillin or vancomycin for
empiric anti-enterococcal management of CA-IAI in higher-
risk patients, if the patient is not being treated with
piperacillin-tazobactam or imipenem-cilastatin (Grade 2-B).
6.4c. We do not recommend routine use of empiric anti-
fungal therapy for management of CA-IAI in higher-risk
patients (Grade 1-B). We suggest empiric use of antifungal
therapy for management of CA-IAI in critically ill patients
with an upper gastrointestinal source (Grade 2-B).
C. Other considerations for empiric antimicrobial therapy
of patients with CA-IAI
Q 6.5. What agents can be used for initial empiric anti-
microbial therapy of CA-IAI in patients with major re-
actions to b-lactam antibiotics?
Q 6.6. What agents can be used for initial empiric anti-
microbial therapy of CA-IAI in patients who reside in
geographic areas with a high prevalence of ESBL-
producing Enterobacteriaceae in the community?
Q 6.7. What agents can be used for initial empiric antimi-
crobial therapy of CA-IAI in patients who reside in geo-
graphic areas where there are major resource limitations
precluding use of recommended antimicrobial agents?
Antibiotic selection may be problematic in patients with
hypersensitivity reactions to b-lactam antibiotic agents. Al-
though 5%–10% of patients report a history of a reaction to
penicillin, anaphylactic reactions are uncommon. Moreover,
the majority of patients reporting a penicillin allergy do not in
actuality have one [283,419,420]. Cross-reactivity between
various b-lactam agents is relatively uncommon, and mono-
bactams and carbapenems are generally safe to use in almost
all patients with reactions to penicillins or cephalosporins,
even those with serious reactions [283,421,422]. Nonetheless,
frequently there is a reluctance on the part of clinicians to
prescribe a b-lactam antibiotic agent to any patient with even a
very vague history of a penicillin or other b-lactam allergy.
Based on the review of this evidence and expert opinion,
the task force has identified a fluoroquinolone-based regimen
as a reasonable option for initial empiric treatment of lower-
risk patients with CA-IAI who have a serious reaction to b-
lactam antibiotic agents. If the patient cannot receive a
fluoroquinolone antibiotic agent, a b-lactam antibiotic agent
with a low potential for cross-reaction with the agent pro-
ducing the allergy could be considered. Non-b-lactam alter-
natives such as an aminoglycoside plus metronidazole or
tigecycline are also options, but the potential for decreased
efficacy of these alternative agents is a concern.
For higher-risk patients with CA-IAI, alternatives to b-
lactam antibiotic agents may be quite limited because of ef-
ficacy concerns. The task force has selected aztreonam plus
metronidazole plus vancomycin as a reasonable alternative
for patients with severe b-lactam reactions, because az-
treonam has almost no cross-reactivity with other b-lactam
antibiotic agents. A b-lactam from a different class could also
be considered, given the relatively low cross-reactivity be-
tween b-lactams. Use of a fluoroquinolone-based regimen is
a less-attractive option, because of the relatively widespread
prevalence of fluoroquinolone-resistant Enterobacteriaceae.
The potential for decreased efficacy of aminoglycoside-based
regimens and tigecycline would also argue against their use
as monotherapy for management of CA-IAI in higher-risk
patients with severe b-lactam reactions.
The increasing prevalence of ESBL-producing En-
terobacteriaceae in parts of Latin America, Asia, and
Southern Europe makes selection of empiric antimicrobial
therapy for patients with CA-IAI in those regions more
problematic. Common ESBL-producing strains should be
considered resistant to aztreonam and most cephalosporins
other than cephamycins regardless of in vitro testing. More-
over, ESBL-producing Enterobacteriaceae are frequently
resistant to cephamycins and to fluoroquinolones through
other mechanisms [29,235,397,423,424–428]. Suscept-
ibilities of ESBL-producing strains of Enterobacteriaceae to
tigecycline are generally high, although susceptibilities to
piperacillin-tazobactam and amikacin are somewhat more
variable [28,235,241,429,430]. Carbapenems have reliable
activity against most ESBL-producing Enterobacteriaceae
except for those producing carbapenemases [28,29,235,431].
Based on these data, the task force considers ertapenem to
be the best option for empiric treatment of lower-risk patients
with CA-IAI in regions where there is a high likelihood that
ESBL-producing Enterobacteriaceae are components of the
infection. Tigecycline or an aminoglycoside-based regimen
is an alternative, although less preferable because of efficacy
concerns. Where available, cefoperazone-sulbactam is an-
other potential option, especially since one RCT demon-
strated its efficacy in managing IAI in a region where there is
a high prevalence of ESBL-producing Enterobacteriaceae
[203]. Based on in vitro susceptibility patterns, most cepha-
losporins, including cephamycins, aztreonam, and fluor-
oquinolones, would not be good options [423,424,432].
Nonetheless, recent RCTs have not generally demonstrated
higher clinical failure rates in patients with IAI who were
treated with agents that have poorer activity against ESBL-
producing micro-organisms [203,205,214,220,246,252,253,
255,284,293].
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Based on the principle of ensuring adequate initial empiric
antimicrobial therapy, the task force would select a broad-
spectrum carbapenem as the first choice in treating higher-risk
patients with CA-IAI who reside in regions with a high preva-
lence of ESBL-producing Enterobacteriaceae in the community
[423,424,432]. Another option could be piperacillin-tazobactam
[309], although many authorities advise caution with its use
[423,424,432,433]. The potential for decreased efficacy of
aminoglycosides and tigecycline for treating higher-risk
patients with CA-IAI argues against their use as empiric ther-
apy. Based on in vitro susceptibility profiles and limited
clinical data, ceftolozane-tazobactam and ceftazidime-
avibactam could be options for empiric therapy [263,
264,266,274–276], but these agents are not yet available in
many parts of the world where there is a high prevalence of
ESBL-producing Enterobacteriaceae. Because heavy use
of carbapenems has been associated with selection of
carbapenemase-producing gram-negative bacilli [298,432,
434,435], de-escalation from empiric carbapenem therapy
should be undertaken, whenever possible.
Limitations on the availability of antimicrobial resources
in many parts of the world may preclude use of recommended
antibiotic regimens to treat patients with IAI. Although the
task force recommendations are based primarily on evidence
of efficacy, the absolute risk of a worse outcome with use of a
non-recommended regimen compared with a recommended
regimen may be relatively small, as illustrated in meta-
analyses comparing use of aminoglycoside-based regimens
to other regimens [207,208]. Inadequate source control is
much more likely than selection of a specific empiric anti-
microbial regimen to lead to an adverse outcome in patients
with IAI [51,61,71,436]. Thus, ensuring access to appro-
priate source control may have a larger impact than pro-
viding ideal, but expensive antimicrobial agents in areas of
resource limitations.
Non-recommended agents or regimens such as ampicillin-
sulbactam, amoxicillin-clavulanate, cefoxitin, cefotetan, or
cefazolin or aminoglycosides in combination with metroni-
dazole or clindamycin have an appropriate spectrum of ac-
tivity for treating patients with IAI and could be used if
available. Recommended oral agents would also be lower-cost
alternatives to more expensive IV agents. Nonetheless, the
potential for decreased efficacy or increased side effects re-
lated to use of non-recommended agents could negate any of
the cost benefits from using less expensive pharmaceuticals.
6.5. We suggest use of a fluoroquinolone-based regimen
for initial empiric antimicrobial therapy of CA-IAI in lower-
risk patients who have had major reactions to b-lactam an-
tibiotic agents (Grade 2-B). We suggest use of an aztreonam-
based regimen for initial empiric therapy of CA-IAI in
higher-risk patients who have had major reactions to b-
lactam antibiotic agents (Grade 2-B). We suggest that a non-
penicillin b-lactam may be used for empiric antimicrobial
therapy of CA-IAI in patients for whom a severe penicillin
allergy has not been documented and for whom the risk-
benefit ratio is believed acceptable (Grade 2-B).
6.6. We recommend against empiric use of most cephalo-
sporin-, aztreonam-, or fluoroquinolone-based regimens for
empiric antimicrobial therapy of CA-IAI in patients who
reside in geographic areas where there is a high prevalence
of ESBL-producing Enterobacteriaceae in the community
(Grade 1-B). We recommend use of ertapenem for empiric
antimicrobial therapy of CA-IAI in lower-risk patients or a
broad-spectrum carbapenem (doripenem, imipenem-
cilastatin, or meropenem) for CA-IAI in higher-risk patients
who reside in such areas (Grade 1-B).
6.7. We suggest that locally available IV or oral agents
having activity against common intra-abdominal pathogens
be used for empiric antimicrobial therapy of CA-IAI in pa-
tients who reside in geographic areas where there are major
resource limitations (Grade 2-C).
7. Selection of empiric antimicrobial therapy for adult
patients with HA-IAI
A. General approach
Q 7.1a. How should patients with HA-IAI be assessed
with respect to their risk of infection with resistant or
opportunistic pathogens?
Q 7.1b. What agents can be used for initial empiric an-
timicrobial therapy of HA-IAI in patients who are iden-
tified as being at risk of resistant pathogens?
The criteria for identifying patients with HA-IAI were
discussed in Section 1 and are listed in Table 7. Epidemio-
logic studies have identified a number of risk factors identi-
fying patients with HA-IAI at risk for harboring resistant or
opportunistic pathogens [15,17,19,22–24,26,32,33,62,77,79,
85–90,110,340,417,418]. The task force believes that En-
terococcus spp., MRSA, resistant gram-negative bacilli, and
Candida spp. are the resistant or opportunistic pathogens of
primary concern for purposes of prescribing antimicrobial
therapy. It is therefore suggested that a patient be assessed
individually as to his or her risk of infection with each of these
distinct micro-organisms. Knowledge of the local microbial
ecology as well as the patient’s exposure to previous antimi-
crobial therapy will also influence antimicrobial selection.
Because of the wide variety of infecting micro-organisms
in patients with HA-IAI and the frequency with which these
pathogens are resistant to antimicrobial agents, these patients
are at risk for a worse outcome because of inadequate empiric
antimicrobial therapy [43,54,58,187,193–195]. At a mini-
mum, the task force believes that patients with HA-IAI
should receive the empiric antimicrobial regimens described
for use in higher-risk patients with CA-IAI. The reco-
mmended agents include piperacillin-tazobactam, cefepime
plus metronidazole, or a broad-spectrum carbapenem; cef-
tazidime plus metronidazole or aztreonam plus metronida-
zole plus vancomycin are potential alternatives (Table 10).
The potential pathogenic role of enterococci in post-
operative infections probably warrants use of an empiric anti-
enterococcal agent in most of these patients as well. Addition
of other agents to this basic regimen should be predicated on
the individualized assessment of the patient’s risk for resis-
tant gram-positive, resistant gram-negative, or fungal path-
ogens [17,18,33,62,197,241,437,438].
7.1a. We suggest that all patients with HA-IAI be assessed
with respect to their separate risks of infection from En-
terococcus spp., MRSA, resistant gram-negative bacilli, and
Candida spp. (Grade 2-B).
7.1b. We suggest that broader-spectrum agents or regi-
mens described for use in higher-risk patients with CA-IAI be
used for the initial empiric antimicrobial therapy of patients
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with HA-IAI. Other empiric agents should be added to the
regimen according to the assessment of the patient’s risk for
an infection from Enterococcus spp., MRSA, resistant gram-
negative bacilli, and Candida spp. (Grade 2-B).
B. Anti-enterococcal therapy
Q 7.2a. How should patients with HA-IAI be assessed
with respect to their risk of infection because of En-
terococcus spp.?
Q 7.2b. Which agents can be used for initial empiric an-
timicrobial therapy of HA-IAI in patients considered at
risk for infection with Enterococcus spp.?
Enterococci are common opportunistic micro-organisms
isolated from patients with HA-IAI, although their patho-
genic role in IAI is still a matter of some debate. Isolation of
enterococci has been associated with a higher risk for an
adverse outcome in many, but not all studies [24,27,49,
58,86,88,89,119,403,408]. Patients in whom HA-IAI devel-
ops after an abdominal operation appear to be at particular risk
for infection from Enterococcus spp. [26,86,88,89,439], as are
patients who have received previous broad-spectrum antibiotic
therapy [111,119]. Other risk factors for isolation of enterococci
in patients with IAI include co-morbid conditions such as heart
disease, chronic obstructive pulmonary disease, and malig-
nancy; higher APACHE II, Simplified Acute Physiology Score
(SAPS) II, or Sequential Organ Failure Assessment (SOFA)
scores; previous hepatobiliary instrumentation; a history of
solid organ transplantation, particularly liver transplantation;
and immunosuppressive therapy [88,89,111,119,439].
Both E. faecalis and E. faecium are encountered relatively
frequently in patients with HA-IAI, with the latter micro-
organism accounting for a substantial proportion of these
enterococcal isolates [24,26,106,119,408,439,440]. More-
over, VRE is being identified increasingly in patients with
enterococcal infections, including HA-IAI, in several areas of
the world [26,115,441,442]. Recent reports suggest that VRE
accounts for more than one-third of enterococcal infections in
the United States, with most of these because of vancomycin-
resistant E. faecium [102,106]. The risk of an infection from
VRE is much higher in patients already colonized with VRE
[93,96,102,103,106]. Risk factors for colonization and in-
fection with VRE also include a prolonged hospital length of
stay, particularly in the intensive care unit, previous surgical
procedures, a high severity of illness or extensive co-
morbidities, and substantial previous exposure to broad-
spectrum antibiotic therapy [102,103,106,115]. Solid organ
transplant patients, especially liver transplant patients, are a
particularly high-risk group of patients for VRE colonization
and infection [103,115,443].
There are conflicting data as to whether or not timely anti-
enterococcal therapy improves outcomes in patients infected
with enterococci [49,86,89,111,119,408,411]. Methodologi-
cally robust trials of anti-enterococcal therapy in higher-risk
patients are lacking. Because of the potential for poor out-
comes with a failure to provide adequate antimicrobial
therapy, however, the task force supports use of anti-
enterococcal therapy in patients with HA-IAI identified as
being at risk for infection with Enterococcus spp. This ther-
apy should be selected on the basis of the likely species and
strains that will be encountered.
Because of the higher risk that E. faecium is a pathogen in
patients with HA-IAI, empiric anti-enterococcal therapy
should be directed against both E. faecalis and E. faecium.
Glycopeptides generally have good activity against non-VRE
strains of E. faecalis and E. faecium, whereas b-lactam an-
tibiotic agents typically lack activity against E. faecium
[324,329,331,332,409,444]. Therefore, the task force suggests
use of vancomycin or teicoplanin for patients with HA-IAI at
risk for infectionwithEnterococcus spp. For patientswithHA-
IAI considered at high risk for infection from VRE, however,
the task force suggests use of empiric linezolid or daptomycin.
Table 10. Summary of Empiric Antimicrobial Therapy for Patients
with Healthcare- or Hospital-Acquired Intra-Abdominal Infection
General approach
Piperacillin-tazobactam, doripenem, imipenem-cilastatin, meropenem, or cefepime plus metronidazole,
with ceftazidime plus metronidazole and aztreonam plus metronidazole plus vancomycin as potential alternatives
Supplemental agents
Potential pathogen Recommendations
Enterococcus faecalis Addition of ampicillin or vancomycin if not using piperacillin-
tazobactam or imipenem-cilastatin
Enterococcus faecium Vancomycin or teicoplanin
Vancomycin-resistant Enterococcus spp. Daptomycin or linezolid
MRSA Vancomycin, teicoplanin, daptomycin, or linezolid
ESBL-producing or AmpC-b-lactamase-
producing Enterobacteriaceae
Use of a broad-spectrum carbapenem
KPC-producing Enterobacteriaceae Combination therapy with a broad-spectrum carbapenem plus
an aminoglycoside, polymyxin, or tigecycline; or ceftazidime-avibactam
MDR strains of Pseudomonas aeruginosa Combination therapy with an aminoglycoside plus colistin,
or ceftolozane-tazobactam or ceftazidime-avibactam
MDR strains of Acinetobacter baumannii Combination therapy with a broad-spectrum carbapenem plus
an aminoglycoside, polymyxin, or tigecycline
Candida albicans An echinocandin (anidulafungin, caspofungin, micafungin)
for critically ill patients, fluconazole for less critically ill patients
Non-C. albicans spp. An echinocandin
MRSA=methicillin-resistantStaphylococcus aureus; ESBL= extended-spectrumbeta-lactamase;KPC=Klebsiella pneumoniae carbapenemase.
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These agents generally have good activity against VRE, with
linezolid having been approved by the FDA for management
of such infections [93,106,115,333,335,445]. Tigecycline also
has good in vitro activity against VRE, but there are only
limited clinical data regarding use of this agent for patients
with HA-IAI because of VRE [443,446,447]. These sugges-
tions for anti-enterococcal therapy in patients with HA-IAI are
summarized in Table 10. With empiric use of any type of anti-
enterococcal agent, treatment should be discontinued or de-
escalated if a resistant enterococcal strain is not identified in
definitive cultures.
7.2a. We suggest that patients with HA-IAI who have a
post-operative infection, have had substantial recent expo-
sure to broad-spectrum antimicrobial therapy, who manifest
signs of severe sepsis or septic shock, or who are known to be
colonized with VRE be considered at risk for infection from
Enterococcus spp. (Grade 2-B).
7.2b. We suggest vancomycin or teicoplanin for empiric
antimicrobial therapy of HA-IAI in patients considered at
risk for an infection from Enterococcus spp. We suggest use
of linezolid or daptomycin for management of HA-IAI in
patients known to be colonized with VRE or considered at
high risk for infection from this organism (Grade 2-B).
C. Anti-staphylococcal therapy
Q 7.3a. How should patients with HA-IAI be assessed
with respect to their risk of infection with MRSA?
Q 7.3b. Which agents can be used for initial empiric an-
timicrobial therapy of HA-IAI in patients considered to be
at risk for infection with MRSA?
Staphylococci are not common pathogens in IAI.
Coagulase-negative staphylococci are most often described
in the context of tertiary peritonitis or recurrent IAI, although
their pathogenic role is uncertain [32,85,90,448]. S. aureus is
rarely isolated from peritoneal cultures of patients with CA-
IAI [23,24,27,62], but is found somewhat more frequently in
cultures from patients with HA-IAI; many of these isolates
are resistant to methicillin [23,24,27,62,340,341,342].
Patients colonizedwithMRSA are at risk for invasiveMRSA
infections [94,97,98,100], including post-operative HA-IAI
[340]. Risk factors for MRSA colonization, which overlap with
those for HAI in general, include advanced age, female gender,
major medical co-morbidities, previous exposure to healthcare-
associated pathogens, residence in a long-term care facility,
recent hospitalization, recent surgery, and a history of recent
exposure to antibiotic agents [100,449–451]. The task force
suggests that patients known to be colonized with MRSA and
those who have several risk factors for MRSA colonization be
considered at risk for HA-IAI because of MRSA.
There are no published studies specifically evaluating an-
timicrobial therapy for IAI related to MRSA. Glycopeptides
are the agents prescribed most commonly for patients with
serious infections from MRSA [334,343–345,358]. Thus,
vancomycin or teicoplanin (where available) could be used for
empiric therapy of HA-IAI if MRSA is a suspected pathogen.
The higher dosages of vancomycin advocated for managing
infections from MRSA [344,452] may be leading to higher
rates of nephrotoxicity with this agent, however [350–352]. In
addition, the overall efficacy of vancomycin for seriousMRSA
infections has been called into question [345–348].
Thus, use of different agents for first-line therapy of MRSA
infections should also be considered [353–355] Both linezolid
and daptomycin appear to have efficacy at least equivalent to
vancomycin for managing serious infections from this organ-
ism and have been used successfully in patients with IAI
[344,348,354–359]. Based on these data, the task force be-
lieves that vancomycin, teicoplanin (where available), line-
zolid, and daptomycin are options for the empiric treatment of
patients with HA-IAI when MRSA is a suspected pathogen
(Table 10). The task force did not encounter sufficient pub-
lished data regardingmanagement of seriousMRSA infections
with other agents active against this organism, including cef-
taroline, tigecycline, telavancin, dalbavancin, and oritavancin,
to make any recommendation regarding use of these agents.
7.3a. We suggest that patients with HA-IAI known to be
colonized with MRSA and those with multiple healthcare-
associated risk factors for MRSA colonization, including
advanced age, co-morbid medical conditions, previous hos-
pitalization or surgery, and significant recent exposure to
antibiotic agents, be considered at risk for infection from
MRSA (Grade 2-B).
7.3b. We suggest vancomycin or teicoplanin, where
available, or linezolid or daptomycin as alternatives, for
empiric antimicrobial therapy of HA-IAI in patients known to
be colonized with MRSA or considered at high risk for in-
fection from this organism (Grade 2-B).
D. Antibacterial therapy for resistant gram-negative or-
ganisms
Q 7.4a. Which patients with HA-IAI should be considered
at risk for infection from resistant gram-negative patho-
gens?
Q 7.4b. What other factors should be considered in se-
lecting empiric antimicrobial therapy for patients with HA-
IAI from suspected resistant gram-negative pathogens?
Q 7.4c. What agents can be used for empiric antimicrobial
therapy of HA-IAI in patients considered at risk for re-
sistant Enterobacteriaceae?
Q 7.4d. What agents can be used for empiric antimicrobial
therapy of HA-IAI in patients considered at risk for MDR,
or XDR, or pan-drug-resistant (PDR) strains of P. aeru-
ginosa or Acinetobacter spp.?
Compared with patients with CA-IAI, those with HA-IAI
are infected with a much wider variety of gram-negative
pathogens, many of which are resistant to various antibiotic
agents [437,453]. Although E. coli is still the most common
gram-negative pathogen identified in HA-IAI, other En-
terobacteriaceae, such as Enterobacter spp., and non–lactose-
fermenting gram-negative pathogens, such as P. aeruginosa
and A. baumannii, are encountered with some frequency [22–
28,33,62,454]. These pathogens develop resistance to antibi-
otic agents through a variety of mechanisms, including
production of an ESBL or an aminoglycoside-modifying en-
zyme, elaboration of efflux pumps, loss of porins, or target site
modifications. Simultaneous resistance to several classes of
antibiotic agents is relatively common with many of these
gram-negative bacteria [239,256,285,317,432,455–458].
The risk factors for HA-IAI because of resistant gram-
negative pathogens mirror those for HA-IAI in general. Hos-
pitalization, recent medical interventions, and pre-existing
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medical co-morbidities are all associated with infection from
these resistant microorganisms [17–19,62,104,439]. Numer-
ous studies have also closely linked previous broad-spectrum
antimicrobial therapywith colonization or infection because of
resistant gram-negative organisms [17–19,99,112–114,116–
118,120–123]. Unfortunately, these risk factors are quite non-
specific and are probably only useful in the extreme for
identifying patients with HA-IAI likely to be infected with one
of these pathogens. Patients known to be previously colonized
or infected with a resistant gram-negative organism, however,
can be suspected of having HA-IAI because of that agent.
Routine surveillance for resistant gram-negative organisms,
however, is rarely performed [91,92,95,99,101,104,105], so
this information will only be available for a minority of pa-
tients with HA-IAI.
The local microbial ecology may be the most important
aspect to consider in evaluating the risk that a patient with HA-
IAI is infected with a resistant gram-negative micro-organism.
Strains of these resistant bacteria are endemic in certain geo-
graphic locales [239,432,434,435,437,453,455,459,460]; this
phenomenon may extend to the individual institution or even
to a specific unit within that institution [461–463]. Thus, up-
dated hospital- or unit-specific antibiograms, where available,
may help determine when a patient with HA-IAI is at risk for
infection with a specific resistant gram-negative pathogen
[194,462,463]. Overall, the task force believes that risk factors
such as prolonged hospitalization, multiple medical interven-
tions, previous broad-spectrum antimicrobial therapy, or a
history of colonization or infection with resistant micro-
organisms should be considered along with local epidemio-
logic information in identifying patients with HA-IAI at risk
for infection from resistant gram-negative pathogens.
Selection of empiric antimicrobial therapy for HA-IAI will
be based not only on the general risk that the patient is in-
fected with a resistant gram-negative micro-organism, but
also on the specific risk for a given pathogen or pathogens.
The goal is to select an empiric regimen likely to be active
against the resistant pathogens the patient may carry, so that
the risk of inadequate antimicrobial therapy is minimized.
The task force has concluded that the agents with broad-
spectrum activity against gram-negative micro-organisms
that were recommended for treatment of higher-risk patients
(Table 10) form the basis for empiric therapy of patients with
HA-IAI. Alternative or additional agents for gram-negative
coverage may be warranted, however, if the patient is at risk
for an MDR- or XDR-pathogen.
Patients with HA-IAI are at risk for infections with ESBL-
producing Enterobacteriaceae, although the risk of this is
highest in certain geographic regions of the world, such as
Asia and Latin America [28,29,31]. Carbapenems are gen-
erally considered the empiric agents of choice for treating
patients with the most common ESBL-producing En-
terobacteriaceae (Table 10) [309,464–466], To avoid exces-
sive carbapenem use, however, de-escalation to other agents,
such as piperacillin-tazobactam, cefepime, an aminoglyco-
side, a cephamycin, a fluoroquinolone, or tigecycline, can be
considered once susceptibilities are known. Unfortunately,
with the exception of tigecycline, ESBL-producing En-
terobacteriaceae are frequently resistant to these other agents
[206,257,423,424,432,467]. Both ceftolozane-tazobactam and
ceftazidime-avibactam have shown efficacy in treating patients
with IAI caused by ESBL-producing Enterobacteriaceae, par-
ticularlyE. coli, but clinical experiencewith these agents is still
limited [263,264,274,275].
Patients with HA-IAI who have had extensive exposure to
the hospital environment and broad-spectrum antimicrobial
therapy may be infected with AmpC–b-lactamase-producing
strains of Enterobacter spp. or other Enterobacteriaceae.
There is relatively little published experience regarding
management of these organisms in patients with HA-IAI.
Broad-spectrum carbapenems are generally considered the
treatment of choice for patients with bacteremia and other
infections because of AmpC–b-lactamase-producing gram-
negative pathogens, and would likely be effective in patients
with HA-IAI from these resistant strains (Table 10) [256–
259,315,468]. Cefepime has been described as an option to
treat patients with these pathogens, despite the recognized
propensity of other cephalosporins to serve as inducers of
these enzymes [257–259,468]. Other agents, including tige-
cycline, aminoglycosides, and fluoroquinolones, may have
activity against AmpC–b-lactamase-producing organisms,
but little information is available regarding their clinical ef-
ficacy [256,257]. Ceftazidime-avibactam has good in vitro
activity against AmpC–b-lactamase-producing Entero-
bacteriaceae [277,469,470], and ceftolozane-tazobactam has
activity against 70% of these strains [265], but clinical ex-
perience using these agents to treat AmpC–b-lactamase-
producing gram-negative pathogens is quite limited.
Carbapenemase-producing gram-negative bacteria present
an even greater challenge to the clinician. There is a paucity
of evidence regarding treatment of patients with HA-IAI who
are infected with these pathogens. Most of the available lit-
erature relates to the treatment of patients with bacteremia
from carbapenemase-producing Enterobacteriaceae, partic-
ularly K. pneumoniae. For treatment of KPC-producing
strains, the combination of a carbapenem with an ami-
noglycoside, a polymyxin, or tigecycline has been associated
with the highest efficacy, at least when the minimum inhib-
itory concentration (MIC) to carbapenems is not too high
[316,317,471,472]. Ceftazidime-avibactam has activity
against KPC-producing strains of Enterobacteriaceae and
thus may provide an option for treating patients with HA-IAI
because of this organism (Table 10) [276,469]. Treatment of
patients with MBL-producing Enterobacteriaceae is more
problematic, because these bacteria are resistant to nearly all
b-lactam antibiotic agents, although aztreonam may be an
exception. Combination therapy, using agents such as a
polymyxin, tigecycline, or fosfomycin, among others, is
generally advocated [434,473].
Some patients with HA-IAI may be infected with MDR,
XDR, or PDR strains of gram-negative bacteria such
as Pseudomonas spp. and Acinetobacter spp. [474]. These
highly resistant micro-organisms may be found in patients
characterized as having tertiary peritonitis [33,87,475]. Se-
lection of empiric therapy in these patients is individualized,
based on previous culture and susceptibility data, the pa-
tient’s history of previous antimicrobial exposure, and the
type of resistant pathogens encountered in the local envi-
ronment. For these MDR, XDR, and PDR pathogens, com-
bination regimens are generally used. Depending on the
suspected micro-organism, this may or may not include a
broad-spectrum b-lactam antibiotic agent, an aminoglyco-
side, a polymyxin, tigecycline (not applicable for Pseudo-
monas), rifampin, or fosfomycin (Table 10) [318,476–481].
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Ceftolozane-tazobactam has activity against many MDR
and XDR strains of Pseudomonas resistant to other b-lactam
antibiotic agents [265,266]; ceftazidime-avibactam may also
have some enhanced activity against these strains as well
[277,279]. These newer agents, however, are not particularly
active against Acinetobacter spp. Experience with these
agents in critically ill patients is still quite limited. Overall, no
ideal regimen has been identified for managing HA-IAI in
patients infected with these highly resistant pathogens.
7.4a. We suggest that patients with HA-IAI who have re-
ceived substantial previous broad-spectrum antimicrobial
therapy, have had prolonged hospitalizations, have under-
gone multiple invasive interventions, or are known to have
been colonized or infected with a resistant gram-negative
organism be considered at risk for infection from a resistant
gram-negative pathogen (Grade 2-B).
7.4b. We suggest use of local epidemiologic data and an-
tibiograms for selecting empiric antimicrobial therapy of
HA-IAI in patients considered at risk for infection with re-
sistant gram-negative pathogens (Grade 2-B).
7.4c. We suggest a broad-spectrum carbapenem, with
ceftolozane-tazobactam or ceftazidime-avibactam as poten-
tial alternatives, for empiric antimicrobial therapy of HA-IAI
in patients considered at risk for infection with ESBL-
producing Enterobacteriaceae (Grade 2-B). We suggest a
broad-spectrum carbapenem, with ceftazidime-avibactam as
a potential alterative, for empiric antimicrobial therapy of
HA-IAI in patients considered at risk for infection with
AmpC–b-lactamase-producing Enterobacteriaceae (Grade
2-B). We suggest combinations of a carbapenem with an ami-
noglycoside, a polymyxin, and/or tigecycline, or ceftazidime-
avibactam as an alternative, for empiric antimicrobial therapy
of HA-IAI in patients considered at risk for infection with
carbapenem-resistant Enterobacteriaceae (Grade 2-B).
7.4d. We suggest combinations of a b-lactam, including
ceftolozane-tazobactam, an aminoglycoside, and/or a poly-
myxin, for empiric antimicrobial therapy of HA-IAI in patients
considered at risk for infection from MDR, XDR, or PDR
strains of P. aeruginosa (Grade 2-B). We suggest combinations
of a carbapenem, an aminoglycoside, a polymyxin, and/or ti-
gecycline for empiric antimicrobial therapy of HA-IAI in pa-
tients considered at risk for infection fromMDR, XDR, or PDR
strains of Acinetobacter spp. (Grade 2-B).
E. Antifungal therapy
Q 7.5a. Which patients with HA-IAI should be considered
at risk for infection from Candida spp.?
Q 7.5b. What agents can be used for empiric antifungal
therapy of HA-IAI in patients considered at risk for a
candidal infection?
Risk factors for invasive candidal infections in hospital-
ized patients, particularly critically ill patients, include a
previous surgical procedure, a history of broad-spectrum
antimicrobial therapy, pancreatitis, use of parenteral nutri-
tion, presence of invasive catheters, medical co-morbidities
including diabetes mellitus, cardiac disease, renal failure, or
immunosuppression, and multiple sites of colonization with
Candida spp. [416,482–489]. These risk factors are generally
derived from studies of patients with candidemia and may not
be directly applicable to patients with HA-IAI. Studies that have
more closely examined specific risk factors for Candida peri-
tonitis have identified recurrent gastrointestinal perforations
[490], upper gastrointestinal perforations [110,413,416,417],
surgically treated pancreatitis [490], and previous receipt of
antimicrobial therapy [107–110] as predisposing factors for
HA-IAI from Candida spp. Colonization with Candida at
multiple sites has been used to identify patients at high risk of an
invasive candidal infection [490–493,], but the utility of this
observation has been disputed [494].
Mortality rates of 20%–64% have been recorded in pa-
tients with HA-IAI from Candida spp., with at least some of
the deaths being directly attributed to the candidal infection
itself [56,109,412.413,418,483,495,496]. Delays in effective
antifungal therapy have been associated with increased
deaths in patients with candidemia and other invasive can-
didal infections, particularly those with septic shock
[56,375,412,415,489].
Antifungal agents applicable to the empiric treatment of
patients with HA-IAI potentially because of Candida spp. in-
clude the polyenes (amphotericin B in its various formulations),
triazoles (fluconazole and voriconazole), and echinocandins
(anidulafungin, caspofungin, and micafungin). Evidence from
RCTs and a meta-analysis suggest that echinocandins are more
efficacious than triazoles and less toxic than polyenes when
treating patients with candidal infections, particularly those
who are critically ill [361,362,364,365,371–373].
Although these clinical trials primarily enrolled subjects
with candidemia, not Candida peritonitis, the task force be-
lieves these findings should apply to severely ill patients with
HA-IAI potentially from Candida. Thus, an echinocandin is
recommended for empiric treatment of these patients withHA-
IAI. Nonetheless, fluconazole was effective at preventing
Candida peritonitis when used preemptively in patients at high
risk for an infection with this organism [366]. For patients who
are less critically ill, the task force suggests that empiric flu-
conazole should suffice in most patients. Historically, am-
photericin B was the primary antifungal agent used to treat
patients with intra-abdominal candidiasis; however, use of this
agent has fallen into disfavor because of its toxicity [360,364].
It is not currently recommended except when other, less toxic,
agents cannot be used to manage the infection [497–501].
AlthoughC. albicans is the most common yeast found with
IAI, non-C. albicans species, including C. glabrata, C.
parapsilosis, and C. tropicalis, are isolated with increasing
frequency [375,502–504]. Candida glabrata may be intrin-
sically resistant or demonstrate dose-dependent susceptibility
to fluconazole; voriconazole has much better activity against
this organism [505]. The echinocandins are highly active
against nearly all Candida spp. Thus, voriconazole or an
echinocandin are options in patients at risk for or known to be
colonized or infected with a fluconazole-resistant species of
Candida [367–369,505].
7.5a. We suggest that patients with HA-IAI because of upper
gastrointestinal perforations, recurrent bowel perforations, or
surgically treated pancreatitis, those who have received pro-
longed courses of broad-spectrum antibiotic therapy, and
those who are known to be heavily colonized with Candida be
considered at increased risk for infection from Candida
spp. (Grade 2-B). We suggest that patients with HA-IAI found
to have yeast on a Gram stain of infected peritoneal fluid or
tissue be considered to have a candidal infection (Grade 2-B).
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7.5b. We recommend an echinocandin (anidulafungin,
caspofungin, or micafungin) for empiric antifungal therapy
of HA-IAI in severely ill patients considered at risk for in-
fection from Candida spp. (Grade 1-B). We suggest fluco-
nazole can be used for empiric antifungal therapy in less
severely ill patients with HA-IAI considered at risk for in-
fections from Candida spp. (Grade 2-B). We suggest an
echinocandin or voriconazole for empiric antifungal therapy
of patients with HA-IAI considered at risk for infection be-
cause of a fluconazole-resistant non-C. albicans strain
(Grade 2-B).
8. Timing of antimicrobial therapy
Q 8.1. When should antimicrobial therapy be initiated in
patients with a diagnosis of IAI?
Q 8.2. Should additional antimicrobial therapy be adminis-
tered to patients undergoing source control procedures for
IAIwho are already receiving empiric antimicrobial therapy?
There is little definitive evidence on the timing of anti-
microbial therapy for patients with IAI. In patients with
sepsis or septic shock, a substantial proportion of whom
present with IAI, several cohort and retrospective studies
have demonstrated increased deaths if antimicrobial therapy
is delayed [506–508]. Based on these data, the Surviving
Sepsis Campaign recommends initiation of antimicrobial
therapy within one hour of identifying a patient with sepsis or
septic shock [6]. Nonetheless, some studies have failed to find
an association between a delay of antimicrobial therapy and
death for up to five hours in such patients [509–512]. Although
these conflicting data question whether a one-hour time win-
dow should be considered a rigid standard for delivering anti-
infective therapy once the diagnosis of IAI with sepsis has
been made, the task force believes that early administration of
antimicrobial agents represents a reasonable goal. It also needs
to be recognized, however, that there are additional priorities
in the acute management of IAI with sepsis, such as preparing
the patient for definitive source control.
There are little data with regard to antimicrobial timing for
patients with IAI who do not meet sepsis criteria. In general,
the task force believes it is reasonable to initiate antimicrobial
therapy as soon as feasible in these patients, as had been
recommended in the previous guideline [4]. Withholding
antimicrobial therapy until definitive peritoneal cultures can
be obtained is not justified, because of the prolonged delay in
effective antimicrobial therapy that could entail.
There are also important considerations with regard to
timing of antimicrobial delivery relative to a source control
procedure. Even though an established infection is already
present in patients with IAI, the general principles of anti-
microbial prophylaxis for surgical procedures still apply.
Guidelines for prevention of surgical site infection specify
administration of most prophylactic antibiotics within one
hour of the surgical incision to ensure that adequate blood and
tissue concentrations are present [238,513–515]. A number
of observational studies have provided evidence in support of
this recommendation [516–520].
A patient with IAI may have had an antimicrobial agent
administered several hours before a source control procedure,
however. Under those circumstances, adequate serum and
tissue concentrations of the agent may not be present during
that procedure. Therefore, the task force recommends re-
administration of an anti-infective agent at the time of a
source control intervention if more than two half-lives have
elapsed since the previous dose. This is based on surgical site
infection prevention guidelines recommending re-dosing of
prophylactic agents intra-operatively if the length of the
procedure exceeds two half-lives of the agent in question
[238,514,521,522]. Because dissemination of pathogenic
micro-organisms may occur during less-invasive source
control procedures as well, it seems reasonable to adhere to
this recommendation for source control interventions other
than operative procedures. The task force also endorses re-
administration of antibiotics intra-operatively during source
control if two antibiotic half-lives have elapsed since the
previous dose.
8.1. We suggest initiation of empiric antimicrobial therapy
within one hour or as soon as possible thereafter of the time
the diagnosis of IAI is made in patients presenting with sepsis
or septic shock (Grade 2-B). We also suggest initiation of
antimicrobial therapy as soon as feasible in other patients
with IAI, taking into account plans for subsequent source
control (Grade 2-C).
8.2. We recommend re-administration of an antimicrobial
agent within one hour before the start of a source control
procedure for IAI if two half-lives of the agent will have
passed at the time the intervention is initiated (Grade 1-B).
9. Dosing of antimicrobial agents in adult patients
Q 9.1. What dosages of antimicrobial agents should be
used for management of IAI in adult patients?
Q 9.2. Should adjusted dosages of antimicrobial agents be
used for management of IAI in adult patients who have
substantial renal impairment?
Q 9.3. Should adjusted dosages of antimicrobial agents be
used for management of IAI in adult patients who have
substantial hepatic impairment?
Q 9.4. Should adjusted dosages of antimicrobial agents be
used for management of IAI in obese patients?
Q 9.5. Should alternative dosing schedules, such as pro-
longed or continuous infusion of selected agents, be used
for management of IAI in critically ill patients or those
infected with resistant pathogens?
Standard dosing recommendations for antimicrobial
agents used in the treatment of patients with IAI are listed in
Table 11. These dosing recommendations have been derived
from the information published in RCTs (see Supplementary
Tables; see online supplementary material at www.liebertpub
.com/overview/surgical-infections/53/) and supplemental
publications describing individual agents, from the pre-
scribing information for specific antimicrobials approved by
the FDA [523], and from a standard pharmacology text [524].
For lower-risk patients with CA-IAI who do not have sub-
stantial renal or hepatic impairment or severe obesity, the
task force believes these dosage recommendations should be
fairly accurate, because they reflect dosing from clinical trials
primarily enrolling lower-risk subjects without major organ
impairment [3,389].
Critically ill patients may benefit from adjusted dosing of
many antimicrobial agents. The evidence supporting this for
patients with IAI is mostly indirect, however. Critical illness
may impact the volume of distribution (Vd) and clearance of
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Table 11. Dosing of Antimicrobial Agents
Agent Standard dose Renal dose
Aminoglycosides
Amikacin 7.5mg/kg IV q8-12h 7.5mg/kg IV q12–72h based on serum drug levels
Gentamicin 1.5-2.5mg/kg IV
q8h–12h;
4-7mg/kg IV q24h
1.5-2.5mg/kg IV q12–48h based on serum drug levels
Tobramycin 1.5–2mg/kg IV q8h; 4-7mg/kg IV q24h 1.5-2mg/kg IV q12–72h based on serum drug levels
Penicillin/b-lactamase inhibitor combinations
Ampicillin-sulbactam 1.5–3 g IV q6h 1.5–3 g IV q12–24h
Amoxicillin-clavulanate 1.2 g IV q6–8h 1.2 g IV, then 0.6 g IV q12–24h
Ticarcillin-clavulanate
(not currently available)
3.1 g IV q6h 1-2 g IV q12–24h
Piperacillin-tazobactam 3.375–4.5 g IV q6h 2.25 g IV q6–8h
Cephalosporins (including cephamycins) and cephalosporin-b-lactamase inhibitor combinations
Cefoxitin 1–2 g IV q6h 0.5–1 g IV q8–48h
Cefotetan 1–2 g IV q12h 0.5–1 g IV q12–24h
Cefazolin 1–2 g IV q8h 1 g q12–24h
Cefuroxime 1.5 g IV q8h 0.75 g IV q12–24h
Cefotaxime 1–2 g IV q6-8h 0.5–1 g IV q8–24h
Ceftriaxone 1–2 g IV q24h No dosing adjustment; check blood
levels with dialysis
Ceftazidime 1–2 g IV q8h 0.5–1 g IV q12–24h
Cefepime 1–2 g IV q12h 0.5–2 g IV q24h
Cefoperazone-sulbactam:
1:1 ratio
2:1 ratio
1–2 g IV q12h
1.5–3 g IV q12h
No dosing adjustment; maximum daily
sulbactam dosage of 1–2 g depending
on degree of renal impairment
Ceftolozane-tazobactam 1.5 g IV q8h 750mg IV q8h or 375mg IV q8h depending
on degree of renal impairment
Ceftazidime-avibactam 2.5 g IV q8h 0.94–1.25 g IV q8–48h depending
on degree of renal impairment
Monobactam
Aztreonam 1–2 g IV q8h 1–2 g IV, then 0.5–1 g IV q6–12h
Carbapenems
Ertapenem 1 g IV q24h 0.5 g IV q24h
Doripenem 0.5 g IV q8h 0.25–0.5 g IV q8–12h
Imipenem-cilastatin 0.5–1 g IV q6–8h 0.125–0.5 g IV q6–12h
Meropenem 1–2 g IV q8h 0.5–1 g IV q12–24h
Fluoroquinolones
Moxifloxacin 400mg IV q24h No dosing adjustment
Ciprofloxacin 400mg IV q12h 200–400mg IV q18–24h
Levofloxacin 500–750mg IV q24h 250–750mg IV q24–48h
Glycylcycline
Tigecycline 100mg IV, then 50mg IV q12h No dosing adjustment
Anti-anaerobic agents
Clindamycin 600–900mg IV q6–12h No dosing adjustment
Metronidazole 1 g IV, then 0.5 g IV q6-8h No dosing adjustment
Agents with activity against gram-positive organisms
Ampicillin 1–2 g IV q4–6h Reduce frequency of dosing to q6h–q24h
depending on degree of renal impairment
Daptomycin 4–6mg/kg q24h 4–6mg/kg q48h
Linezolid 600mg IV q12h No dosing adjustment
Teicoplanin 400mg IV q12h· 3 doses,
then 400mg IV q24h
Reduction of daily dosage to one-half to one-third
depending on degree of renal impairment
Vancomycin 10–20mg/kg IV q12h 10–20mg/kg IV q24h with subsequent dosing
based on serum drug levels
Antifungal agents: Azoles
Fluconazole 400mg IV q24h, then 200mg IV q24h 200mg IV q24h, then 100mg IV q24h
or after hemodialysis
Voriconazole 6mg/kg q12h · 2 doses,
then 3–4mg/kg q12h
IV formulation not recommended because of
accumulation of SBECD (sulfobutyl ether
beta-cyclodextrin sodium) vehicle
Antifungal agents: Echinocandins
Anidulafungin 200mg IV, then 100mg IV q24h No dosing adjustment
Caspofungin 70mg IV, then 50mg IV q24h No dosing adjustment
Micafungin 100mg IV q24h No dosing adjustment
Antifungal agents: Polyenes
Amphotericin B deoxycholate 1–1.5mg/kg IV q24h 1–1.5mg/kg IV q48h
Amphotericin B lipid complex,
liposomal amphotericin B
5mg/kg IV q24h No dosing adjustment
IV = intravenous.
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antimicrobial agents. The Vd for hydrophilic antibiotic agents,
such as b-lactams, aminoglycosides, and glycopeptides, may
be expanded as a result of administration of large volumes of
IV fluids, and further exacerbated by fluid shifts into the ex-
travascular space [525–527]. Increased renal clearance of an-
tibiotic agents may also occur in some critically ill patients
[525,526,528]. These alterations could lead to suboptimal
blood or tissue concentrations, with the potential for treatment
failure if the infection is because of less susceptible pathogens
[525–529]. For b-lactams, aminoglycosides, tigecycline, van-
comycin, and polymyxins, some clinical studies have found
improved outcomes in selected critically ill patients treated
with higher dosages or shorter dosing intervals, particularly in
those patients infected with less susceptible organisms [478–
480,525,526,530,531].
Thus, the task force believes that altered antimicrobial
dosing regimens, including higher initial loading doses, may
be useful in selected patients with IAI. Critically ill patients,
however, may also have impaired renal function, leading to
decreased antibiotic clearance, and a risk for antibiotic tox-
icity [525–528,532]. Therefore, use of higher dosages or al-
tered dosing intervals in critically ill patients with IAI needs
to be individualized.
Dosing adjustments of antimicrobial agents cleared primarily
by renal elimination are frequently necessary in patients with
IAI who have impaired kidney function. Most antimicrobial
agents do not require dosage adjustments until the glomerular
filtration rate (GFR) decreases below 60mL/min. The GFR is
typically estimated according to the Cockcroft-Gault formula
[533,534], which relies on serum creatinine measurements.
Other methods for determining estimated GFR (eGFR) are
available, which may be preferable to the Cockcroft-Gault
method; however, these also lack accuracy and precision, par-
ticularly in critically ill patients [535–537]. Because the eGFR
heavily influences dosing of antimicrobial agents in patients
with renal impairment, the treating clinician should be aware of
pitfalls associated with these calculations of eGFR.
In general, the initial dosage of most antimicrobial agents
should not be altered in patients with impaired renal function,
because initial drug concentrations will primarily reflect Vd
and not clearance [526,527,538,539]. Subsequent dosing of
antimicrobial agents will typically be altered according to the
eGFR [539]. Table 11 provides general recommendations for
antimicrobial dosing adjustments in patients with impaired
kidney function [523,526,539].
Antimicrobial dosing adjustments in patients with renal
dysfunction can be expedited using therapeutic drug moni-
toring [527,539]. Commercial assays are commonly available
for the measurement of blood concentrations of vancomycin
and aminoglycosides, although not for most other antibiotic
agents. Therapeutic drug monitoring may be of particular va-
lue when the GFR fluctuates during the course of antimicrobial
therapy. Antimicrobial dosing in patients with renal dysfunc-
tion can also be facilitated by consultation with a clinical
pharmacist familiar with use of antimicrobial agents. This may
be particularly important in patients undergoing various forms
of renal replacement therapy, such as intermittent hemodial-
ysis or continuous veno-venous hemofiltration-dialysis. Spe-
cific recommendations for antimicrobial dosing in patients
undergoing renal replacement therapy are beyond the scope of
this guideline, but several reviews provide information on this
subject [527,536,538–540].
There is far less information available regarding antimi-
crobial dosage adjustments in patients with hepatic dysfunc-
tion. Liver disease has an impact primarily on the dosing of
antibiotic agents cleared by hepatic metabolism; thus, hepatic
dysfunction can lead to accumulation of certain anti-infective
agents and a risk of associated toxicity [528,541,542]. Table 12
summarizes recommendations made by Halilovic and Heintz
[542] for dosing of some hepatically cleared antibiotic agents
used in the treatment of patents with IAI.
Alternative dosing regimens for obese patients should also
be considered. Obesity may have a major impact on the Vd of
antimicrobial agents. In general, the Vd of hydrophilic anti-
biotic agents correlates better with the lean body mass or
ideal body weight, whereas the Vd of lipophilic antibiotic
agents correlates better with total body weight. For many
antibiotic agents of interest, an adjusted body weight calcu-
lation, which adds a percentage of the excess body weight to
the ideal body weight, has been used to predict Vd [543–548].
Obese patients with a higher Vd may benefit from a higher
initial dose of a given antimicrobial agent.
Renal clearance of antibiotic agents can also be affected by
obesity. In the absence of intrinsic renal disease, obesity
generally produces an increase in creatinine clearance.
Standard equations for creatinine clearance, however, such as
the Cockcroft-Gault formula [533], may produce misleading
values [545,549], and corrective formulas, such as the
Salazar-Corcoran equations [550], have not been fully vali-
dated [551]. Calculations of eGFR may be particularly prone
to error in critically ill obese patients [535,543,545], making
dosage adjustments in these patients quite problematic.
Recommendations based on pharmacokinetic principles
have been developed for the dosing of individual antibiotic
Table 12. Antimicrobial Dosage Adjustments in Patients with Cirrhosis
Agent Suggested adjustment
Cefotaxime No dosage adjustment
Ceftriaxone Consider 50% reduction in patients with Child-Pugh class C cirrhosis
Moxifloxacin No dosage adjustment
Ciprofloxacin No dosage adjustment
Tigecycline Decrease maintenance dosage to 25mg q12h in patients with Child-Pugh class C cirrhosis;
no change in initial loading dosage
Metronidazole Decrease dosage to 500mg q12–24h in patients with Child-Pugh class A, B, or C cirrhosis
Clindamycin Decrease dosage by 50% in patients with Child-Pugh class C cirrhosis
Linezolid No dosage adjustment; use cautiously in patients with Child-Pugh class C cirrhosis
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agents or classes in obese patients. These include ami-
noglycosides [543–545,548,552–556], various b-lactam an-
tibiotic agents [531,543–546,556–563], fluoroquinolones
[543,544,548,556,564–569], clindamycin [548,569], vanco-
mycin [344,452,544,545,548,556], linezolid [570,571], and
daptomycin [545,548,556,572,573]. Suggestions for dosing
of these antibiotic agents in obese patients are summarized in
Table 13. As of yet, however, there are little data doc-
umenting improvements in clinical outcomes with use of
these alternative dosing strategies. In fact, obesity has not
been uniformly identified as a significant risk factor for an
adverse outcome in patients with IAI [574,575],
Continuous or prolonged (over 3–4 h) antibiotic infusion,
as opposed to intermittent infusion (over 30–60min), is a
therapeutic tactic designed to take advantage of the phar-
macokinetic and pharmacodynamic properties of specific
antibiotic agents to maximize their clinical efficacy. The
primary class of antibiotic agents that has been assessed using
continuous or prolonged infusion are b-lactams. The main
pharmacodynamic parameter believed to be important in a
bacteriologic response to b-lactams is the time that the local
concentration is above the MIC of the specific bacterium
(ideally, 40% or more of the dosing interval). This time is
enhanced by continuous or prolonged infusion [576–580].
One study in patients with IAI found that continuous infusion
of cefotaxime resulted in peritoneal fluid concentrations of
the antibiotic at least five times greater than the MICs of the
infecting Enterobacteriaceae [581].
Meta-analyses comparing continuous or prolonged anti-
biotic infusion to conventional intermittent infusion in a
broad range of patients with various types of infections have
come to conflicting conclusions with regard to the efficacy of
this approach, however [579,580,582]. A recent large RCT of
patients with severe sepsis, 25% of whom had an abdominal
source, did not demonstrate any advantage to continuous
infusion; results in patients with IAI were not reported sep-
arately [583]. A single RCT comparing continuous versus
intermittent infusion of piperacillin-tazobactam in patients
with IAI (Supplementary Table P; see online supplementary
material at www.liebertpub.com/overview/surgical-infections/
53/) also did not demonstrate any advantage to the continuous
infusion approach [584]. A separate analysis of pharmaco-
kinetic and pharmacodynamic parameters and the MICs of
the isolated pathogens in this trial suggested that either ap-
proach would likely have sufficed in these patients, however
[585]. Thus, while continuous or prolonged antibiotic infu-
sion appears safe and effective for patients with IAI, it re-
mains unknown if there is a demonstrable clinical benefit to
its use. The task force believes that this approach could be
considered when treating potentially less susceptible strains
of gram-negative pathogens in critically ill patients with IAI.
9.1. We recommend use of standard dosages of antimi-
crobial agents for lower-risk patients with CA-IAI who are
not severely obese and who do not have substantial renal or
hepatic impairment (Grade 1-B). We suggest use of higher
dosages of antimicrobial agents for selected higher-risk pa-
tients with CA-IAI or HA-IAI (Grade 2-B).
9.2. We suggest use of adjusted dosages of antimicrobial
agents, based on available clinical outcome data, standard
pharmacokinetic parameters, and therapeutic drug moni-
toring, where applicable, for management of IAI in patients
with significant renal impairment (Grade 2-B).
9.3. We suggest use of adjusted dosages of selected, hepa-
tically cleared antimicrobial agents for management of IAI in
patients who have substantial hepatic impairment (Grade 2-B).
9.4. We suggest use of adjusted dosages of selected anti-
microbial agents, based on available clinical outcome data
and pharmacokinetic parameters, for management of IAI in
obese patients (Grade 2-B).
9.5. We suggest that prolonged or continuous infusion of b-
lactam antibiotic agents does not need to be used routinely for
treatment of patients with IAI, but is an option for management
of IAI in critically ill patients and those at risk for infection
with resistant gram-negative pathogens (Grade 2-B).
10. Duration of antimicrobial therapy
Q 10.1a. Should antibiotic agents be given to patients with
severe or necrotizing pancreatitis who do not have a
documented peri-pancreatic infection?
Q 10.1b. Should antibiotic agents be given to patients
with uncomplicated acute colonic diverticulitis?
Q 10.2. Which patients should be considered to have
intra-abdominal contamination only, and receive antimi-
crobial therapy for no greater than 24 hours?
Q 10.3a. What should the duration of antimicrobial ther-
apy be for patients with established IAI?
Table 13. Antimicrobial Dosage Adjustments in Obese Patients
Agent Suggested Adjustment
Aminoglycosides Base dosage on adjusted body weight (ideal body weight plus 40% of the excess weight
above ideal weight)
b-lactam/b-lactamase
inhibitor combination
Use dosages at the higher end of treatment range, or use standard dosages with therapeutic
drug monitoring in critically ill obese patients
Cephalosporin Use of dosages at the higher end of treatment ranges, or use standard dosages with
therapeutic drug monitoring in critically ill obese patients
Fluoroquinolones Use dosages at the higher end of treatment ranges, or base dosage on adjusted body weight
(ideal body weight plus 45% of the excess over ideal body weight)
Clindamycin Use higher dosages up to 4.8 g/d in patients with a body mass index greater than 40 kg/m2
Vancomycin Base dosage on actual body weight, with limitation of the total dose to 4g/d
Linezolid Dosage adjustment for obesity not currently recommended
Daptomycin Base dosage on total body weight
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Q 10.3b. What should the duration of antimicrobial
therapy be for patients with established IAI in whom a
definitive source control was not performed?
Q 10.4. Should patients with secondary bacteremia from
IAI receive a longer course of antimicrobial therapy?
Q 10.5. Should immunosuppressed patients with IAI re-
ceive longer courses of antimicrobial therapy?
Limiting the duration of antimicrobial therapy in patients
with IAI and other infections is an important antimicrobial
stewardship measure. Short duration therapy should de-
crease the development of antimicrobial resistance as well
as lessen the chance that the patient will have an adverse
reaction to an antimicrobial agent [197,529,586]. Anti-
microbial agents have been given to patients with or at risk
for IAI for a number of reasons, including prevention of
infection in patients with a non-infectious inflammatory
process such as acute pancreatitis, peri-operatively for an
uncomplicated IAI such as non-perforated appendicitis, for
intra-abdominal contamination that has occurred as a result
of trauma or iatrogenic injury, or for an established com-
plicated IAI.
The use of antibiotic agents to prevent infection in patients
with severe or necrotizing pancreatitis had been advocated
previously. Six RCTs of antibiotic prophylaxis for patients
with severe pancreatitis have been published since 2000
(Supplementary Table Q; see online supplementary material
at www.liebertpub.com/overview/surgical-infections/53/)
[587–592]. None showed any impact on death or on most
measures of morbidity, although two showed a decrease in
the incidence of infection, mainly extra-pancreatic infections
[588,590]. Recent meta-analyses of these and earlier studies
have, for the most part, demonstrated little benefit to the use
of antimicrobial agents in patients with severe or necrotizing
pancreatitis who do not have an established infection (Supple-
mentary Table R; see online supplementary material at www
.liebertpub.com/overview/surgical-infections/53/) [593–598].
One meta-analysis showed a survival benefit with use of
prophylactic antibiotic agents, but only if cohort studies were
included along with RCTs [599]. Other meta-analyses have
suggested some reductions in rates of secondary pancreatic
infection, need for operative intervention, occurrence of non-
pancreatic infections, or hospital length of stay, but without
changes in deaths or other global outcomes [600–603]. These
benefits, however, were not detected when analyzing only
higher quality or more recent studies [598,604]. Concerns
have also been raised about increased bacterial resistance as a
result of treating patients with severe pancreatitis with pro-
phylactic antimicrobials [109,588,589]. Based on the lack of
clear efficacy and the potential risk of increased bacterial
resistance, the task force recommends against use of antibi-
otic agents to prevent infection in patients with severe or
necrotizing pancreatitis.
The need for antibiotic agents in the management of un-
complicated acute sigmoid diverticulitis has come into
question. Two retrospective studies found that many patients
with acute colonic diverticulitis could be treated entirely
without antibiotic agents [605,606]. A subsequent large RCT
of this hypothesis (Supplementary Table S; see online sup-
plementary material at www.liebertpub.com/overview/
surgical-infections/53/) found no differences in outcomes in
patients with uncomplicated, left-sided diverticulitis who
received antibiotic agents and IV hydration versus those who
received IV hydration alone [607]. A recent Cochrane review
suggests that antibiotic agents may not be necessary, al-
though calling for additional high quality trials [608]. Thus,
omitting use of antimicrobial therapy in selected lower-risk
patients with acute, uncomplicated sigmoid diverticulitis
appears to be a reasonable option. It would be premature to
conclude, however, that this approach should be used in
higher-risk patients, such as those receiving immunosup-
pressive therapy.
Many patients, such as patients with penetrating abdomi-
nal trauma, present with intra-abdominal contamination
without having an established IAI at the time of a surgical
procedure. Antimicrobial use for such patients falls into a
gray area between surgical prophylaxis and treatment for IAI.
Guidelines for surgical prophylaxis generally recommend no
more than 24 hours of antibiotic therapy to prevent surgical
site infection [238,515]; in fact, the need for any post-
operative antibiotic administration has been questioned
[609,610].
Several lines of evidence support limiting peri-operative
antibiotic therapy to no more than 24 hours in patients with
intra-abdominal contamination, even though such patients
are at increased risk for infection. In three RCTs included in
the previous evidence review [3], infectious outcomes were
similar in patients with abdominal contamination as a result
of traumatic injury treated with 24 hours compared with five
days of antibiotic therapy post-operatively [611–613]. The
duration of intra-abdominal contamination previously de-
fined as differentiating contamination from an established
infection was 24 hours for an upper gastrointestinal (stomach,
duodenal, biliary) source and 12 hours for a lower gastroin-
testinal (small bowel, colon) source [2,4]. There is also evi-
dence that post-operative antibiotic therapy can be limited to
no more than 24 h in patients with uncomplicated IAI.
Recent RCTs (Supplementary Table T; see online sup-
plementary material at www.liebertpub.com/overview/
surgical-infections/53/) have found no benefit to more than
24 hours of antibiotic therapy in patients with non-perforated
appendicitis and patients undergoing cholecystectomy for
acute cholecystitis [614,615]. Older, allocation-based studies
reviewed previously [3] demonstrated similar rates of post-
operative infection in patients with non-perforated or ische-
mic gastrointestinal processes treated with peri-operative
antibiotic agents only compared with historical controls re-
ceiving more prolonged courses of therapy [616,617].
Therefore, for most patients undergoing source control for
intra-abdominal contamination without an established in-
fection or for an uncomplicated IAI in which the source
control procedure can completely eradicate the infection, the
task force concluded that antimicrobial use should be limited
to no more than 24 hours.
There are increasingly strong data that duration of anti-
microbial therapy for patients with established IAI can be
somewhat shorter than had been used in the past. Older
studies suggested no differences in outcome comparing five
days with longer courses of antimicrobial therapy for patients
with gastrointestinal perforations who had adequate source
control [616–618]. More recent retrospective cohort studies
have also found no significant differences in the rates of post-
operative infections in patients with complicated appendicitis
who received shorter duration of antimicrobial therapy
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(generally less than five days) versus longer duration therapy
(five days or more) [619,620]. In fact, some retrospective
studies suggested that patients receiving prolonged antimi-
crobial therapy for IAI were at increased risk of secondary
infections and death [621,622].
Two recent RCTs (Supplementary Table U, see online
supplementary material at www.liebertpub.com/overview/
surgical-infections/53/) also support a decreased duration of
therapy for IAI. A smaller study found three days of anti-
biotic therapy was as effective as five or more days of
therapy in patients with mild to moderate IAI, 50% of whom
had perforated appendicitis [623]. A larger RCT supported
by the SIS (the STOP-IT trial) demonstrated that a fixed
four-day course of antimicrobial therapy was as effective as
a longer, symptom-based duration of therapy (average of
eight days of antimicrobial therapy). Importantly, this latter
trial restricted the number of patients with complicated
appendicitis to 15%. In addition, the mean APACHE II
score was approximately 10, suggesting the patients in this
trial were more severely ill than those in many prospective
trials of antimicrobial therapy that have used a longer du-
ration of therapy [82]. Overall, the results of this and other
studies suggest that a 4-day duration of therapy is adequate
for most patients with IAI.
The duration of antimicrobial therapy for patients with IAI
treated without a source control procedure (such as those with
complicated diverticulitis or a peri-appendiceal phlegmon
managed non-operatively) is open to question. Most patients
selected for non-operative management are likely lower-risk
patients who have robust host defenses, which allows them to
locally control the infection. There are very little data on
standardized approaches to antimicrobial therapy in such
patients; even when antibiotic duration is described, the ra-
tionale for a given duration is rarely discussed. Previous
studies have shown that resolution of fever, leukocytosis, and
paralytic ileus is associated with a high likelihood of
treatment success in patients with IAI who undergo defini-
tive source control [624,625], making it reasonable to dis-
continue anti-infective agents at that time. The consensus of
the task force was that lower risk-patients who did not un-
dergo definitive source control could have antimicrobial
therapy discontinued at the time of resolution of these
symptoms and did not have to undergo a prolonged course
of therapy. If signs of infection persisted after five to seven
days, however, those patients should be considered to have
had treatment failure and undergo imaging and other studies
to determine whether or not a definitive source control
should be undertaken.
There is a wide variation in the duration of antimicrobial
therapy for treatment of patients with secondary bacteremia,
including that from an abdominal source [626]. Recent
studies suggest that patients with transient secondary blood
stream infections do not need more than seven days of anti-
biotic treatment. One study of critically ill patients with
secondary blood stream infections, including those from a
peritoneal source, found no difference in outcomes among
patients receiving shorter (seven days or fewer) versus longer
courses of antimicrobial therapy [627]. A systematic review
and meta-analysis of duration of antibiotic therapy among
critically ill patients with secondary bacteremia also found
that patients who received shorter courses of anti-infective
therapy, generally defined as seven or fewer days, had out-
comes similar to patients receiving longer courses of therapy
[628]. Thus, the task force has suggested that patients with
transient bacteremia because of IAI can have antimicrobial
therapy limited to seven days.
There are some patients with IAI for whom shorter-course
antimicrobial therapy might not necessarily be appropriate.
One group of patients at higher risk for treatment failure are
those who receive immunosuppressive medications, such as
patients who have undergone solid organ transplant proce-
dures. These patients are frequently treated with prolonged
antimicrobial therapy for any infection, including IAI. Defi-
nitive data are not available to draw any conclusions as to the
efficacy of shorter courses of antimicrobial therapy in these
patients. It is also uncertain if short course therapy should be
used in critically ill patients with severe sepsis and septic
shock. Although the STOP-IT trial did not demonstrate any
benefit of prolonged antimicrobial therapy in any subgroup of
patients, including those with an APACHE II score greater
than 10 [82], relatively few severely ill patients with sepsis or
septic shock were enrolled in the trial. There is anecdotal
evidence that stopping antimicrobial therapy in critically ill
patients with uncontrolled tertiary peritonitis may lead to
increased deaths [629]; however, such patients may actually
be experiencing treatment failure, for which further anti-
infective treatment would generally be warranted. Overall,
the task force has concluded that shorter course antimicrobial
therapy can be used in most patients with IAI, but that some
caution may be needed when applying this principle to im-
munosuppressed patients or those with ongoing signs of
sepsis or septic shock.
10.1a. We recommend against the use of antibiotic agents
to prevent infection in patients with severe or necrotizing
pancreatitis (Grade 1-B).
10.1b. We suggest that antibiotic therapy may not be
necessary for the treatment of lower-risk patients with un-
complicated acute colonic diverticulitis (Grade 2-B).
10.2.We recommend that antimicrobial therapy be limited to
24 hours in patients with traumatic bowel perforations oper-
ated on within 12 hours (Grade 1-A), patients with gastrodu-
odenal perforations operated on within 24 hours (Grade 1-C),
patients with acute or gangrenous appendicitis in the absence
of perforation (Grade 1-A), patients with acute or gangrenous
cholecystitis in the absence of perforation (Grade 1-A), or
patients with ischemic, non-perforated bowel (Grade 1-C).
10.3a. We recommend no more than four full days (96 h) of
antimicrobial therapy for patients with IAI who had an ad-
equate source control procedure (Grade 1-A).
10.3b. We suggest that no more than 5–7 days of antimi-
crobial therapy be provided to patients with established IAI
in whom a definitive source control procedure is not per-
formed. We suggest that clinical parameters, including fever,
leukocytosis, and adequacy of gastrointestinal function, be
assessed periodically to determine whether antimicrobial
therapy can be discontinued sooner. We suggest that patients
who do not respond fully to antimicrobial therapy within 5–
7 days be reassessed for a potential source control inter-
vention (Grade 2-C).
10.4. We suggest that most patients with secondary bac-
teremia because of IAI who have undergone adequate source
control and are no longer bacteremic can have antimicrobial
therapy discontinued after seven days (Grade 2-B).
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10.5. There are insufficient data to evaluate duration of
therapy in patients receiving immunosuppressive medica-
tions (no recommendation).
11. Pathogen-directed antimicrobial therapy
Q 11.1a. Should lower-risk patients with CA-IAI have
antimicrobial therapy changed on the basis of culture
results?
Q 11.1b. Should higher-risk patients with CA-IAI and
those with HA-IAI have antimicrobial therapy changed
on the basis of culture results?
Q 11.1c. Can treatment of patients with highly resistant
organisms, isolated as part of a mixed peritoneal culture
in patients with HA-IAI, be deferred?
Q 11.2. Should antimicrobial therapy be de-escalated or
streamlined on the basis of culture results in patients with
IAI?
The use of culture data to guide antimicrobial therapy is an
established principle for the treatment of patients with in-
fectious diseases [6,197,200]. It is unclear, however, whether
this principle should be applied routinely to patients with IAI.
Indirect evidence provides little support for routine pathogen-
directed therapy in lower-risk patients with CA-IAI. As dis-
cussed in Section 3, routine cultures in these patients have
been found to provide little benefit, suggesting that altering
therapy on the basis of those results would have little impact
[186,188–191,630]. Further, recent RCTs have not identified
higher failure rates in lower-risk patients who receive a
narrower-spectrum versus a broader-spectrum antimicrobial
regimen, despite the occasional isolation of micro-organisms
resistant to a narrower-spectrum agent [215,225,226,228–
230,249–253,294,295,300]. Finally, the use of shorter cour-
ses of antimicrobial therapy [82,623], as recommended in the
previous Section, would make use of pathogen-directed
therapy moot in many lower-risk patients with IAI. There-
fore, the task force does not believe that routine pathogen-
directed antimicrobial therapy is necessary in lower-risk
patients who are making a satisfactory response to empiric
therapy. Alteration of the antimicrobial regimen is appro-
priate, however, in patients who do not respond to initial
therapy and are classified as having treatment failure, dis-
cussed further in Section 12.
There may be a greater rationale for providing pathogen-
directed therapy to higher-risk patients with CA-IAI and HA-
IAI. Altering an initially inadequate antimicrobial regimen
according to culture results appeared to be important in
patients with pneumonia or bacteremia, although results
were not as good in those patients as they were in those
whose initial empiric regimen provided adequate coverage
[197,199,200]. There is relatively little direct evidence as to
whether this approach also applies to higher-risk patients
with IAI. One retrospective study found that altering an ini-
tially inadequate antimicrobial regimen did not improve
outcomes in patients with IAI, although not all of the patients
in the study would be considered at higher risk [49]. None-
theless, based on the potential deleterious consequences of
inadequate antimicrobial therapy in higher-risk patients, the
task force believes it is reasonable to adjust that therapy on
the basis of culture results in higher-risk patients with CA-IAI
or HA-IAI. As with lower-risk patients, however, this is
probably unnecessary in patients who are nearing completion
of a course of therapy and have already exhibited satisfactory
clinical responses.
Peritoneal cultures from some higher-risk patients may
reveal a highly resistant micro-organism along with larger
numbers of less resistant pathogens. It is uncertain whether a
definitive antimicrobial regimen must be active against all of
the isolated micro-organisms or just against the predominant
ones. Published information specifically examining this
question does not exist. The task force has therefore not made
any recommendation on this question.
De-escalation or streamlining of antimicrobial therapy may
be an option for higher-risk patients with CA-IAI and those
with HA-IAI once definitive culture results are available. De-
escalation may include conversion from a broader-spectrum to
a narrower-spectrum antibiotic agent, eliminating duplicative
agents if a single agent will suffice to manage the isolated
organisms, and discontinuation of agents effective against
gram-positive, gram-negative, or fungal pathogen if those
micro-organisms are not isolated. In selected patients, chang-
ing to an oral rather than an IV agent may also be an option
[197]. Several studies have described de-escalation in critically
ill patients with sepsis from an abdominal source, although not
all have reported the results in patients with IAI separately
[146,198,631–636]. Importantly, none of these studies have
identified any adverse effects of de-escalation, and some have
suggested decreased deaths in patients who underwent de-
escalation [146,198,635]. Based on the available data, the task
force recommends that de-escalation or streamlining of anti-
microbial therapy be employed whenever feasible.
11.1a. We recommend against changing antimicrobial
therapy on the basis of culture results in lower-risk patients
with CA-IAI who have a satisfactory clinical response to
source control and empiric antimicrobial therapy (Grade
1-B).
11.1b. We suggest modifying antimicrobial therapy in
higher-risk patients with CA-IAI and HA-IAI if culture results
identified organisms resistant to the initial empiric regimen
and further antimicrobial therapy is planned (Grade 2-C).
11.1c. There are insufficient data to make any recom-
mendation regarding modification of antimicrobial therapy
in patients with HA-IAI who have a highly resistant organism
isolated as a minor component of a mixed peritoneal culture
(no recommendation).
11.2. We recommend routinely de-escalating or stream-
lining antimicrobial therapy in higher-risk patients with CA-
IAI and HA-IAI to the narrowest-spectrum agent or agents
having activity against the isolated micro-organisms, once
definitive culture results are available (Grade 1-B).
12. Treatment failure
A. Source control for treatment failure
Q 12.1a. What are the clinical indicators of source control
failure in patients with IAI?
Q 12.1b. When should patients with IAI be assessed for
source control failure?
Q 12.1c. What diagnostic maneuvers should be under-
taken in patients who are suspected of having source
control failure?
Q 12.1d. What therapeutic approach should be undertaken
with patients with failure of initial source control?
SIS GUIDELINES ON INTRA-ABDOMINAL INFECTION 47
Q 12.1e. When should further source control procedures
be undertaken in patients considered to have a treatment
failure?
Q 12.1f. Should abdominal fluid or tissue cultures be
obtained in patients with treatment failure?
After initial source control, the clinician may be faced with
the task of recognizing and developing a therapeutic plan for
patients who fail that intervention. The diagnosis of source
control failure may be problematic. Symptoms and signs of
recurrent or ongoing IAI, such as abdominal pain, rebound
tenderness, ileus, fever, or leukocytosis, are not specific,
being quite common in all post-operative patients. Further,
these signs may not be present in some patients with recurrent
or ongoing IAI. Use of risk factors to identify patients with
source control failure, such as those outlined in Section 1, are
also insufficient to make a diagnosis in patients with source
control failure. Source control failure will actually develop in
only a fraction of these higher-risk patients, particularly when
the initial procedure was considered adequate [172].
Several studies have demonstrated that changes in physi-
ologic parameters and other clinical problems that become
manifest at or beyond post-operative day two are far more
predictive of source control failure than the patient status at
the time of the initial source control procedure. Adverse
trends in individual measures of heart rate, temperature, the
ratio of the arterial partial pressure of oxygen to the fractional
inspired oxygen concentration (PaO2:FIO2), C-reactive pro-
tein level, procalcitonin level, SAPS II or multiple organ
failure (MOF) or multiple organ dysfunction syndrome
(MODS) scores, the development of a fascial dehiscence, or
the finding of inadequacy of empiric antimicrobial coverage
are all associated with a higher risk of source control failure
[15,32,50,57,70,81,637,638]. Thus, the task force would
recommend using these temporal signals to help identify
patients with a high likelihood of failed source control.
Models combining trends in various risk factors or physi-
ologic scores may have greater potential for predicting source
control failure, although none of the current models provide
high certainty. Serial MODS scores were used as triggers for
on-demand re-laparotomy in one RCT, but there was still a
relatively high 31% rate of negative re-laparotomy [170].
A related study found that the combination of changes in
several physiologic parameters predicted a positive re-
laparotomy, but even the best model had an overall accuracy
of approximately 80% [57]. Thus, although the decision to
intervene in a patient with presumed source control failure
may be aided by use of such models, clinical acumen still
needs to be exercised to accurately identify patients with
source control failure.
Death is significantly higher in patients with IAI who have
a failure of the index source control procedure [48,51,61,71,
84,126,637,639]. Moreover, the time to re-operation may be
a further determinate of outcome, with therapeutic delays
greater than 24–48 hours being associated with increased
deaths [51,81]. Thus, early identification of the patient with
source control failure through diagnostic imaging or re-
laparotomy would be beneficial. Negative diagnostic studies
or re-laparotomies, however, may lead to complications as
well as increases in resource utilization. The opinion of the
task force is that diagnostic investigation or therapeutic in-
terventions should be strongly considered in patients who
have progressive deterioration or no improvement in in-
flammatory markers or signs of organ function 48 hours after
the index intervention, and in those patients who show evi-
dence of ongoing inflammation 5–7 days after the index
procedure.
In most patients, the imaging study of choice to investigate
treatment failure is contrast-enhanced computed tomo-
graphic (CT) imaging [640–642]. The CT scans are generally
quite sensitive in detecting infected intra-abdominal fluid
collections, particularly when compared with physical ex-
amination, laboratory studies, and other imaging modalities
[643–645]. The CT scans, however, do not necessarily dif-
ferentiate infected from uninfected post-operative fluid col-
lections [646–648]. The CT scans may also be less useful for
detecting infections because of early anastomotic leaks
[649,650]. It has generally been accepted that the utility of
contrast-enhanced CT scans increases the longer it is after
initial source control. One report suggested, however, that a
good diagnostic yield is obtained even at 3–7 days after the
index procedure with current generation CT scanners [651].
Nonetheless, because of the risk of false negative imaging in
patients with IAI who have early treatment failure, excessive
reliance should not be placed solely on CT scanning to de-
termine the need for re-intervention.
Optimal re-intervention in patients with source control
failure, as with the index source control procedure, should
include measures directed at the elimination, drainage, or
control of infected fluid and tissue collections and the pre-
vention of ongoing contamination. Operative morbidity,
however, is generally high in patients with source control
failure, particularly in those who have already undergone
extensive abdominal operations. Thus, when feasible, use of
less invasive procedures should be considered. For localized
fluid collections, percutaneous drainage is generally rec-
ommended [128,149]. Even when complete source elimina-
tion is not technically possible, however, less invasive
techniques may still be beneficial as temporizing measures,
as has been demonstrated for patients with widespread in-
fected pancreatitis [143–145,652]. Overall, the task force
supports the concept that some attempt at source control
should be undertaken in patients with recurrent or ongoing
IAI, because outcomes in these patients are poor in the ab-
sence of source control, even with continuation of antimi-
crobial therapy. The nature of that source control procedure,
however, needs to be individually tailored to the patient,
taking into consideration both the risks and benefits of the
proposed intervention.
There are scant data regarding timing of source control for
IAI in patients with treatment failure. The task force believes
that undertaking source control within 24 hours of diagnosis
is appropriate based on the limited data available [49,146]. In
critically ill patients with treatment failure following an index
procedure, however, the time to re-operation appears to be a
determinate of outcome [51,81,147,148]. Thus, when treat-
ment failure is established in a critically ill patient, efforts to
achieve source control should be undertaken as expeditiously
as possible.
Patients with source control failure are typically at risk for
infections with more resistant pathogens than those who have
CA-IAI andmay be at risk for highly resistant micro-organisms
if they have had significant exposure to the healthcare envi-
ronment and particularly previous antimicrobial therapy
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[17,22–24,26,27,32,43,62,86,88,89]. Inadequate empiric anti-
microbial therapy has been independently associated with
death in these patients [43,54,58,187,193–195]. Thus, there is a
rationale for obtaining peritoneal cultures in patients with
source control failure, just as there is generally for any higher-
risk patient with IAI. These data are essential for pathogen-
directed therapy [42,197,199,200], and may provide the basis
for de-escalation of initially broad-spectrum antimicrobial
therapy [4,6,196–198].
12.1a. We recommend using measures of ongoing or
progressive systemic inflammation or organ system dys-
function to identify patients with likely source control failure
(Grade 1-B).
12.1b. We suggest that patients be assessed for source
control failure if there is progressive organ dysfunction
within the first 24–48 hours after source control, if there is no
clinical improvement in organ dysfunction 48 hours or more
after source control, or if there are persistent signs of in-
flammation 5–7 days after source control (Grade 2-C).
12.1c. We suggest that patients who clinically deteriorate
or fail to improve within 48–72 hours of the initial procedure
be considered for abdominal exploration (Grade 2-C). We
recommend that patients suspected of treatment failure after
48–72 hours of the initial source control procedure undergo
CT scanning, with percutaneous aspiration or drainage of
any potentially infected fluid collections (Grade 1-B).
12.1d. We recommend utilization of the least invasive ap-
proach that will either achieve definitive source control or will
sufficiently control the infection such that there is resolution of
the inflammatory response and organ dysfunction (Grade 1-B).
12.1e. We suggest that further source control be undertaken
within 24 hours when failure of source control is identified
(Grade 2-C). We suggest that patients with physiologic in-
stability or progressive organ dysfunction should undergo
further source control as soon as feasible (Grade 2-B).
12.1f. We recommend obtaining peritoneal cultures rou-
tinely in patients with source control failure, such that
pathogen-directed antimicrobial therapy can be utilized
(Grade 1-C).
B. Antimicrobial therapy for treatment failure
Q 12.2a. How should antimicrobial therapy be approached
in patients with IAI who have treatment failure?
Q 12.2b. How should antimicrobial therapy be ap-
proached in patients with IAI who have clinical evidence
of treatment failure but have negative imaging studies for
persistent or recurrent IAI?
Q 12.2c. How should antimicrobial therapy be approached
in patients with IAI who have clinical evidence of treat-
ment failure and imaging studies showing inflammation
but no discrete intra-abdominal source of infection ame-
nable to source control?
Q 12.2d. How should antimicrobial therapy be ap-
proached in patients with IAI who have clinical evidence
of treatment failure and imaging studies showing persis-
tent or recurrent IAI, but in whom adequate source con-
trol cannot be achieved?
Early treatment failure in patients with IAI, occurring
within 48 hours of source control, is typically the result of an
unsuccessful initial intervention and not to a failure of anti-
microbial therapy. The limited amount of anti-infective
agents these patients have received is unlikely to have exerted
much selection pressure on the pathogens that predominated
at the time of the index procedure. In contrast, patients with
late treatment failure, occurring after 48 hours, are likely to
have a somewhat more resistant microbial flora because of
longer-duration antimicrobial therapy. The differences be-
tween the micro-organisms associated with CA-IAI and HA-
IAI attest to this selection pressure [15,22–28,32,33]. The
consensus of the task force is that continuation of previous
antimicrobial therapy is appropriate in most patients with IAI
who experience early treatment failure. Broader-spectrum
empiric antimicrobial therapy, however, tailored to the ex-
pected risk of resistant pathogens, should be provided to pa-
tients with late treatment failure; if feasible, a switch in the class
of antibiotic agents being administered should be considered.
Although successful management of IAI is usually her-
alded by resolution of fever, leukocytosis, and gastrointesti-
nal dysfunction, these signs may persist in some patients,
even in the absence of ongoing infection [653,654]. Patients
who have persistent signs of inflammation should undergo
diagnostic investigations to determine whether there is re-
current or persistent IAI, or an alternate source of infection. If
diagnostic studies have negative results, further antimicrobial
therapy for IAI is not generally warranted. Retrospective
analyses have indicated that use of prolonged antibiotic
courses, even in patients with ongoing fever or leukocytosis,
does not provide any benefit [618,621,622].
Prospective studies using procalcitonin measurements to
determine length of antimicrobial therapy also provided in-
direct evidence that treatment could be safely discontinued,
even if not all signs of inflammation had resolved [655,656].
Moreover, the recent STOP-IT trial found that patients with
IAI randomized to antimicrobial therapy continued two days
beyond resolution of fever, leukocytosis, and ileus fared no
better than patients randomized to having antibiotic agents
stopped at four days, whether or not these signs were still
present; this finding applied even to patients with higher
APACHE II scores [82]. Taken together, these data support
the tasks force’s suggestion that antimicrobial therapy be
discontinued in patients with IAI who have some clinical
signs of treatment failure but whose imaging studies show no
clear infectious source.
Imaging studies may be equivocal in some patients who
have ongoing fever, leukocytosis, or ileus after an initial
course of antimicrobial therapy for IAI. These studies may
not identify a discrete source of infection, but may show areas
of ongoing inflammation or small fluid collections within the
abdomen, which cannot be accessed percutaneously. The
importance of these findings is obscure. The task force did not
identify any substantiative body of literature that addresses
therapeutic approaches for such patients. Antimicrobial
therapy alone, however, has been used for treating patients
with some localized inflammatory processes because of IAI,
such as a peri-appendiceal phlegmon or a small intra-
abdominal abscess related to diverticular or appendiceal
disease [131–135,140–142]. Based on these considerations,
the task force suggests that selected patients with clinical
signs of treatment failure whose diagnostic studies show
ongoing inflammation may receive a trial course of repeat
antimicrobial therapy, preferably using agents distinct from
those administered initially. Once this brief course of
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antimicrobial therapy is completed, however, the patient
should not be given further anti-infective agents unless there
is clear evidence of clinical deterioration or an imaging study
documents progression of the inflammatory process.
Further source control should be the first consideration for
treating patients with recurrent or persistent IAI identified by
imaging studies. Further intervention may not be feasible,
however, if the risk of surgical re-exploration is excessive
and less invasive techniques cannot address the source of the
infection. A decision made by the patient or a surrogate may
also preclude further attempts at source control. The only
option for these patients, then, is further antimicrobial ther-
apy. There are few data regarding optimal anti-infective
treatment of these patients. The task force suggested ap-
proach is based, in part, on current management practices for
patients with infected pancreatitis. If at all possible, antimi-
crobial therapy should be guided by microbiologic data;
potentially, cultures can be obtained by diagnostic techniques
such as a fine needle aspiration when definitive source control
is not an option [657,658]. Patients should be followed clin-
ically and undergo repeat imaging studies while on antimi-
crobial therapy. If the patient’s clinical examination improves
substantially or if imaging studies reveal that the infection has
abated, antimicrobial therapy can be discontinued. If subse-
quent imaging studies or a change in the patient’s condition
make source control a viable option, a procedure should be
attempted. Periodic cessation of antimicrobial therapy should
be attempted at intervals, even in the setting of persistent
systemic inflammation, because indefinite treatment with an-
timicrobial agents will likely lead to development of resistant
organisms. Nonetheless, antimicrobial therapy should not be
discontinued in certain patients with IAI, particularly critically
ill patients with uncontrolled tertiary peritonitis or worsening
sepsis with organ failure [8,629].
12.2a. We suggest that patients with IAI who have early
treatment failure and undergo repeat source control within
48 hours of the initial source control intervention do not need
to have antimicrobial therapy changed (Grade 2-C). We
suggest that patients with IAI who have late treatment failure
should have antimicrobial therapy changed to agents ap-
propriate for HA-IAI; if feasible, the class of antibiotic being
provided should be switched (Grade 2-C).
12.2b. We suggest that patients with IAI who have clinical
evidence of treatment failure but negative imaging studies for
recurrent or persistent IAI have antimicrobial therapy dis-
continued (Grade 2-B).
12.2c. We suggest that patients with IAI who have clinical
evidence of treatment failure and imaging studies showing
ongoing intra-abdominal inflammation undergo a trial of
additional antimicrobial agents appropriate for HA-IAI,
using a different class of agents if feasible; if there is no
clinical response to this antimicrobial trial within a few
days, antimicrobial therapy should be discontinued, and
only reinstated if there is evidence of clinical deterioration
(Grade 2-C).
12.2d. We suggest that patients with IAI who have clinical
evidence of treatment failure and imaging studies showing
recurrent or persistent IAI, but in whom further source control
cannot be achieved, have antimicrobial therapy continued;
antimicrobial therapy should be discontinued when clinical
signs of systemic inflammation or organ dysfunction abate
(Grade 2-C). We suggest that these patients be monitored for
resistant pathogens, with antimicrobial therapy adjusted as
necessary to treat such pathogens (Grade 2-C).
13. Treatment of pediatric IAI
Q 13.1a. What are the preferred agents for initial empiric
antimicrobial therapy of lower-risk pediatric patients
older than one month (45wks post-conceptional age) with
CA- IAI?
Q 13.1b. What are the preferred agents for initial empiric
antimicrobial therapy of higher-risk pediatric patients
older than one month (45wks post-conceptional age) with
CA-IAI and those with HA-IAI?
Q 13.2a. What should the duration of antimicrobial ther-
apy be for pediatric patients older than one month (45wks
post-conceptional age) with IAI?
Q 13.2b. Should supplemental oral antimicrobial therapy
be provided to pediatric patients with IAI after they have
received IV therapy?
Q 13.2c. Should outpatient IV antimicrobial therapy be
provided to pediatric patients with IAI who can be dis-
charged from the hospital?
Q 13.3. How should treatment failure be managed in
pediatric patients with IAI?
Q 13.4a. How should pediatric patients less than one
month old (45wks post-conceptional age) with necro-
tizing enterocolitis (NEC) or intestinal perforation be
treated?
Q 13.4b. What are the preferred antimicrobial agents for
initial empiric therapy of pediatric patients less than
one month old (45wks post-conceptional age) with
IAI?
Q 13.4c. What should be the duration of antimicrobial
therapy for pediatric patients with IAI less than one
month old (45wks post-conceptional age)?
Q 13.5. What dosages of antimicrobial agents should be
used for treatment of pediatric patients with IAI?
The most common IAI encountered in children outside of
the neonatal age group is complicated appendicitis; IAI from
other sources is observed much less frequently [659]. As with
adults, empiric antimicrobial therapy directed against gram-
negative Enterobacteriaceae and anaerobic bacteria is ap-
propriate for children with perforated appendicitis and other
types of IAI [660,661]. Previously, a combination of ampi-
cillin, an aminoglycoside, and an anti-anaerobic agent was
considered the gold standard in treating pediatric patients
with IAI. Numerous studies, however, have demonstrated
efficacy of other antimicrobial regimens for managing IAI in
these patients [328,661]. RCTs published before 2000 are
included in the previous evidence review [3], and newer
studies are summarized in Supplementary Table V; see online
supplementary material at www.liebertpub.com/overview/
surgical-infections/53/. These RCTs support use of ticarcillin-
clavulanic acid [220,662,663], piperacillin-tazobactam
[225,327], ertapenem [205,214,220], imipenem-cilastatin
[664,665], meropenem [290,666], cefoperazone-sulbactam
[203], and combinations of cefotaxime [225,667], ceftriax-
one [204,212,319,668], or ceftazidime [210] with metroni-
dazole or clindamycin. In addition, cefuroxime has been
approved for use in pediatric patients [523], and cefepime
[669] and aztreonam [670] have efficacy for managing
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serious pediatric infections, although studies have not spe-
cifically addressed their use in pediatric IAI.
Age-based restrictions to use of fluoroquinolone antibiotic
agents in pediatric patients were advocated in the past. In-
vestigational studies documented cartilage injury in weight-
bearing joints of juvenile canines [671,672], although the
importance of these findings was uncertain. A systematic
review of the literature suggested that any musculoskeletal
adverse events developing in pediatric patients were revers-
ible [303]. The American Association of Pediatrics Com-
mittee on Infectious Diseases has recommended the use of
fluoroquinolones in certain clinical scenarios, and many
centers have adopted this practice [304]. The task force has
therefore suggested that ciprofloxacin with metronidazole
can be used as an alternative regimen for treating pediatric
patients with IAI when other regimens are not suitable, par-
ticularly in patients who have major reactions to b-lactam
antibiotic agents.
As with adult patients, data demonstrating superiority of
any specific antimicrobial regimen for the management of
IAI in pediatric patients are lacking [328]. Thus, the task
force recommendations regarding selection of specific anti-
microbial agents are based on factors such as toxicity, con-
venience, and cost, with particular emphasis placed on
considerations of antimicrobial stewardship. For CA-IAI in
lower-risk pediatric patients older than one month, mono-
therapy with ertapenem or combination therapy with cefo-
taxime or ceftriaxone plus metronidazole are recommended.
An alternative regimen, not nearly as well investigated, is
cefuroxime plus metronidazole. The use of ciprofloxacin
plus metronidazole can be considered in patients with severe
b-lactam reactions (Table 14). The use of aminoglycoside-
based regimens is discouraged, because of evidence of de-
creased efficacy [207,208] as well as the toxicity associated
with these agents.
Although recommended by some, the task force does not
advocate use of routine anti-pseudomonal coverage for
lower-risk pediatric patients with CA-IAI. Pseudomonas
spp. has been isolated with variable frequency from perito-
neal cultures of pediatric patients with complicated appen-
dicitis. One series identified P. aeruginosa in 31% of such
cultures [673], but the incidence was substantially lower in
other series [20,393,674]. In addition, RCTs have not dem-
onstrated improved outcomes in pediatric patients receiving
regimens with anti-pseudomonal coverage compared with
patients receiving regimens without that coverage
[203,205,220,226,675].
There is minimal evidence with regard to antimicrobial
therapy of higher-risk children with CA-IAI or those with
HA-IAI. The task force suggests that recommendations for
higher-risk pediatric patients parallel those for higher-risk
adult patients. Broader-spectrum empiric therapy should be
provided initially in pediatric patients with severe sepsis or
septic shock, because of the potential for inadequate therapy
if a more resistant organism, such as Pseudomonas spp., is
encountered. Use of piperacillin-tazobactam, imipenem-
cilastatin, or meropenem is suggested in these patients. Al-
ternative regimens, not as well studied in pediatric patients,
include ceftazidime or cefepime plus metronidazole. Addi-
tional coverage of Enterococcus spp., MRSA, MDR gram-
negative bacilli, or yeast should be considered in pediatric
patients with HA-IAI, if they have risk factors for infection
with those resistant micro-organisms.
Previously, pediatric patients were frequently prescribed
seven or more days of IV antibiotic therapy after source
control for perforated appendicitis or other types of IAI
[387,673]. A recent RCT indicated that five days of IV an-
timicrobial therapy was sufficient for these patients (Sup-
plementary Table W; see online supplementary material at
www.liebertpub.com/overview/surgical-infections/53/) [319].
Other authorities have advocated earlier discontinuation of
antimicrobial therapy in pediatric patients with IAI, either
based on a fixed duration of therapy or resolution of clinical
signs of infection [328,661,676,677]. Although RCTs have
found that a 3–4 day course of antimicrobial therapy is ade-
quate in adult patients [82,214,623], the task force recom-
mends a five-day total duration of antimicrobial therapy in
pediatric patients with IAI, because of the lack of evidence on
shorter-duration therapy in those patients.
There is increasing acceptance of the option to transition
pediatric patients to oral antibiotic agents once they are
afebrile and tolerating a regular diet. Two RCTs in pediatric
patients found a switch to oral amoxicillin-clavulanic acid
equivalent to use of IV therapy only (Supplementary Table
O; see online supplementary material at www.liebertpub.
com/overview/surgical-infections/53/) [319,320]. Other ret-
rospective studies suggested this agent or a combination of
trimethoprim-sulfamethoxazole plus metronidazole were
adequate to complete a course of antimicrobial therapy
[387,388].
There are no data, however, indicating that administering
oral antibiotic agents after completing a full course of IV
antibiotic agents provides any additional benefit [319,677].
Thus, oral antibiotic agents should be used only to complete a
recommended five-day course of antimicrobial therapy and
not to extend therapy beyond that [328,678]. Similarly, be-
cause there are no data suggesting a benefit of additional IV
antibiotic agents beyond five days [319,661,678], the use of
outpatient IV antimicrobial therapy would generally be
Table 14. Recommended Empiric Antimicrobial
Regimens for Pediatric Patients Older
than One Month with Community-Acquired
Intra-Abdominal Infection*
Lower-risk patients Higher-risk patients
Preferred regimens
Cefotaxime or ceftriaxone
plus metronidazole
Piperacillin-tazobactam
Ertapenem Imipenem-cilastatin
Meropenem
Alternative regimens
Cefuroxime plus
metronidazole
Ceftazidime or cefepime
plus metronidazolea
Aztreonam plus metronidazole
plus vancomycin
Optional regimens
Ciprofloxacin or
levofloxacin plus
metronidazole
*More than 45 weeks post-conceptual age.
aUse of an agent effective against Enterococcus spp. is suggested
in patients with severe sepsis/septic shock who receive a
cephalosporin-based regimen.
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unnecessary for most pediatric patients with IAI. Outpatient
IV therapy to complete a five-day course could be considered
in the infrequent patient with IAI because of a resistant or-
ganism for which no oral agent was suitable. Overall, in the
absence of treatment failure, the task force recommends
against use of additional oral or IV antibiotic agents beyond
five days in pediatric patients with IAI.
In pediatric IAI, complications developing after manage-
ment of perforated appendicitis are the most common ex-
amples of treatment failure. One large observational study
documented a 13% risk of an intra-abdominal abscess in
pediatric patients with perforated appendicitis [677]. Percu-
taneous drainage of an abscess provides adequate source
control, although small abscesses may be treatable with an-
tibiotic agents alone [679,680]. Further antimicrobial therapy
should follow the principles outlined previously for adult
patients with treatment failure. There is no evidence that
prolonged antimicrobial therapy benefits pediatric patients
with a post-operative abscess. In the presence of adequate
source control, the task force suggests nomore than seven days
of antimicrobial therapy for treatment failure in children.
These patients may be converted to oral therapy to complete
their course of therapy [319], as is done for children with
primary IAI. In the absence of adequate source control, how-
ever, such as in patients with continued soilage of the abdomen
from an appendiceal stump leak, more prolonged antimicro-
bial therapy may be warranted, with the proviso that definitive
source control should be attempted whenever feasible.
IAI in neonatal patients developsmost commonly as a result
of NEC or spontaneous intestinal perforation; other etiologies,
such as post-operative IAI, are also encountered [659]. Source
control in premature infants is generally considered impera-
tive. Both laparotomy with resection and peritoneal drainage
have been used, however, to treat patients with spontaneous
and NEC-induced intestinal perforations [681]. Two RCTs
(Supplementary Table X; see online supplementary material at
www.liebertpub.com/overview/surgical-infections/53/) com-
paring these two approaches showed no differences in mor-
tality; however, considerably different rates of salvage
laparotomy were observed in patients treated with initial
peritoneal drainage in the two studies [682,683].
There is little prospective evidence regarding optimal an-
timicrobial therapy for infants with IAI. A few RCTs com-
paring antibiotic regimens for patients with NEC have been
published, but these have evaluated primarily treatment of
patients with clinical evidence of NEC without overt perfo-
ration; the studies have not addressed directly antimicrobial
therapy of patients with established IAI due to intestinal
perforation [684]. Thus, recommendations for antimicrobial
therapy are based primarily on indirect evidence from studies
of NEC and expert opinion [685–687]. In general, the task
force believes that antimicrobial therapy in neonatal patients
with IAI should conform to the general principles outlined for
treatment of HA-IAI. Multi-drug combinations have fre-
quently been used in this high-risk population [688], but
monotherapy providing equivalent broad-spectrum gram-
negative coverage is acceptable. Selective addition of agents
with activity against enterococci, MRSA, and yeast should be
considered in patients with risk factors for these resistant
organisms, most commonly previous broad-spectrum anti-
biotic use. Vancomycin has been used for infections sus-
pected to be from MRSA or ampicillin-resistant enterococci.
Amphotericin B and fluconazole have been prescribed for
fungal peritonitis. Once source control has been achieved, the
task force suggests that antimicrobial therapy be continued
for 7–10 days. These consensus recommendations for anti-
microbial treatment of neonatal patients up to one month of
age with IAI are shown in Table 15.
Dosing recommendations for pediatric patients both
younger and older than one month are listed in Table 16.
Where possible, these dosing recommendations are derived
from RCTs (Supplementary Table X; see online supple-
mentary material at www.liebertpub.com/overview/surgical-
infections/53/) performed in pediatric patients. Other sources
include the prescribing information for specific antimicrobial
agents approved by the FDA [523] and a standard pharma-
cology text [524]. As with adult patients, standard dosing is
appropriate for nearly all lower-risk children with CA-IAI.
Higher doses, however, may be reasonable in critically ill
pediatric patients, who may have an increased volume of
distribution and/or accelerated clearance of antimicrobial
agents. Optimal dosing of many antimicrobial agents in the
neonatal age group is extrapolated from data on older chil-
dren, because pharmacokinetic studies on these younger pa-
tients are frequently lacking.
13.1a. We recommend ertapenem or a combination of
cefotaxime or ceftriaxone plus metronidazole for empiric
antimicrobial therapy of CA-IAI in lower-risk pediatric pa-
tients older than one month (45wks post-conceptional age)
(Grade 1-A). We suggest cefuroxime plus metronidazole as
an alternative regimen for empiric treatment of these pedi-
atric patients (Grade 2-B). We suggest ciprofloxacin or le-
vofloxacin plus metronidazole as acceptable regimens for
empiric treatment of selected pediatric patients with IAI if
other agents cannot be used, particularly for those pediatric
patients with life-threatening b-lactam reactions (Grade 2-
B). We suggest cefoperazone-sulbactam, where it is avail-
able, as an acceptable option for empiric therapy of CA-IAI
in lower-risk pediatric patients (Grade 2-B).
13.1b. We suggest piperacillin-tazobactam, imipenem-
cilastatin, or meropenem for empiric antimicrobial therapy
of CA-IAI in higher-risk pediatric patients older than one
month (45wks post-conceptional age) (Grade 2-A). We also
Table 15. Summary of Empiric Antimicrobial
Therapy for Pediatric Patients Less than One
Month Old with Intra-Abdominal Infection*
General recommendation
Ampicillin, gentamicin, plus metronidazole
Ampicillin, cefotaxime, plus metronidazole
Meropenem
Additional agents
Potential pathogen Suggestion
Enterococcus spp. Use of ampicillin if E. faecalis
is suspected, or use of vancomycin
instead of ampicillin if a penicillin-
resistant Enterococcus spp.
is suspected
MRSA Use of vancomycin if MRSA suspected
Candida spp. Use of amphotericin B or fluconazole
*Less than 45 weeks post-conceptual age.
MRSA=methicillin-resistant Staphylococcus aureus.
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Table 16. Dosages of Antimicrobial Agents for Pediatric Patients
Age
Agent
Children older than
one month of agea
Term infants to
one month of agea
Aminoglycosides
Amikacin 5–7.5mg/kg IV q8h
Gentamicin 2.5mg/kg IV q8h 4-5mg/kg IV q24–48h
Tobramycin 2–2.5mg/kg IV q8h
Aminopenicillin
Ampicillin 100–400mg/kg/d IV in divided doses q6h 50mg/kg IV q6–12h
b-lactamase/b-lactamase inhibitor combinations
Ampicillin-sulbactam 100–200mg ampicillin/kg/d IV
in divided doses q6h
Ticarcillin-clavulanate
(Not currently available)
200–300mg/kg/d IV in divided doses q4–6h
Piperacillin-tazobactam 240–300mg/kg/d IV in divided doses q6–8h
Cephalosporins
Cefoxitin 80–160mg/kg/d IV in divided doses q6–8h
Cefotetan 20–40mg/kg IV q12h
Cefazolin 25–50mg/kg in 3–4 divided doses q6-8h
Cefuroxime 75-200mg/kg/d IV in divided doses q6–8h
Cefotaxime 50–180mg/kg/d IV in divided doses q4–6h
for patients <50 kg; adult dosages
for patients >50 kg
50mg/kg IV q8–12h
Ceftriaxone 50–100mg/kg/d IV in 1–2 divided doses
Ceftazidime 30–50mg/kg IV q8h
Cefepime 50mg/kg IV q12h (£16 y and £40 kg);
adult dosages for >16 y or >40 kg)
Cephalosporin/b-lactamase inhibitor combination
Cefoperazone-sulbactam:
1:1 ratio
2:1 ratio
40–80mg/kg/d divided q6–12h
30–60mg/kg/d divided q6-12h
Monobactam
Aztreonam 30mg/kg IV q6–8h (>9 mo)
Carbapenems
Ertapenem 15mg/kg IV q12h (£12 y); adult dosages for >12 y
Imipenem/cilastatin 15–25mg/kg IV q6h
Meropenem 30–120mg/kg/d IV in divided doses q8h 20mg/kg IV q8–12h
Fluoroquinolones
Ciprofloxacin 20–30mg/kg/d IV in divided doses q12h
Levofloxacin 10mg/kg IV q12h (6 mo to 5 y);
10mg/kg IV q24h (‡5 y)
Anti-anaerobic agents
Clindamycin 20–40mg/kg/d IV in 3–4 divided doses 5–7.5mg/kg IV q8–12h
Metronidazole 22.5–40mg/kg/d IV in divided doses q8h 15mg/kg IV q12–24h
Agents with activity against resistant gram-positive organisms
Vancomycin 10mg/kg IV q6h 10–15mg/kg IV q8-12h
Teicoplanin 10mg/kg IV q8–12h · 3 doses,
then 6–10mg/kg IV q24h
Linezolid 10mg/kg IV q8h (<12 y)
Antifungal agents
Amphotericin B deoxycholate 1–1.5mg/kg IV q24h 1mg/kg/d IV or
1.5mg/kg IV q48h
Amphotericin B lipid complex,
amphotericin B, colloidal
dispersion, liposomal
amphotericin B
5mg/kg IV q24h 5mg/kg IV q24h
Caspofungin 70mg/m2 IV x 1 dose, then 50mg/m2 q24h
Fluconazole 3–12mg/kg IV q24h 3–12mg/kg IV q24h
aOlder or younger than 45 weeks post-conceptual age.
IV = intravenous.
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suggest these agents for empiric therapy of HA-IAI in pedi-
atric patients (Grade 2-B). We suggest ceftazidime or cefe-
pime plus metronidazole as alternative regimens for empiric
treatment of CA-IAI or HA-IAI in these pediatric patients
(Grade 2-B). We suggest aztreonam plus metronidazole plus
vancomycin as an acceptable regimen for empiric treatment
of selected pediatric patients if other agents cannot be used,
particularly for pediatric patients with life-threatening b-
lactam reactions (Grade 2-B). We suggest addition of am-
picillin or vancomycin as empiric anti-enterococcal therapy
of CA-IAI in higher-risk patients and those with HA-IAI if the
patient is not being treated with piperacillin-tazobactam or
imipenem-cilastatin (Grade 2-B).
13.2a.We recommend nomore than five full days (120 h) of
antimicrobial therapy of IAI in pediatric patients older than
one month (45wks post-conceptional age) who have had
adequate source control (Grade 1-A).
13.2b. We recommend against use of additional oral an-
timicrobial therapy for IAI in pediatric patients who have had
adequate source control, unless given to complete a total
antimicrobial course of five days (Grade 1-B).
13.2c. We recommend against use of additional outpatient
IV antimicrobial therapy for IAI in pediatric patients who
have had adequate source control, unless given to complete a
total antimicrobial course of five days (Grade 1-B).
13.3. We recommend that pediatric patients with treatment
failure be managed in an analogous fashion to adult patients
with treatment failure (Grade 1-C). We suggest using the
least invasive means of providing adequate source control
and using a standard course of IV antibiotic agents; a change
in antibiotic class may be considered in these patients (Grade
2-C). We recommend against use of IV antibiotic agents
beyond seven days for children with perforated appendicitis
who have a post-operative abscess (Grade 1-C).
13.4a. We recommend either laparotomy or peritoneal
drainage as source control in addition to antimicrobial
therapy for pediatric patients less than one month of age
(45wks post-conceptional age) with NEC or intestinal per-
foration (Grade 1-A).
13.4b. We suggest use of ampicillin, gentamicin, and met-
ronidazole or clindamycin; ampicillin, cefotaxime, and met-
ronidazole or clindamycin; ormeropenem in pediatric patients
less than onemonth of age (45wks post-conceptional age) with
IAI. Vancomycin may be used instead of ampicillin if there is
suspected infection with penicillin-resistant Enterococcus
spp. or MRSA. Fluconazole or amphotericin B can be added if
there is a suspected infection with Candida spp. (Grade 2-C).
13.4c. We suggest a 7–10 day course of antimicrobial
therapy for pediatric patients less than one month of age
(45wks post-conceptional age), particularly for those with
NEC (Grade 2-C).
13.5. We recommend use of standard pediatric dosages for
various antimicrobial agents for lower-risk pediatric patients
with CA-IAI (Grade 1-B). We suggest use of higher pediatric
dosages, where applicable, for higher-risk patients with CA-
IAI and those with HA-IAI (Grade 2-C).
Recommendations for Future Investigations
The development of this revised guideline for the man-
agement of IAI has uncovered numerous problems for which
data are inadequate to allow firm conclusions. Key questions
remain both with respect to optimal source control and to
utilization of antimicrobial therapy in patients with IAI.
Many recommendations in these guidelines are stratified
based on the perceived risk that a given patient will have an
adverse outcome. An adverse outcome has been defined
variably in the literature and may refer to treatment failure or
to death. Treatment failure, in turn, has been variably defined,
ranging from persistent signs of infection to a need for further
invasive interventions for source control. At present, a simple
tool for calculating risk of either treatment failure or death
does not yet exist.
One goal of future investigations would be to construct and
validate simple, reliable tools for assessing risk of source
control failure and death, such that they can be utilized for
planning source control and antimicrobial therapy at the point
of care. Relatively simple, revised criteria for identifying pa-
tients with sepsis or septic shock have been proposed by the
Society of Critical CareMedicine and the European Society of
Intensive Care Medicine [80], which may simplify the iden-
tification of patients with IAI who have sepsis or septic shock.
For purposes of treating patients with IAI, however, additional
measures are needed, because not all higher-risk patients with
IAI meet these revised criteria for sepsis or septic shock.
Options for source control in patients with IAI continue to
evolve. Relatively few new procedures have been evaluated
prospectively. There is little doubt that less invasive procedures
can provide adequate source control for patients with IAI, and
that extensive procedures performed to maximize source
control may produce greater morbidity and death than less
extensive procedures. Nonetheless, less invasive source control
measures may not lead to improved patient outcomes. New
procedures should be adequately investigated and not adopted
prematurely for patient care. An example is the current con-
troversy over the use of less invasive procedures for managing
Hinchey Stage III and IV complicated diverticulitis [154–159].
Given the wide variety of potential source control inter-
ventions that could be tested, it is unrealistic to expect RCTs
can be used to analyze even a small fraction of these ap-
proaches. Non-randomized cohort studies, however, can
provide valuable information, particularly if care is taken to
ensure that control patients are carefully matched with regard
to prognostic factors. The use of large, multi-institutional
databases, such as that obtained from the Complicated Intra-
Abdominal Infection Observational Study, can facilitate
these observations and make them more generalizable
[26,438]. The SIS and similar organizations should consider
developing similar databases to analyze best practices with
regard to source control.
The principles of antimicrobial therapy for patients with IAI
are well established. The increasing prevalence of ESBL-
producing and fluoroquinolone-resistant strains of E. coli and
other gram-negative organisms in patients with IAI, however,
could have a major impact on antimicrobial selection [28].
These resistance concerns extend to patients with CA-IAI as
well as those with HA-IAI. As of yet, it is unclear whether the
outcomes of lower-risk patients with CA-IAI will significantly
worsen because of these resistant organisms. Although data
from a number of RCTs suggest that narrower-spectrum em-
piric antimicrobial agents are still effective in these patients
[204,205,220,225,228–230,252,255,294–296], larger-scale,
contemporary investigations are needed to determine the impact
of this increasing resistance on outcomes in patients with IAI.
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Future investigations should focus on preventing the
number of deaths in higher-risk patients, both those with CA-
IAI and those with HA-IAI. In general, the adequacy of initial
empiric antimicrobial therapy has been thought to have a
major impact on the deaths and morbidity of higher-risk
patients [43,54,58,71,187,193–195]. This guideline recom-
mends use of empiric anti-enterococcal and antifungal ther-
apy in many of these patients, and also recommends use of
empiric agents that have broader-spectrum activity against
gram-negative pathogens. The increase in resistant micro-
organisms makes the selection of appropriate empiric anti-
microbial agents for these patients more difficult, but overuse
of broad-spectrum agents may lead to even greater resistance
problems. The hypothesis that outcomes in severely ill pa-
tients with IAI are improved by using broader-spectrum
empiric antimicrobial effective against all the expected
pathogens should be evaluated prospectively through a
methodologically sound trial to determine whether empiric
use of broad-spectrum antimicrobial agents, as well as anti-
enterococcal, anti-MRSA, and antifungal agents, is actually
necessary. To better examine this hypothesis, RCTs of new
antimicrobial agents with activity against resistant micro-
organisms should include adequate numbers of severely ill
patients likely to harbor such resistant pathogens.
There are relatively few new anti-infective agents on the
horizon that are likely to overcome these resistance problems,
and none is likely to be a panacea. Among newer agents
undergoing investigation, published phase II data are avail-
able only for the use of eravacycline and imipenem-cilastatin
with relabactam in patients with IAI [689,690]. Most patients
with IAI will therefore continue to be treated with conven-
tional antimicrobial agents. The application of the principles
of antimicrobial stewardship will be of utmost importance in
conserving these antimicrobial resources. Stratification of
empiric antimicrobial therapy according to patient risk and
de-escalation of broad-spectrum therapy once culture results
have been obtained have been emphasized in this guideline as
approaches to antimicrobial stewardship. There is a strong
potential, however, that newer diagnostic microbiologic mo-
dalities, which provide information on the presence of im-
portant pathogens within hours rather than days, will allow
earlier deployment of pathogen-directed antimicrobial therapy.
As these methodologies mature, prospective studies should be
undertaken to document their potential benefits not only in
improving outcomes in patients with IAI, but also in decreas-
ing use of broad-spectrum empiric anti-infective therapy.
Other means of promoting antimicrobial stewardship have
also been endorsed with these recommendations. Decreasing
the duration of antimicrobial therapy to the minimum nec-
essary to achieve a maximal clinical benefit is another fun-
damental principle of antimicrobial stewardship. The SIS
STOP-IT trial has provided valuable data indicating that
duration of therapy can be safely limited in adult patients with
IAI [82]. Limiting duration of antimicrobial therapy even
further, for example, to two days in patients with perforated
appendicitis, has been proposed [617]; this hypothesis could
be evaluated rigorously in future studies.
Optimizing dosing of antimicrobial agents provides an-
other means of conserving antimicrobial resources. Altered
pharmacokinetic parameters are common in critically ill
patients, including those with IAI, with resultant underdosing
and overdosing of anti-infective agents. The use of extended
infusions to optimize pharmacodynamics of these agents is an
attractive approach, but has not yet shown to have clear
clinical benefits in patients with IAI. Optimization of anti-
microbial dosing for patients at the extremes of age, obese
patients, and those with renal or hepatic impairment has not
been investigated sufficiently; such studies should be con-
sidered, because these are common risk factors in the most
severely ill patients with IAI.
Patients with treatment failure are at substantially in-
creased risk for morbidity and death. The ideal means of
providing source control in these patients has not been fully
elucidated. There are clearly trade-offs between less ag-
gressive approaches, which may lead to incomplete source
control, and more invasive approaches, which may lead to
excess procedural morbidity and death. The development of
more standardized approaches to source control in these pa-
tients could potentially improve the outcomes of these se-
verely ill patients.
There are also numerous questions related to the treatment
of pediatric patients with IAI. The use of less invasive pro-
cedures for source control in pediatric patients with IAI is
becoming widespread. Careful evaluation as to the efficacy of
these interventions should be ongoing. Although there is
good evidence that non–aminoglycoside-based antimicrobial
regimens provide equivalent if not superior results in most
pediatric patients with IAI, aminoglycoside-based regimens
continue to be widely used in neonatal patients. Studies of
alternative regimens are needed to avoid the potential side
effects of these agents. Another important question is whe-
ther or not antimicrobial therapy can be limited further in
pediatric patients with IAI; extended duration therapy is still
frequently used in these patients.
Although this guideline has focused on the management of
patients with IAI, ongoing investigations into the patho-
physiology of IAI should not be discounted. These investi-
gations may provide an avenue toward novel ways of treating
patients with these infections. The pioneering studies per-
formed nearly 50 years ago on the importance of both aerobic
gram-negative bacilli and anaerobic organisms in the path-
ophysiology of IAI led directly to the principles used today for
providing antimicrobial therapy to these patients. Currently,
some of the most exciting work relates to the role of the gas-
trointestinal microbiome as a contributor to both illness and
health. With the advent of increasingly sophisticated tools to
identify the wide variety of micro-organisms associated with
gastrointestinal tract pathology, our understanding of the in-
tricate relationship between the resident microbial population
and the host will be greatly amplified. It would not be unex-
pected that antimicrobial therapy and potentially source con-
trol approaches for patients with IAI will be modified through
the use of this knowledge. It is even possible that future
therapy of IAI could involve use of probiotic agents to restore a
healthy internal ecosystem within the gastrointestinal tract,
rather than the antibiotic agents currently used.
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